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Obesity is the most common antenatal comorbidity, affecting one in five of the 
antenatal population in the UK. It is associated with adverse outcomes for mother 
and baby in both the short and long term. Increasing data suggest that maternal 
obesity may programme offspring later life obesity and premature mortality, with 
high birth weight being a marker for increased risk. The mechanism by which 
maternal obesity causes excessive neonatal birth weight is incompletely understood 
but considerable evidence implicates insulin resistance and/or hyperglycaemia. There 
are currently no effective interventions to mitigate the effects of obesity during 
pregnancy. In this thesis, we present the findings from a randomised, double blind, 
placebo controlled trial designed to examine the efficacy of metformin, an insulin-
sensitising agent, in obese pregnant women. The aim of the trial was to determine 
whether giving metformin to obese pregnant women from between 12 and 16 weeks’ 
gestation until birth, would improve maternal and fetal outcomes. The primary 
outcome measure was birth weight of the baby, using this as a surrogate marker for 
the future life risk of the child developing obesity.  
 
Nested within this large clinical trial were a series of mechanistic sub-studies. To 
examine the effect of metformin on maternal insulin resistance at 36 weeks’ 
gestation, we used the hyperinsulinaemic euglycaemic clamp with concomitant use 
of stable isotope tracers. This enabled us to characterise in greater detail insulin 
sensitivity, endogenous glucose production and lipolysis. To determine the effect of 
metformin on maternal and fetal body composition we used magnetic resonance 
imaging and spectroscopy. This allowed us to quantify subcutaneous and intra-
abdominal adipose tissue deposition and hepatic and skeletal muscle ectopic lipid 
deposition in the mother; and to measure subcutaneous adipose tissue deposition, 
hepatic lipid and hepatic volume in the fetus. To determine the effect of metformin 
on maternal endothelial function, we measured endothelium-dependent flow-
mediated dilatation at the beginning and end of pregnancy. Change in diameter of the 
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brachial artery in response to a flow stimulus created by arterial occlusion was 
measured using ultrasound imaging.  
 
We found no significant effect of metformin on birth weight. Mean birth weight was 
3463 g (SD 660) in the placebo group and 3462 g (SD 548) in the metformin group 
(adjusted mean difference in z score –0·029, 95% CI –0·217 to 0·158; p=0·7597). 
Subjects taking metformin did demonstrate increased insulin sensitivity (M/I 
difference between means during high dose insulin of 0.02 [95% CI 0.001 to 0.03] 
milligrams per kilogram fat free mass per minute per pmol/L, p=0.04) but also 
enhanced endogenous glucose production (difference between means 0.54 [95% CI 
0.08 to 1.00] milligrams per kilogram fat free mass per minute, p=0.02), compared 
with those taking placebo. We did not demonstrate any differences between 
treatment groups in maternal subcutaneous and intra-abdominal adipose tissue, or 
ectopic lipid deposition, or in fetal body fat distribution and liver volume. 
Participants in both treatment groups demonstrated a decline in endothelium-
dependent flow-mediated dilatation between early and late pregnancy but there were 
no differences in the magnitude of that decline between the treatment groups. 
 
In conclusion, metformin, administered to obese, non-diabetic pregnant women, does 
not have any significant effect on birth weight of the baby. Our clamp studies 
demonstrated that subjects taking metformin were indeed more insulin-sensitive than 
those taking placebo, but the higher endogenous glucose production in this group 
suggests a reduced ability to suppress hepatic glucose production in response to 
insulin. This increased glucose flux may in part explain the lack of effect of 
metformin on fetal nutrition and growth. We can conclude that metformin, should 
not be used as an intervention in obese pregnant women to prevent excess birth 
weight. The global obesity epidemic is one of the greatest public health challenges 
we face and the cycle of disadvantage continues to be perpetuated to the next 
generation. The lack of any effective interventions for this high-risk group remains a 




Obesity during pregnancy is common. This is of concern because obese women have 
an increased risk of complications including diabetes and pre-eclampsia. There is 
also an increased risk for their babies to be born larger than average, or to be 
stillborn. In addition, there may be harmful effects of maternal obesity that persist 
into the baby’s adult life, including a higher risk of obesity and premature death. 
 
We don’t know how obesity causes these problems. We do know that obese pregnant 
women have higher blood glucose and respond less well to the hormone insulin than 
lean pregnant women, i.e. they are ‘insulin resistant’. This means that the food 
supply to the baby is potentially too great, leading to a higher birthweight. The link 
between insulin resistance and high birthweight has already been demonstrated, as 
has a link between high blood glucose and greater risk of pregnancy problems. 
 
The aim of this study was to see whether giving obese pregnant women a drug called 
metformin reduced the risk of them having a larger than average baby. Metformin is 
safe to take during pregnancy and works by reducing insulin resistance. 
 
We recruited 449 women to take part in the study. They were randomly assigned to 
receive treatment with either metformin or placebo tablets during their pregnancy. A 
subgroup of the women participating in the study took part in some extra 
experiments to examine the effect of metformin on insulin resistance in greater 
detail. Some participants also had magnetic resonance scans to examine the effect of 
metformin on fat distribution in the body and in the developing fetus. Additionally, 
some participants had an extra test to look at the effect of metformin on blood vessel 
function. 
 
The results showed the average birthweight of babies born to women in both groups 
was similar, 3463 g in the placebo group and 3462 g in the metformin group. There 
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was no increased risk of a bad outcome in either of the groups with the exception of 
nausea and vomiting which were more common in the metformin group. In the more 
detailed tests, we found that metformin did make the body slightly less insulin 
resistant but there was no overall effect on blood glucose. There was no effect of 
metformin on body fat distribution in the mother or baby, or on blood vessel 
function. 
 
We can conclude that metformin is not an effective treatment for obese pregnant 
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1. Chapter 1 Introduction 
1.1. Background 
The World Health Organisation (WHO) defines overweight or obesity as abnormal 
or excessive fat accumulation that may impair health1. The diagnosis of obesity is 
commonly made on the basis of a body mass index (BMI: weight in kilograms 
divided by the square of the height in meters, kg/m2) exceeding a defined threshold, 
usually 30 kg/m2. Obesity is a chronic disease with a multifactorial aetiology that 
leads to serious health consequences. Well-established contributory causes include 
genetic, environmental and behavioural factors but there is now mounting evidence 
that the intra-uterine environment to which we are exposed also plays an important 
role in our risk of developing obesity. 
  
Rates of obesity have risen alarmingly in recent decades2. The majority of the 
world’s population now live in countries where overweight and obesity is 
responsible for more deaths than underweight3. In general, men have higher rates of 
overweight (BMI greater than 25 kg/m2) but women have higher rates of obesity. In 
common with global trends, around 20% of women booking for antenatal care in the 
UK are obese, making it the commonest antenatal comorbidity. The adverse effects 
of maternal obesity on pregnancy complications for both the mother and fetus are 
well established and cover every aspect of pregnancy from pre-conception to the 
puerperium. For the fetus, there is a greater risk of miscarriage4, and fetal 
abnormality5, iatrogenic preterm birth6 and a one- to five-fold increased risk of 
stillbirth7, 8. During her pregnancy, an obese woman has a two-fold increased risk of 
developing pre-eclampsia9 and a three to four fold increased risk of venous 
thromboembolism10 and gestational diabetes11. Around the time of delivery, 
induction of labour, caesarean section, postpartum haemorrhage and infection are all 
more likely11-13. Finally, a recurring theme of the confidential enquiries into maternal 
deaths of recent decades has been obesity14. 
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In addition to these immediate complications, there is mounting evidence of a 
detrimental effect on the longer-term health of offspring of women who are obese 
during pregnancy15-17. Increasingly, data suggest that maternal obesity may 
programme offspring later life obesity, with high birthweight being a marker for 
increased risk. Our own recent work also suggests that offspring of obese pregnant 
women are at increased risk of premature death in adulthood18. 
 
1.2. Evidence for mechanisms linking maternal obesity to offspring obesity 
The mechanism by which maternal obesity causes excessive neonatal birthweight 
and later life ill health is not clearly understood. As previously mentioned, obesity is 
a multifactorial disease and unpicking the relative contributions of genetics, 
environment, behaviour and programming or epigenetics continues to be a 
challenging area of research.  
 
The ‘developmental overnutrition hypothesis’ was first proposed in the 1950s by 
Pederson to explain the association between maternal diabetes and excessive growth 
of the fetus19. Pederson postulated that the greater delivery of glucose to the fetus 
resulted in fetal hyperinsulinaemia in order for the fetus to manage its 
hyperglycaemia. This in turn caused insulin-mediated excessive fetal growth. This 
hypothesis has subsequently been broadened to include other fuel sources that may 
contribute to fetal hyperinsulinaemia and excessive growth such as free fatty acids 
and amino acids and more recently to include exposure to obesity in general as a 
risk20, 21. A number of animal studies support the hypothesis that maternal obesity 
has a permanent impact on offspring obesity, body composition and cardiometabolic 
health, along with an increasing number of human studies. 
 
1.2.1. Evidence from animal studies 
Timing of exposure to the insult appears to be important in the resulting offspring 
phenotype.  In most rodent studies of maternal obesity, animals are fed an 
obesogenic diet until significantly heavier than control animals, and then continue on 
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the same diet throughout pregnancy and lactation. This means the effect of obesity 
cannot be separated from that of overnutrition. However, there may be particular 
windows of development during which maternal obesity has a detrimental effect. 
There are some rodent data to suggest that maternal obesity impairs oocyte quality 
and thus development of the early embryo, suggesting that programming effects in 
the offspring occur even before fertilisation22. Other studies have employed cross-
fostering techniques that demonstrate the importance of overnutrition purely during 
pregnancy23, while some suggest diet during pregnancy and lactation is important24-
26. 
 
In addition to the programming effects of maternal obesity on offspring obesity, it 
seems there is also an impact on body composition, which may impact on lifelong 
cardiometabolic health. Rat offspring of mothers fed a junk food diet during 
pregnancy or both pregnancy and lactation exhibited increased intramuscular lipid 
content with altered gene expression of genes important for muscle growth and 
metabolism27, 28. Similar changes have also been demonstrated in sheep exposed to 
maternal obesity, in association with increased expression of inflammatory markers 
and altered AMP-activated protein kinase signalling29-31. This could have an impact 
on muscle size and strength in later life, and therefore ability to keep physically 
active. Additionally, intramuscular lipid and altered gene expression is likely to be 
important in the development of peripheral insulin resistance. Indeed, one study 
demonstrated that offspring of obese mice exhibit changes in insulin signalling and 
muscle mitochondrial complex activity in early adulthood32. 
 
A further extension of the developmental overnutrition hypothesis encompasses 
some evidence that programming of appetite control and neuroendocrine function 
may also occur. For example, offspring of mice fed a highly palatable diet during 
pregnancy and lactation demonstrate hyperphagia prior to the development of 
obesity33, and rat offspring exposed to a junk food diet in pregnancy develop a 
preference for fatty, sugary, salty foods compared to control animals34. This may 
reflect programmed changes to the hypothalamus, which is important for regulation 
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of appetite. Furthermore, one study in sheep in which direct infusions of glucose 
were administered into the fetuses in late gestation found altered expression of 
orexigenic peptides in the fetal hypothalamus, suggesting prenatal overnutrition may 
alter the brain sufficiently to impact on appetite regulation35. 
 
1.2.2. Evidence from human studies  
The alarming rise in maternal obesity rates has been accompanied by a rise in babies 
born large for gestational age36 and childhood obesity, including very early onset of 
obesity in the first six months of life37, 38. Maternal obesity is undoubtedly associated 
with fetal overgrowth39 and there are numerous studies which link high birthweight 
with an increased risk of obesity in later life17. There are several observational and 
cohort studies which demonstrate an association between maternal obesity and 
effects on offspring adiposity at all stages in life from infancy, through childhood 
and into adulthood40-44. These studies and others lend strong support to the 
overnutrition hypothesis but do not really provide mechanistic evidence of an effect 
of obesity itself, rather than, for example metabolic disturbance commonly 
associated with obesity such as gestational diabetes. Many are based on historical 
cohorts that may rely on weight or BMI data being self-reported or in cohorts where 
the prevalence of obesity was much less than it is today. The evidence of a causal 
effect of obesity itself is more compelling at the extreme of obesity. For example, 
Smith et al examined offspring of women who had undergone bariatric surgery 
between pregnancies and showed offspring after maternal weight loss to be leaner, 
with greater insulin sensitivity and more a favourable lipid profile45. 
 
Gestational weight gain (as opposed to obesity per se) is positively associated with 
offspring obesity in childhood and adulthood46-51. Human studies specifically 
addressing dietary components in the context of maternal overnutrition are difficult 
to perform but the degree of gestational weight gain may be a reflection of the 
nutritional environment to which the fetus is exposed. However, interpretations of 
the findings of most of these studies is again limited as many use self-reported pre-
pregnancy BMI and do not have detailed measurements of maternal weight and body 
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composition during pregnancy. It remains unclear whether gestational weight gain is 
a causal intrauterine mechanism. It is a multifactorial risk and reflects a number of 
different components (e.g. various maternal fat depot sites, fetal weight, placental 
weight) and only by separating these out (e.g. with detailed imaging in pregnancy) 
would it be possible to interpret the findings fully. 
 
1.2.3. Epigenetics 
Epigenetics, the study of how changes in gene activity during development cause 
specific phenotypes to emerge over the lifetime of an individual52, has been strongly 
implicated in the developmental origins of health and disease. The large and rapid 
increase in the worldwide prevalence of obesity cannot be explained by changes in 
the genome. Human epigenetic research to date has primarily focused particularly on 
maternal under-nutrition but has demonstrated that epigenetic changes mediated by 
the maternal environment can be transmitted to subsequent generations53. Animal 
studies have shown that maternal diet can induce epigenetic changes in offspring and 
cause long-term alterations in gene expression of genes involved in obesity54. For 
example, in primates exposure to a high fat diet has been associated with global as 
well as gene-specific alterations in DNA methylation and histone modifications55. In 
a human study, maternal hyperglycaemia was shown to correlate with placental 
leptin gene DNA methylation levels56. More recently, consistent methylation 
changes in genes closely associated with adult obesity have been demonstrated57. 
Such epigenetic processes may well be part of the mechanism underlying 
developmental overnutrition but this is young field of research and findings must be 
replicated before robust conclusions can be drawn. 
 
1.2.4. Insulin resistance 
Considerable evidence implicates insulin resistance and/or hyperglycaemia as the 
causal mechanism by which maternal obesity cause excessive neonatal birthweight. 
Pre-existing maternal diabetes, particularly with poor glycaemic control, has long 
been recognised to be associated with poor obstetric outcomes and fetal macrosomia. 
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More recently, several studies have demonstrated that treating hyperglycaemia at 
levels below those associated with overt diabetes outwith pregnancy, reduces the risk 
of adverse pregnancy outcome. The Australian Carbohydrate Intolerance Study in 
Pregnant women trial group (ACHOIS) published a randomised controlled trial of 
treating mild hyperglycaemia in pregnant women who did not reach existing 
diagnostic criteria for gestational diabetes58. The investigators found the treatment 
group demonstrated a reduction in the composite endpoint of perinatal death, 
shoulder dystocia, bone fracture and nerve palsy, all of which are associated with 
macrosomia.  Similarly a trial by Landon et al demonstrated a reduction in 
macrosomia, shoulder dystocia, caesarean delivery and hypertensive disorders in 
women treated for mild hyperglycaemia59. In 2008, the landmark trial The 
Hyperglycaemia and Adverse Pregnancy Outcomes (HAPO) study was published60. 
This was a multinational, prospective, blinded, observational study of almost 25 000 
pregnant women. It was designed to evaluate the relationship between maternal 
glucose concentrations and adverse pregnancy outcome. HAPO confirmed that there 
was a linear relationship between hyperglycaemia and birthweight, with no clear 
threshold above which adverse events occurred.  
 
Although these informative studies were not restricted to obese pregnant women, we 
do know that obese pregnant women are more insulin resistant and hyperglycaemic 
than their lean counterparts62. This enhances nutrient availability for the fetus with 
consequent excessive growth. For example, there is strong correlation between the 
degree of insulin resistance in late pregnancy and both birthweight and fat-free mass 
at birth63. It is logical to assume that this enhanced exposure to hyperglycaemia of 
the developing fetus of an obese mother is a plausible causative mechanism of 
excessive fetal growth and subsequent life long risk of obesity. An intervention in 
pregnancy in obese women to improve insulin sensitivity and thus reduce fetal 
exposure to hyperglycaemia may well reduce the risk of fetal overgrowth. Lifestyle 
modification, primarily in the form of dietary modification and exercise are possible 
candidates for such an intervention and the outcome of trials of such interventions 
are discussed below. An alternative to these strategies is pharmacotherapy. 
Metformin is an insulin sensitising agent, which is safe for use in pregnant women. 
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This thesis describes the findings from a multicentre, double-blind, randomised-
controlled trial of metformin versus placebo in obese pregnant women with the 
primary outcome of birthweight, and a number of nested substudies to examine the 
mechanism of any effect of treatment.  
 
1.3. Interventions in pregnancy to reduce excess birthweight in offspring of 
obese pregnant women 
 
To date, all of the interventions that have been trialled in overweight or obese 
pregnant women to reduce the risk of excess birthweight in the offspring have 
involved modifications to diet, lifestyle or a combination of both. 
 
There have been several systematic reviews of studies evaluating such interventions 
in pregnancy but only two have been limited to overweight and obese women, Dodd 
et al in 201064 and Oteng-Ntim et al in 201265. Three further randomised trials have 
been published since these reviews, the LIMIT trial (Limiting weight gain in 
overweight and obese women during pregnancy to improve health outcomes: the 
LIMIT randomised controlled trial)66, the LiP (Lifestyle in Pregnancy) Study67, and 
UPBEAT (UK Pregnancies Better Eating and Activity trial)68. 
 
The review by Dodd et al examined nine randomised controlled trials, including 743 
women. Seven trials compared a dietary intervention with standard antenatal care. 
Two of the studies evaluated the effect of an exercise intervention but outcomes did 
not include effect on infant birthweight in these studies. Only three trials reported 
outcome data for the primary outcome large-for-gestational-age (LGA) infants, with 
no significant difference between those who received the intervention and those who 
did not (366 women; risk ratio 2.20; 95% CI 0.84 to 4.86). Four studies examined 
effect on gestational weight gain and again there was no statistically significant 
difference in this outcome (416 women; weighted mean difference -3.10kg; 95% CI -
 8 
8.32 to 2.13). The overall conclusion of the review was that the evidence of benefit 
for this type of intervention in overweight or obese women is not clear. However, the 
authors note the quality of all the included studies was poor to fair and further high 
quality, suitably powered randomised trials are urgently needed.  
 
The review by Oteng-Ntim et al included 13 randomised trials and six non-
randomised trials. Again, overall quality of the trials was deemed to be suboptimal, 
with five of the RCTs judged to be of medium quality and the rest of low quality. Six 
of the studies included large-for-gestational-age as an outcome, but there was no 
evidence that the interventions were associated with a lower prevalence of this 
outcome (1008 women, OR 0.91; 95% CI 0.62 to 1.32). There were seven studies 
that examined effect on birthweight and although there was a trend towards an effect 
of the intervention, this did not reach statistical significance (1133 women, mean 
difference -56.64; 95% CI -120.15 to 6.88). The authors reach a similar conclusion 
that further meta-analyses will be unlikely to refine the quality of the evidence and 
that large-scale suitably powered trials are required.  
 
One such trial has since been published – the LIMIT trial66. This was a multicentre 
randomised controlled trial of a diet, exercise and behavioural intervention versus 
standard care for overweight or obese women (BMI>25 kg/m2, median BMI of 
cohort 31.1 kg/m2). The primary outcome was infants born large-for-gestational-age 
(>90th centile for gestation). The trial recruited to target a total of 2212 women and 
was adequately powered to detect a 30% reduction in LGA infants. There was no 
significant difference in the risk of infants born LGA in the lifestyle advice group, 
compared with standard care group (19% versus 21%; adjusted relative risk 0.90; 
95% CI 0.77 to 1.07, p=0.24). 
 
The LiP (Lifestyle in Pregnancy) Study67 was a smaller trial of 360 women, all of 
who were obese (BMI 30-45 kg/m2, median BMI 33kg/m2). They were randomised 
to receive a lifestyle intervention, which included dietetic advice, gym membership, 
physical training and personal coaching. The primary end-point was a combination 
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of five obstetric and neonatal outcomes: emergency caesarean section, pre-
eclampsia, GDM, LGA and admission to the neonatal unit, with a score of 1 point for 
each outcome. There was no significant difference in combined scores (0.65 for the 
intervention, versus 0.67 for the control group, p=0.39). Birthweight was in fact 
significantly higher in the intervention group (median 3742g vs 3596g, p=0.039). 
Gestational weight gain was significantly lower in the intervention group (7.0kg vs 
8.6kg; p=0.01). However, as with many of the previous studies, the authors note that 
ultimately they were underpowered, with power calculations being based on the 
expectation of a larger difference in gestational weight gain between groups than was 
actually found. 
 
The UPBEAT study similarly found no effect of a lifestyle intervention on the 
incidence of gestational diabetes nor large for gestational age infants68. 
 
At the time of initiation of the EMPOWaR study, there were no randomised 
controlled trials of pharmacotherapy as an intervention for obese pregnant women. 
Given the evidence of a lack of effect from lifestyle interventions, pharmacotherapy 
is an important next step. Other than the work presented in this report, we are aware 
of two other on-going studies of the effect of metformin as a pharmacological 
intervention in obese pregnant women (MOP: NCT01273584 and 
GRoW:ACTRN12612001277831), one of which has now been published69. 
 
1.4. Metformin 
Galega officinalis, the French lilac, was prescribed in medieval Europe to relieve the 
intense urination associated with what has since become known as diabetes mellitus 
70. The hypoglycaemic properties of the active ingredient in the plant, guanidine, 
have long been recognised. Metformin, a synthetic biguanide (two linked guanidine 
rings), was developed in the 1920s and used for many years in Europe to treat 
diabetes prior to being approved by the FDA in the USA in the mid 1990s for use in 
type 2 diabetes. It is now the most commonly prescribed oral anti-diabetic drug 
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world wide, taken by 150 million people each year. And yet, its actual mechanism of 
action remains incompletely understood. 
 
Metformin is not metabolised. It accumulates in the liver following absorption 
through the intestinal epithelium and transfer via the portal vein. The liver is its 
primary site of action. It is excreted unchanged by the kidneys. 
 
Metformin acts primarily to suppress hepatic glucose production but it also increases 
peripheral glucose utilisation and inhibits adipose tissue lipolysis. The exact 
molecular locus of metformin’s effects remains unclear but its action on AMPK 
activation seems to play a central role71. Its effect on glucose metabolism appears to 
be mediated via its action on the mitochondrial respiratory chain and consequent 
activation of AMPK. Metformin inhibits the mitochondrial respiratory complex I 
leading to reduced ATP production and activation of AMPK72, 73. In the liver, the 
activation of AMPK decreases lipid synthesis and suppresses gluconeogenesis in 
hepatocytes, resulting in decreased circulating insulin and glucose. However, 
metformin also has AMPK-independent effects on glucose metabolism as mice 
deficient in AMPK demonstrate metformin-induced inhibition of glucose 
production74. 
 
1.5. Metformin in pregnancy 
The use of metformin is endorsed by the National Institute for Health and Care 
Excellence (NICE) for the treatment of gestational diabetes (GDM)75. There are no 
placebo-controlled randomised trials of the use of metformin in pregnancy, but 
several trials have compared metformin with alternative agents for the treatment of 
GDM. There have been several recent systematic reviews of these trials including 
those by Balsells et al, 201576 and Zhao et al, 201577, and a literature review by 
Singh et al, 201578. Additionally, two other randomised trials, Beyou et al, 201579 
and George et al, 201580 have been published since these meta-analyses were 
performed.   
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The meta-analysis by Balsalls et al76 compared metformin with insulin and with 
glibenclamide for the treatment of GDM. Fourteen primary outcomes were 
considered. Compared with insulin, metformin reduced maternal weight gain (mean 
difference −1.14 [95% CI −2.22 to −0.06] kg), reduced gestational age at delivery 
(mean difference −0.16  [95% CI −0.30 to −0.02] weeks), and increased preterm 
birth (risk ratio 1.50 [95%CI 1.04 to 2.16]). Compared with glibenclamide, 
metformin reduced maternal weight gain (mean difference −2.06 [95% CI −3.98 to 
−0.14] kg), was associated with lower birth weight (mean difference −209 [95% CI 
−314 to −104] kg), reduced the risk of macrosomia (risk ratio 0.33 [95% CI 0.13 to 
0.81]), and reduced the risk of large for gestational age newborns (risk ratio 0.44 
[95% CI 0.21 to 0.92]). Zhao et al77 demonstrated that, compared with insulin, 
metformin reduced the risk of pregnancy-induced hypertension (risk ratio 0.54 [95% 
CI 0.31 to 0.91]), but there were no differences in effects on neonatal hypoglycemia, 
large-for-gestational age infants, respiratory distress syndrome, phototherapy or 
perinatal death. 
 
The literature review78 reported that the majority of studies found no difference in 
glycaemic control between metformin and insulin groups, and suggested that 
although there is a growing body of evidence to suggest a role for metformin in 
GDM management, much of this was from single site small studies, and that further 
studies are needed to inform guidelines. 
 
In one of the randomised trials not included in the systematic reviews above, and 
which recruited 159 women, metformin was demonstrated to be superior to 
glibenclamide because it was associated with a reduction in risk of 16.1% (95% CI 
2.5% to 29.7%; p=0.02) in the primary outcome, a composite of macrosomia, 
hypoglycaemia, need for phototherapy, respiratory distress, stillbirth or neonatal 
death and birth trauma, largely due to a higher incidence of hypoglycaemia in the 
glibenclamide group81. In the RCT by Beyuo et al79 (n=104), which compared 
metformin with placebo, with the addition of  insulin if required to maintain 
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glycaemic control, postprandial glucose levels were significantly lower in the 
metformin group. 
 
There are few randomised trials of metformin versus placebo in pregnant women 
without GDM. Both published studies were of women with polycystic ovary 
syndrome82, 83, with one being a pilot of the other. Although a significant difference 
in a composite of severe pregnancy and postpartum complications was seen in the 
smaller study comparing metformin 850mg twice daily with placebo (n=40)82, there 
were no significant differences in the outcomes of pre-eclampsia, preterm delivery or 
gestational diabetes in the larger study comparing metformin 2000mg daily of 
metformin with placebo (n=259)83, although women in the metformin group gained 
less weight. 
 
1.6. Hypotheses and aims 
The work in this thesis presents the full trial protocol and findings from the 
EMPOWaR trial (Efficacy of metformin in pregnant obese women; a randomised 
controlled trial). This was a double-blind randomised-controlled trial of metformin 
versus placebo given to obese pregnant women between 12 and 16 weeks’ gestation 
until delivery.  
 
We hypothesised that metformin administered to obese women during pregnancy 
would reduce birth weight centile in their babies and consequently their future life 
risk of obesity and metabolic syndrome. 
 
A number of nested substudies were included to test the following hypotheses: 
 
• Participants taking metformin, compared to those taking placebo, would 
demonstrate improved insulin sensitivity, as measured by the 
hyperinsulinaemic euglycaemic clamp. 
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• Improving insulin sensitivity with metformin would result in less deposition 
of lipid in the more insulin sensitive sites (i.e. visceral, hepatic and skeletal 
muscle), as measured using magnetic resonance imaging techniques. 
 
• Fetuses’ of mothers exposed to metformin in pregnancy would accumulate 
less excess fat, compared to those exposed to placebo, as measured by 
magnetic resonance imaging techniques. 
 
• Improving insulin sensitivity in obese pregnant women with metformin 
would result in improved endothelial function in late pregnancy, as measured 
by flow-mediated dilatation. 
 
The primary aim of the trial was to determine whether metformin could reduce future 
life risk of obesity in the baby. We used birth weight centile as a surrogate marker 
for future life events as its predictive value has been shown in large epidemiological 
studies84.  
 
The aims of the nested substudies were as follows: 
 
• To measure hepatic and peripheral insulin sensitivity and rates of lipolysis in 
obese pregnant women, taking either metformin or placebo, at 36 weeks’ 
gestation. 
 
• To quantify and compare fat distribution in obese pregnant women exposed 
to either placebo or metformin in early and late third trimester. 
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• To quantify and compare hepatic and skeletal muscle lipid in obese pregnant 
women exposed to either placebo or metformin in early and late third 
trimester. 
 
• To optimise an MR imaging protocol for measurement of fetal liver volume, 
fetal subcutaneous fat and fetal hepatic lipid deposition. 
 
• To quantify and compare fetal liver volume, fetal subcutaneous fat and fetal 
hepatic lipid in fetuses of obese women exposed to metformin or placebo 
during pregnancy. 
 
• To optimise the technique of FMD for use in obese pregnant women. 
 
• To measure FMD in early and late pregnancy in obese pregnant women 
participating in the EMPOWaR trial. 
 
• To compare endothelial function in obese pregnant women taking metformin 
with those taking placebo and with an additional group of lean pregnant 
controls. 
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2. Chapter 2 Protocol for Efficacy of Metformin in 
Pregnant Obese Women: a Randomised controlled trial 
(EMPOWaR) 
 
This chapter details the full protocol for the EMPOWaR trial and was published in 
BMJ Open, prior to completion of the clinical trial in accordance with Consolidated 
Standards of Reporting Trials (CONSORT) guidance85, as Chiswick CA, Reynolds 
RM, Denison FC, et al. Efficacy of metformin in pregnant obese women: a 
randomised controlled trial. BMJ Open 2015;5:e006854.doi:10.1136/bmjopen-2014-
006854 
 
We made some changes to the protocol after recruitment began, but before 
generation of the statistical analysis plan, publication of the protocol as detailed in 
this chapter, and unblinding and analysis. A full summary of all protocol changes is 




Increasing evidence suggests obesity has its origins prior to birth. There is clear 
correlation between maternal obesity, high birth weight and offspring risk of obesity 
in later life. It is also clear that women who are obese during pregnancy are at greater 
risk of adverse outcomes, including gestational diabetes and stillbirth. The 
mechanism(s) by which obesity causes these problems is unknown, although 
hyperglycaemia and insulin resistance are strongly implicated. We present a protocol 
for a study to test the hypothesis that metformin will improve insulin sensitivity in 
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obese pregnant women, thereby reducing the incidence of high birth weight babies 
and other pregnancy complications. 
Methods and analysis 
The Efficacy of Metformin in Pregnant Obese Women, a Randomised controlled 
(EMPOWaR) trial is a double-masked randomised placebo-controlled trial to 
determine whether metformin given to obese (BMI >30 kg/m2) pregnant women 
from 12-16 weeks’ gestation until delivery reduces the incidence of high birth weight 
babies. A secondary aim is to test the mechanism(s) of any effect. Obese women 
with a singleton pregnancy and normal glucose tolerance will be recruited prior to 16 
weeks’ gestation and prescribed study medication, metformin or placebo, to be taken 
until delivery. Further study visits will occur at 28 and 36 weeks’ gestation for 
glucose tolerance testing and to record anthropometric measurements. Birth weight 
and other measurements will be recorded at time of delivery. Anthropometry of 
mother and baby will be performed at 3 months post-delivery. As of January 2014, 
449 women had been randomised across the UK. 
Ethics and dissemination 
The study will be conducted in accordance with the principles of Good Clinical 
Practice. A favourable ethical opinion was obtained from Scotland A Research 
Ethics Committee, reference number 10/MRE00/12. Results will be disseminated at 
conferences and published in peer-reviewed journals. 
Trial registration number 
ISRCTN51279843 
Strengths and limitations of this study 
• This is the first multicenter, double-masked, randomised-controlled trial to 
examine the effect of metformin in obese pregnant women without diabetes. 
• We will use a recognised surrogate (birthweight centile) as a marker of future life 
risk of obesity in the offspring. 
• Follow-up of the offspring is limited to the early postnatal phase. 
 




Rates of obesity, as defined by a BMI greater than 30 kg/m2, are rising alarmingly in 
the United Kingdom and throughout the world. Around 27% of adults in Scotland are 
now obese and 32% of Scottish children have a weight outwith a healthy range for 
their age86. Obesity rates in England87 and the United States88 are similar. The 
increase in average BMI during pregnancy over the last twenty years has been well 
documented89. Rates of maternal obesity in women booking for antenatal care in the 
United Kingdom are now around 20%. There has also been a substantial increase in 
mean birth weight and in the incidence of being born large for gestational age over 
the past few decades36. The secular rise in maternal weight at delivery appears to be 
the factor most strongly correlated with the increase in birth weight36, 62. Positive 
correlations have also been shown between birth weight and both maternal pre-
gravid weight90-92 and weight gain in pregnancy93, with odds of high birth weight 
some 2.4 times greater in morbidly obese compared with lean women94.  
 
This increase in mean birth weight is of concern because it is linked to an increased 
likelihood of child and adult obesity. A systematic review showed a positive 
correlation between birth weight and obesity during adulthood17. The association 
between high birth weight and later life obesity is also supported by two large 
epidemiological studies15, 16, both of which found obesity to be a long-term correlate 
of high birth weight. A subsequent prospective study found that children who were 
large for gestational age at birth and exposed to an intrauterine environment of 
maternal obesity are also at increased risk of developing metabolic syndrome84. Our 
own recent work suggests that offspring of obese pregnant women are at increased 
risk of premature death in adulthood18. Thus, the increase in rates of maternal obesity 
are setting up a vicious cycle, leading to increased birth weight and increased rates of 
child and adult obesity, contributing to an epidemic of obesity which has become one 
of the most significant contributors to global ill health. 
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Women who are obese during pregnancy are also themselves at greater risk of a 
number of adverse outcomes, including, gestational diabetes11, pre-eclampsia9 and 
stillbirth7, 8. The mechanism(s) by which maternal obesity increases pregnancy and 
peripartum complications are unclear, but there are likely several candidate 
mechanisms including hyperglycaemia and increased insulin resistance. 
 
Clearly an intervention is urgently required. Lifestyle interventions (e.g. diet and 
exercise) are a logical approach and are currently being trialled, for example, UK 
Pregnancies Better Eating and Activity Trial (UPBEAT), Poston 
(ISRCTN89971375) although studies hitherto have shown no evidence of benefit66, 
95, 96. A recent meta-analysis of dietary and lifestyle interventions suggests dietary 
interventions may be of some benefit over physical activity or mixed interventions in 
reducing maternal weight gain. However, there was no effect on birth weight, the 
incidence of large for gestational age babies, and clinically important adverse 
outcomes97. 
 
In this study, we test the hypothesis that the insulin-sensitising agent metformin 
reduces birth weight centile in the offspring of obese pregnant women. The principal 
action of metformin includes improvement of insulin resistance in liver and skeletal 
muscle, along with improved endothelial function, increased peripheral uptake of 
glucose, improved lipid profile, redistribution of fat from visceral to subcutaneous 
depots and antioxidant effects98, all of which are likely to contribute to its clinical 
efficacy in reducing adverse outcomes in obese pregnant women. 
 
Considerable evidence implicates insulin resistance or hyperglycaemia as the 
mechanism by which maternal obesity causes excessive neonatal birth weight. 
Whilst modest insulin resistance is physiological in pregnancy and generates 
maternal glucose, free fatty acids and amino acids as substrates for fetal growth, 
obese pregnant women are more insulin resistant than their lean counterparts62 
leading to a further amplification of nutrient availability with consequent excessive 
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fetal growth. There is a strong correlation between insulin resistance in late gestation 
and both birth weight and fat-free mass at birth63. The Hyperglycaemia and Adverse 
Pregnancy Outcomes (HAPO) trial60 confirms that there is a linear relationship 
between hyperglycaemia and birth weight, even at glucose levels not usually 
considered abnormal during pregnancy. The Australian Carbohydrate Intolerance 
Study in Pregnant Women (ACHOIS)58 confirms that treating hyperglycaemia can 
substantially reduce both the incidence of large for gestational age babies and other 
perinatal complications. Thus, metformin, by reducing insulin resistance, could have 
a major impact in reducing excess birth weight in obese pregnant women.  
 
This study is timely because of emerging evidence about the safety and efficacy of 
metformin. It is a licensed first line therapy for the treatment of type 2 diabetes and is 
endorsed by the National Institute for Health and Care Excellence (NICE) as a 
treatment for gestational diabetes99.  
 
There are few previous studies testing the effects of metformin in pregnant women in 
the absence of diabetes. A small randomised study of 40 pregnant women with a 
history of polycystic ovary syndrome (PCOS), a condition often accompanied by 
insulin resistance, showed that metformin reduced pre-defined pregnancy 
complications from 32% in the placebo group (n=22) to 0% in the metformin group 
(n=18) (p=0.01)82. However, a larger study by the same group, which randomised 
274 women with PCOS to either metformin or placebo throughout pregnancy, 
showed no significant differences in the prevalence of preterm birth, pre-eclampsia 
and gestational diabetes83. There was also no difference in birth weights of the babies 
in the two groups. However, the mean BMI of the participants in these studies was 
less than 30 kg/m2. In the Metformin in Gestational diabetes (MiG) study, which 
compared the effect of metformin versus insulin in women with gestational diabetes 
100, there were no differences in birth weight between the offspring. However, weight 
gain in pregnancy, a known additional driver of birth weight90, was lower in the 
metformin group (difference of 1.6 kg, p<0.001). By two years of age, offspring of 
   
 
20 
the participants randomised to metformin had greater subcutaneous fat, but overall 
body fat was the same as in children whose mothers were treated with insulin alone, 
suggesting that the ‘metformin offspring’ have smaller deposits of visceral, 
metabolically active fat101. Further follow-up is required to examine whether these 
findings persist into later life and whether children exposed to metformin will be 
more insulin sensitive.  
 
Importantly, if metformin is to be effective in reducing high birth weight in obese 
women, it should not increase the proportion of babies with low birth weight. The 
studies mentioned above, and another small study, on women with a mean BMI less 
than 30 kg/m2 are reassuring on this point82, 83, 102. 
 
2.3. Hypothesis 
We hypothesise that metformin administered to obese women during pregnancy will 
reduce birth weight centile in their babies and consequently their future life risk of 
obesity and metabolic syndrome. 
 
2.4. Aim 
To determine if metformin administered to obese women during pregnancy reduces 
birth weight centile in their babies, using birth weight as a surrogate marker of the 
future life risk of obesity and metabolic syndrome in the offspring. 
 
2.5. Objectives 
2.5.1. Primary objective 
To determine the efficacy of metformin (up to 2500 mg daily), given to obese 
pregnant women from between 12 and 16 weeks gestation until delivery, in reducing 
gestational age-adjusted and sex-adjusted birth weight centile of the baby. 




2.5.2. Secondary objectives 
• To determine the pattern of association between insulin resistance and adverse 
pregnancy outcomes, including incidence of pregnancy-induced hypertension, 
pre-eclampsia, caesarean section, postpartum haemorrhage, maternal weight gain 
during pregnancy, and incidence of the baby’s admission to the neonatal unit. 
• To determine the effect of metformin on maternal body composition 
• To determine the effect of metformin on neonatal body composition  
• To determine the effect of metformin on maternal inflammatory and metabolic 
variables (measured at 28 and 36 weeks’ gestation) and on neonatal 
inflammatory variables (measured in cord blood at birth). 
• To confirm that metformin does not increase the rate of babies with a low birth 
weight centile. 
• To determine the efficacy (as opposed to the effectiveness) of metformin when 
analysis is restricted to those with pharmacological circulating levels of drug. 
 
A series of nested sub-studies will also be performed with the following objectives 
• To determine the effect of metformin on maternal cortisol levels in obese 
pregnant women 
• To determine the effect of metformin on hepatic and peripheral insulin sensitivity 
at 36 weeks’ gestation in obese pregnant women 
• To determine the effect of metformin on endothelium-dependent flow-mediated 
dilatation in obese pregnant women 
• To determine the effect of metformin on maternal subcutaneous and visceral 
adipose tissue deposition and hepatic and skeletal muscle ectopic fat deposition 
during pregnancy 
• To determine the effect of metformin on fetal liver volume and subcutaneous fat 
deposition 
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• To determine the effect of metformin on myometrial contractility and myometrial 
glycogen storage in obese pregnant women 
• To determine the effect of metformin on placental glucocorticoid receptor and 
11HSD 1 and 2 mRNA levels. 
 
2.6. Centre(s) 
Seventeen hospitals in the UK. 
 
2.7. Design 
The design is a double-masked randomised placebo-controlled trial, with embedded 
sub-studies to explore mechanism of action of metformin, in a population of ~400 
obese pregnant women (Figure 1). 
  





Figure 1 Flow chart of participants in the EMPOWaR trial 
  




2.8. Inclusion and exclusion criteria 
2.8.1. Screening phase inclusion criteria 
• Caucasian obese (BMI >30 kg/m2) pregnant women between 12+0 and 16+0 
weeks’ gestation; 
• Age greater than or equal to 16 years; 
• Signed informed consent form. 
 
2.8.2. Screening phase exclusion criteria 
• Non-Caucasian; 
• BMI < 30 kg/m2; 
• Gestation > 16+0 weeks; 
• Pre-existing diabetes; 
• Gestational diabetes in a previous pregnancy; 
• Systemic disease at the time of trial entry, with the disease either requiring 
regular medication or having required treatment with systemic steroids in the past 
3 months; 
• Previous delivery of a baby < 3rd centile by weight; 
• Previous pregnancy complicated by pre-eclampsia prompting delivery before 32 
weeks’ gestation; 
• Known sensitivity to metformin hydrochloride or any of the excipients; 
• Acute conditions at the time of trial entry with the potential to alter renal function 
such as dehydration sufficient to require intravenous infusion, severe infection, 
shock, intravascular administration of iodinated contrast agents; 
• Acute or chronic diseases which may cause tissue hypoxia such as cardiac or 
respiratory failure, recent myocardial infarction, hepatic insufficiency, acute 
alcohol intoxication, alcoholism; 
• Lactation; 
• Multiple pregnancy. 




2.8.3. Randomisation exclusion criteria following screening 
• Gestational diabetes mellitus (GDM) in index pregnancy (diagnosed with 75 g 
oral glucose tolerance test using WHO criteria, see Table 1). Participants are also 
excluded if glucose tolerance test is diagnostic of GDM based on the criteria used 
in the recruiting centre.  
• Known liver or renal failure or dysfunction at the time of trial entry tested prior 
to randomisation (defined as variable outwith the reference range shown in Table 
2). 
 
Time (hours) Blood glucose (mmol/L) 
0 > 7.0 
2 > 7.8 




Urea 2.5-6.6 mmol/L 
Creatinine < 85 mol/L 
Sodium 135-145 mmol/L 
Potassium 3.6-5.0 mmol/L 
Bilirubin 3-16 mol/L 
ALT 10-60 IU/l 
Table 2 Reference ranges for biochemical parameters used in the EMPOWaR protocol 




2.8.4. Ineligible and non-recruited participants 
No further information will be collected on women who are ineligible solely because 
of abnormalities in glucose tolerance, liver or renal function, other than the number 
of such women for inclusion in trial metrics. 
 
Telephone or face-to-face interviews will be carried out to explore the reasons for 
eligible women declining to participate. 
 
2.9. Methods 
We will recruit women attending maternity hospitals in the UK. Women who fulfil 
all the potential eligibility criteria and who express an interest in the study will be 
provided with the participant information sheet and given at least 24 hours to 
consider participation. They will then be asked to provide written informed consent. 
Following consent, participants will have screening blood tests including liver and 
renal function and a 75 g oral glucose tolerance test, to determine eligibility for 
randomisation. Participants will have demographics, medical history, height, weight 
and anthropometry measurements (waist, hips, mid-arm, mid-thigh circumference; 
tricep, bicep and subscapular skinfolds) recorded at this visit.  
 
2.9.1. Randomisation 
Eligible subjects will be randomly assigned to active treatment with metformin or an 
identical looking placebo. This will be documented in the patient’s paper case record 
and/or computer file to show the woman’s participation in the trial. 
 
Participants will be randomised via a web portal connected to a central 
randomisation facility based at the trial data centre, the Edinburgh Clinical Trials 
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Unit, University of Edinburgh. Baseline eligibility data will be required before 
randomisation. Participants will be randomised in a 1:1 ratio to metformin or 
placebo. Randomisation will be stratified by treatment centre and BMI 30-39 kg/m2 
versus >40 kg/m2. 
 
2.9.2. Concealment of allocation 
Randomising subjects to active or placebo tablets will achieve concealment of 
allocation. Placebo tablets will appear identical to active treatment, so that the 
participant is masked to treatment allocation. The outcomes will be measured by 
clinicians and investigators masked to treatment allocation. Masking will not be 
broken until after data entry is complete, the validity of the data is checked, all 
queries resolved, the patient populations agreed and the database locked. Any 
clinically indicated emergency unmasking will be recorded prospectively. 
 
2.9.3. Intervention 
Metformin tablets (or matched placebo) 500 mg administered from as soon as 
practicable after the point of randomisation (and certainly between 12 and 16 weeks’ 
gestation) until delivery of the baby. The dose regimen is as follows: week 1, 500 mg 
once daily; week 2, 500 mg twice a day; week 3, 500 mg three times a day; week 4, 
500 mg morning and lunchtime and 1000 mg in the evening; week five until delivery 
of the baby, 1000 mg in the morning and evening and 500 mg at lunchtime. All doses 
are taken with food and dose escalation should continue to either the maximum 
tolerable dose or 2500 mg, whichever is higher. 
 
2.9.4. Dose changes 
The local investigator or participant may alter the treatment regimen at his/her 
discretion, so long as the maximum daily dose does not exceed 2500 mg. Changes to 
the treatment dose will be recorded in the electronic case report form (eCRF) as soon 
as practicable. 




2.9.5. Other medications 
Alcohol is prohibited due the increased risk of lactic acidosis. Iodinated contrast 
agents may increase the risk of renal failure, hence, if they are required, metformin 
should be discontinued for at least 48 hours from immediately prior to contrast agent 
administration until after renal function has been re-evaluated and found to be 
normal. Clinicians prescribing glucocorticoids (systemic and local routes), 2-
adrenoreceptor agonists and ACE inhibitors should be aware that they might amplify 
or diminish the hypoglycaemic effect of metformin. 
 
2.9.6. Study assessments 
Following randomisation, study assessments for glucose tolerance testing and other 
tests will occur as detailed in Table 4 and Table 4.  





























Review inclusion and exclusion criteria, give 
patient information leaflet 
X         
Consent Form  X        
Demographics and medical history  X        
Height, weight and anthropometry  X    X   X 
Bloods for liver function/renal function/full lipid 
profile/CRP 
 X    X    
75g OGTT and stored sample for 
inflammatory and metabolic indices 
 X   X X    
Randomisation    X       
 Study Drug dispensed   X  X     
Unused Study Drug /packaging returned     X   X  
Review SAEs, complete side effect 
questionnaire, record complications 
   X X X X X  
Labour and delivery information including 
birthweight, mode of delivery, EBL 
       X  
Baby’s weight and anthropometry        X X 
Table 3 Summary of EMPOWaR study visits for all participants 
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Visit Number 1 2 3 4 5 6 7 8 9 
Gestation 10-16 weeks 10-16 weeks 12-16 weeks 
18-20 
weeks 





Saliva samples for cortisol measurements   X  X X    
Bodpod measurements  X (OR VISIT 3) X (OR VISIT 2)   X   X 
Hyperinsulinaemic euglycaemic clamp      X    
FMD   X   X    
MR scan     X X    
Cord blood & placenta biopsy        X  
Myometrium biopsy (if delivered by CS)        X  




Table 4 Summary of EMPOWaR study visits for participants enrolled in substudies
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Maternal anthropometric measurements recorded at baseline, 36 weeks’ gestation 
and 3 months postpartum, will include waist; hip; upper arm and thigh circumference 
and bicep, tricep and subscapular skinfold thickness. Neonatal anthropometric 
measurements recorded within 72 hours of birth and at 3 months of age will include 
head circumference, and tricep and subscapular skinfold thickness. Length and 
weight will be recorded in order to calculate ponderal index.  
 
Fasting maternal blood samples obtained at baseline, 28 and 36 weeks’ gestation will 
be stored for future analysis of inflammatory and metabolic indices, including (but 
not limited to) insulin, C reactive protein (CRP), interleukin (IL)-6, leptin, 
plasminogen activator inhibitor (PAI)1/PAI2 ratio, cortisol, lipids, and non-esterified 
fatty acids. Cord blood obtained at the time of delivery will also be taken for 
measurement of glucose and stored for future measurement of the inflammatory and 
metabolic indices listed previously. 
 
Women who develop gestational diabetes (according to site specific diagnostic 
criteria) should be given insulin whilst maintaining study treatment and blinding. 
 
Table 4 documents the timing of the nested sub-studies in which a subgroup of 
subjects will participate. A summary of these is given below. 
 
2.9.7. Saliva samples 
Diurnal cortisol levels will be measured in saliva samples collected at baseline, 28 
and 36 weeks’ gestation. Saliva will be collected in salivettes at bed-time and on 
waking. Samples will be stored at -80 C. Cortisol will be measured by enzyme-
linked immunosorbant assay (ELISA). Participants at all study sites will be invited to 
provide saliva samples. 
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2.9.8. Body composition 
Maternal fat mass will be measured using air displacement plethysmography (BOD 
POD®, www.lifemeasurement.com) at baseline, 36 weeks’ gestation and 3 months 
postpartum. Neonatal fat mass will be measured using the same technique (PEA 
POD®, www.lifemeasurement.com) within 72 hours of birth and at 3 months of age. 
Only participants at the Edinburgh site will be invited to take part in this substudy. 
 
2.9.9. Hyperinsulinaemic euglycaemic clamp 
A subgroup of women will undergo a hyperinsulinaemic euglycaemic clamp study at 
36 weeks’ gestation to characterise the relative effects of metformin on hepatic and 
peripheral insulin sensitivity. Only participants at the Edinburgh site will be invited 
to take part in this substudy. 
 
2.9.10. Flow mediated dilatation 
Endothelium-dependent flow-mediated dilatation will be measured in a subgroup of 
participants at baseline and again at 36 weeks’ gestation. Change in diameter of the 
brachial artery following a flow stimulus created by arterial occlusion will be 
measured using continuous two-dimensional grayscale ultrasound imaging. Only 
participants at the Edinburgh site will be invited to take part in this substudy. 
 
2.9.11. MRI and spectroscopy 
A subgroup of participants will be scanned at 28 and 36 weeks’ gestation using a 
Verio 3 Tesla MRI system. T1-weighted acquisitions will be used to measure 
maternal subcutaneous and visceral fat; fetal liver volume; and fetal subcutaneous 
fat. Images will be analysed using the software programme SliceOmatic. This 
programme uses knowledge-based image processing to label pixels as fat or non-fat 
components and the adipose tissue mass derived using a mathematical model. 
Hepatic and skeletal muscle lipid content will be measured using 1H-magnetic 
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resonance spectroscopy. Only participants at the Edinburgh site will be invited to 
take part in this substudy. 
 
2.9.12. Myometrial biopsies 
A biopsy of the lower segment myometrium will be obtained from consenting 
subjects who are delivered by caesarean section. The biopsies will be divided, with 
one portion placed in physiological saline for contractility studies and the other snap 
frozen for glycogen storage measurements. Participants at all study sites will be 
invited to consent to myometrial biopsy in the event of delivery by caesarean section. 
 
2.9.13. Participant compliance 
Compliance will be recorded in a treatment diary and by counting of unused tablets. 
Additionally, gas chromatography mass spectrometry will be used to analyse 
metformin levels in blood samples from participants in the third trimester. 
 
2.10. Outcomes  
2.10.1. Primary outcome 
Z-score corresponding to the gestational age-adjusted and sex-adjusted birth weight 
centiles of the baby. 
 
2.10.2. Secondary outcomes 
• Maternal insulin resistance at 36 weeks’ gestation, which will be correlated with 
adverse pregnancy outcomes. 
• Maternal anthropometry and body composition at 16 and 36 weeks’ gestation and 
3 months postpartum. 
• Baby anthropometry and body composition at birth and 3 months of age. 
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• Maternal inflammatory markers, lipid and fatty acid indices prior to commencing 
treatment and again at 28 and 36 weeks’ gestation including CRP, IL-6, leptin, 
lipid profile, non-esterified fatty acids, polyunsaturated fatty acids and 
PAI1/PAI2 ratio. 
• Neonatal CRP, glucose, insulin and other inflammatory and metabolic indices as 
previously described  (measured in cord blood at birth). 
• Incidence of low birth weight centile. 
• Gas chromatography mass spectrometry measurement of metformin in maternal 
plasma to determine adherence. 
Secondary outcomes from nested sub-studies; 
• Maternal salivary cortisol levels at baseline, 28 and 36 weeks’ gestation. 
• Hepatic and peripheral insulin sensitivity at 36 weeks’ gestation as measured by 
the hyperinsulinaemic euglycaemic clamp technique. 
• Maternal brachial artery endothelium flow-mediated dilatation measured at 16 
and 36 weeks’ gestation. 
• Maternal subcutaneous and visceral adipose tissue deposition and hepatic and 
skeletal muscle ectopic fat deposition assessed using MRI and magnetic 
resonance spectroscopy. 
• Fetal liver volume and fetal subcutaneous fat deposition assessed using MRI. 
• In vivo measurements of myometrial contractility on myometrial biopsies 
obtained at the time of caesarean section. 
• Placental glucocorticoid receptor and 11HSD 1 and 2 mRNA levels. 
 
2.11. Side effects and adverse events reporting  
Participants are instructed to contact their investigator at any time after consenting to 
randomisation if any symptoms develop. In the case of any events, the investigator 
will initiate the appropriate treatment according to their medical judgement. 
Participants with adverse events (AEs) present at their last visit will be followed up 
until resolution of the event. All AEs and serious adverse events (SAEs) that occur 
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after randomisation will be recorded in detail in the participant’s medical notes. 
SAEs occurring in the mother or baby from the time a participant is randomised until 
30 days after stopping taking study treatment or until 28 days after delivery 
(whichever is later) will be reported to the co-sponsors using the trial documentation. 
The standard definition of a serious adverse event will be used.103 For the purposes 
of this study the following events will not be considered SAEs: miscarriage; preterm 
labour; preterm prelabour spontaneous rupture of membranes; preterm delivery in the 
maternal interest; preterm delivery in the fetal interest; hospitalisation for pregnancy 
induced hypertension; hospitalisation for maternal discomfort; hospitalisation for 
rest; hospitalisation for observation or monitoring for which the woman is admitted 
for a period of less than 12 hours; delivery complications such as caesarean section 
or post partum haemorrhage; admission of the baby to the neonatal unit for a period 
of up to 14 days.  
 
2.12. Statistical analysis plan, including sample size and power calculations 
2.12.1. Birth weight centiles 
In a previous study, the mean (SD) birth weight in a cohort of obese women (mean 
BMI 34 kg/m2) was 4.0 (0.6) kg.104 We hypothesise that metformin will reduce mean 
birth weight by 0.2 kg, corresponding to a reduction in birth weight centile of 
0.33SD. We believe that this reduction is clinically relevant, but is a relatively 
conservative estimate of likely reduction in birth weight centile induced by 
metformin, given that mean birth weight in the study described above in a parallel 
non-obese cohort was 3.4 kg. A sample size of 143 in each group will have 80% 
power to detect a difference in mean birth weight centile of 0.33 SD (the difference 
between a placebo mean of 4.0 kg and a metformin mean of 3.8 kg) at the 5% 
significance level (2-sided) using a two group t-test; a sample size of 163 in each 
group will give the study 85% power to detect these differences. In practice we will 
recruit a larger sample size to allow loss to follow-up. 
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2.12.2. Type of analysis and statistical tests 
The primary analysis will be by intention to treat. Mean birth weight centile will be 
compared between the two groups using a two-sample t-test, but with the analysis 
stratified for the same factors as the randomisation. Correlations within the 
metformin and placebo groups will be used to determine associations between 
insulin resistance and adverse pregnancy outcomes. 
 
2.12.3. Interim analysis and stopping rules 
No formal interim analysis is planned (other than those requested by the Data 
monitoring Committee (DMC)). 
 
2.12.4. Committee oversights 
There is an independent Trial Steering Committee and an independent Data 
Monitoring Committee to oversee the safety of the participants in the trial. 
 
2.13. Discussion 
Despite recognition that obesity represents a major public health problem, and that 
adult obesity may have its origins before birth, there is a lack of any effective 
intervention for obese pregnant women to improve pregnancy outcomes and reduce 
the future life risk of obesity for their offspring. In light of convincing evidence that 
the harmful effects of obesity during pregnancy are related to hyperglycaemia or 
insulin resistance, treatment during pregnancy with metformin is an exciting 
potential therapy. The Efficacy of Metformin in Pregnant Obese Women, a 
Randomised controlled (EMPOWaR) trial is designed to establish whether 
improving insulin sensitivity in pregnancy mitigates some of the adverse risk 
associated with obesity, with the primary aim of examining the effect on the birth 
weight of the baby, using birth weight as a surrogate marker of future life risk of 
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obesity. A series of embedded mechanistic studies will help us to understand more 
about the mechanism of effect of metformin.  
 
If our study finds metformin to be beneficial in reducing excess birth weight in obese 
pregnant women, it presents a potential future therapy where none currently exist. 
Clearly further large studies will be required to corroborate our findings. To our 
knowledge there is currently only one other randomised double-masked placebo-
controlled trial in progress which aims to recruit 850 women with a BMI >35 kg/m2 
and is due to complete in September 2014 (Shehata, 
http://clinicaltrials.gov/show/NCT01273584).  
 
As for any drug trial in pregnant women, safety is clearly a priority. Metformin has 
been used for decades in pregnant women with no evidence of any teratogenic 
effects. We do not expect any adverse effects from teratogenicity in our study 
population. There is no evidence from previous studies that metformin increases the 
incidence of babies with a low birth weight centile and we hope to confirm this with 
our data. Longer-term follow-up studies of the offspring will be needed to assess the 
benefits or adverse effects in later life of antenatal exposure to metformin. 
 
Finally, metformin is an inexpensive drug, costing under £5 per month. Obesity and 
the associated maternal and fetal complications are a huge financial burden on health 
services105. If metformin were found to be effective, its use could contribute to 
significant financial savings for health services.  
 
 
The subsequent chapters of this thesis will describe the findings of this trial as 
described. The results of the primary outcome and the main secondary outcomes are 
reported in Chapter 3. The results of the mechanistic substudies performed by the 
candidate (the HEC study, the MRI studies and the FMD study) are described in 
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Chapters 4, 5 and 6. A full report of all the methods and results, including the other 
substudies, described in this protocol is provided in the NIHR report, included as an 
appendix to this thesis. 
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3. Chapter 3 Effect of metformin on maternal and fetal 
outcomes in obese pregnant women (EMPOWaR): a 
randomised, double-blind, placebo-controlled trial 
 
The work in this chapter has been published in the Lancet Diabetes and 
Endocrinology 
Chiswick C, Reynolds RM, Denison FC, et al. Effect of metformin on maternal and 
fetal outcomes in obese pregnant women (EMPOWaR): a randomised, double-blind, 
placebo-controlled trial. Lancet Diabetes Endocrinol 2015;3:778-86 
 
3.1. Background 
The adverse effects of maternal obesity on short-term pregnancy complications 
include pre-eclampsia9, caesarean section, longer maternal and neonatal hospital 
stay, maternal haemorrhage, infant mortality106 and stillbirth94. Maternal obesity 
during pregnancy is also associated with higher birthweight and neonatal fat mass94, 
107. 
 
Accumulating data suggest that maternal obesity might predispose offspring to later 
life obesity, with high birthweight being a marker for increased risk. Correlations 
between high birthweight and adult obesity have been reported in large 
epidemiological studies15, 16, a systematic review17 and a validated prediction 
model108. The rapid rise in the prevalence of both high birthweight36 and maternal 
obesity mean that their links with later life obesity are a major concern. Indeed, in a 
recent record linkage study18, we showed that maternal obesity was associated with a 
35% increase in the hazard of all cause offspring mortality in adulthood, even after 
adjustment for confounders. As such, an effective intervention applied during 
pregnancy could have a major effect on interruption of the cycle of maternal obesity 
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and offspring obesity and ill health, thus helping to reverse the upward secular trend 
in obesity prevalence.  
 
Much evidence implicates insulin resistance (i.e. when a defined concentration of 
insulin does not effect a predictable metabolic response) and hyperglycaemia as the 
mechanism by which maternal obesity causes excessive neonatal birthweight. Obese 
pregnant women are significantly more insulin resistant and hyperglycaemic than are 
pregnant women of a normal weight62 and several large studies including the 
Camden study109 and the HAPO study60 show a positive association between high 
glucose concentrations and macrosomia, even at glucose concentrations regarded as 
normal during pregnancy.  Additionally, a Cochrane review protocol110 has outlined 
additional potential benefits on mother and baby of metformin in obese pregnant 
women.  
 
In view of these findings, we did this EMPOWaR study111 to test the hypothesis that 
the insulin sensitising drug metformin would reduce birthweight when given to obese 
women during pregnancy. On the basis of findings form other epidemiological 
studies15, 16, 84 a reduction in birthweight would be expected to result in a reduction in 
future life risk of obesity and metabolic syndrome in the offspring. 
  




3.2.1. Study design and participants 
We did this randomised, double-blind, placebo-controlled trial in antenatal clinics at 
15 National Health Service (NHS) hospitals in the UK. Eligible women were aged 16 
years or older, had a BMI of 30 kg/m. or more, and were between 12 and 16 weeks’ 
gestation. We excluded non-white women and those with: pre-existing diabetes; 
gestational diabetes in a previous pregnancy; gestational diabetes diagnosed in the 
index pregnancy before randomisation; systemic disease at the time of trial entry 
(requiring either regular drugs or treatment with systemic corticosteroids in the past 3 
months); previous delivery of a baby smaller than the 3rd percentile for weight; 
previous pregnancy with pre-eclampsia prompting delivery before 32 weeks’ 
gestation; known hypersensitivity to metformin hydrochloride or any of the 
excipients; known liver failure; known renal failure; acute disorders at the time of 
trial entry with the potential to change renal function, such as dehydration sufficient 
to require intravenous infusion, severe infection, shock, intravascular administration 
of iodinated contrast agents, or acute or chronic diseases that might cause tissue 
hypoxia (e.g. cardiac or respiratory failure, recent myocardial infarction, hepatic 
insufficiency, acute alcohol intoxication, or alcoholism); lactating women; and 
women with multiple pregnancy.  
 
The study was approved by the Scotland A research ethics committee (reference 
number 10/MRE00/12) and the Medicines and Healthcare products Regulatory 
Agency (EudraCT number 2009-017134-47). All participants provided written 
information consent. The protocol has been published elsewhere111 and is available 
online. 
 
3.2.2. Randomisation and masking 
We randomly assigned participants (1:1), via a web-based computer-generated block 
randomisation procedure (block size of two to four), to receive metformin or 
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placebo. Randomisation was stratified by study site and BMI band (30–39 vs ≥40 
kg/m.). Participants, caregivers, and study personnel were masked to treatment 
assignment. Members of the independent Data Monitoring Committee had access to 
unmasked data reports, but had no contact with study participants. 
 
3.2.3. Procedures 
Demographics, medical history, and maternal anthropometry were recorded at 
baseline. A formal 75 g oral glucose tolerance test was done in addition to screening 
for liver and renal function. We excluded participants with impaired renal function 
(urea >6.6 mmol/L, creatinine >85 μmol/L, sodium >145 mmol/L, potassium >5.0 
mmol/L), or liver function (bilirubin >16 μmol/L, alanine transferase >60 IU/l), or 
with abnormal lactate (according to local laboratory reference range) or gestational 
diabetes defined by WHO criteria (fasting glucose ≥7.0 mmol/L and 2 h glucose ≥7.8 
mmol/L), or any other local hospital criteria (e.g. International Association of 
Diabetes and Pregnancy Study Groups [IADPSG]112). 
 
Participants received oral metformin 500 mg or matched placebo tablets, in a dose of 
up to five tablets daily in two to three divided doses. Treatment was initiated at 12–
16 weeks’ gestation and continued until delivery of the baby. Treatment started at 
one 500 mg tablet once a day at week 1, and escalated by one tablet a day each week 
over 5 weeks, to reach either the maximum tolerable dose or the maximum permitted 
dose of 2500 mg, whichever was lower. In the case of side effects, participants were 
advised to reduce the current dose to that of the previous week, and wait for 1 week 
before increasing the dose again. The local investigator was allowed to change the 
treatment regimen at their discretion, as long as the maximum daily dose did not 
exceed 2500 mg in three divided doses. Participants were asked to keep a diary of 
drug intake and to bring all drugs to each study visit to monitor compliance. 
Randomised participants were reviewed face to face or by telephone at 18–20, 28, 
36, and 40 weeks’ gestation; around the time of delivery; and 3 months postnatally. 
Pregnancy complications were recorded and women were asked to complete a side-
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effect questionnaire at each review visit until delivery. Maternal anthropometry was 
repeated at 36 weeks’ gestation and 3 months postnatally. The glucose tolerance test 
was repeated at 28 and 36 weeks’ gestation, and blood was stored for measurement 
of inflammatory and metabolic indices. The protocol recommended that women who 
developed gestational diabetes should be given insulin whilst maintaining study 
treatment and blinding. The baby’s weight and anthropometry were recorded at 
delivery and at the 3-month postnatal visit. 
 
3.2.4. Outcomes 
The primary outcome was Z score corresponding to the gestational age, parity, and 
sex-standardised birthweight percentile of liveborn babies delivered at 24 or more 
weeks’ gestation. The main secondary outcome was maternal insulin resistance at 36 
weeks’ gestation. Other secondary outcomes included maternal fasting glucose and 
insulin and 2 h glucose at 36 weeks; maternal anthropometry and body composition; 
baby anthropometry and body composition; maternal inflammatory and metabolic 
outcomes at 36 weeks, including C-reactive protein (CRP), cholesterol, HDL, LDL, 
triglycerides, interleukin (IL)-6, leptin, serum cortisol, non-esterified fatty acids, and 
the ratio of plasminogen activator inhibitor 1 to 2; incidence of low birthweight 
percentile (<3rd and <10th); incidence of other adverse maternal and neonatal 
outcomes, including maternal symptoms; maternal plasma metformin concentration 
to explore tablet taking in the metformin group; and the maternal metabolic (fasting 
glucose and insulin and 2 h glucose) and inflammatory markers at 28 weeks. The 
methods for detection of the blood analytes have been described elsewhere.111 
Secondary mechanistic outcomes as outlined in the published protocol111 were 
obtained in a subset of participants and will be reported elsewhere. We made some 
changes to the protocol after recruitment began, but before generation of the 
statistical analysis plan, publication of the protocol111, and unmasking and analysis. 
Specifically, maternal insulin resistance at 36 weeks’ gestation was originally a co-
primary outcome, but was relegated to a secondary outcome when a substantial 
proportion of participants did not provide a blood sample at 36 weeks. Additionally, 
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we used patient self-reporting of tablet taking to establish treatment compliance and 
inform the per-protocol analysis. 
 
3.2.5. Statistical analysis 
We calculated that a sample size of 143 women in each group would provide 80% 
power, and a sample size of 163 women in each group would provide 85% power, to 
detect a difference in mean birthweight percentile of SD 0.33 (equivalent to the 
difference between a placebo mean of 4.0 kg and a metformin mean of 3.8 kg) at a 
two-sided 5% significance level with a two-group t test. We initially aimed to 
randomise 400 women based on anticipated high compliance and follow-up rates, but 
in a protocol amendment increased our sample size to 450 women when anecdotal 
evidence (without formal testing) suggested that compliance was lower than 
anticipated. We did our primary analysis in the modified intention-to-treat 
population. We also did per-protocol analyses, in which we compared outcomes 
amongst participants who were compliant with treatment. Compliance was 
determined before review of the data or unmasking. To measure compliance we 
calculated the number of weeks from randomisation to delivery for each woman; 
participants reporting (via their study diary) that they took at least one tablet on at 
least 4 days per week for at least half of those weeks were deemed to have been 
compliant. We did not use plasma metformin to measure compliance as no such 
measure of compliance could be done for placebo. We did exploratory analyses of 
secondary outcomes. No formal adjustment was made to any p values to allow for 
the large number of secondary endpoints analysed, and thus p values for secondary 
analyses need to be interpreted conservatively. We also did post-hoc analyses of 
safety outcomes of all reported serious adverse events and the combined adverse 
outcome of stillbirth, neonatal death, termination of pregnancy, or miscarriage. We 
derived birthweight percentiles and Z scores of birthweight percentiles (livebirths 
only) for each patient after adjustment for sex, gestational age, and parity 
(nulliparous vs multiparous) with population-derived charts113. We used a linear 
regression model adjusted for treatment centre and BMI band (30–39 vs ≥40 kg/m.) 
to compare Z scores between the groups and to obtain the adjusted mean difference 
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with 95% CI. This method was also used for other continuous outcomes including 
glucose and insulin and homeostatic model assessment of insulin resistance (HOMA-
IR). When necessary, we did log transformations to achieve normal distribution of 
data before statistical testing. For assessment of CRP concentration in the umbilical 
cord, we used Kruskal–Wallis one-way analysis of variance because this variable 
could not be transformed into a normal distribution. We used unadjusted logistic 
regression for binary outcomes and Fisher’s exact test when the event counts were 
small. Relevant denominators were either all participants randomised for whom 
information was available, or those having a livebirth for whom information was 
available. We did analyses with SAS (version number 9.3). A trial steering and a 
data and safety monitoring committee oversaw the study. The trial was registered, 
ISRCTN number 51279843. 
 
3.2.6. Role of the funding source 
The funder of the study had no role in study design, data collection, data analysis, 
data interpretation, or writing of the report. The corresponding author had full access 
to all the data in the study and had final responsibility for the decision to submit for 
publication. 
  





Between Feb 3, 2011, and Jan 16, 2014, inclusive, we randomly assigned 449 
participants to the placebo group (n=223) or the metformin group (n=226), of whom 
434 (97%) were included in the modified intention-to-treat analysis (Figure 2 ).  




Figure 2 EMPOWaR trial profile 
 
The most common reasons for non-participation were a concern that study drugs 
might be harmful to the baby, and low awareness about the adverse effects of obesity 
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on pregnancy outcome. Baseline demographics, medical history, and maternal 
anthropometry were similar between groups (Table 5). 




 Placebo Metformin 
 n=223 n=226 
Demographics and lifestyle (participant) Mean or number (n)1 SD or % Mean or number (n) SD or % 
Age (years)  28.9 5.1 28.7 5.8 
Currently smokes 31 13.9% 40 17.7% 
Currently drinks alcohol 9 4.0% 3 1.3% 
Illicit drug use 1 0.4% 0 0% 
Highest educational qualification  
 school for <  16 years 79 35.4% 75 33.1% 
school for > 16 years 144 64.6% 151 66.9% 
At least one previous pregnancy ≥12 weeks’ gestation 161 (220) 73.2% 147 65.0% 
Systolic blood pressure (mmHg) 119.4 10.4 117.6 10.8 
Diastolic blood pressure (mmHg) 68.9 7.3 68.0 7.8 
                                                 
1 For this table “n” is shown where it is different from the number at the top of the table 
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Gestation at baseline (days) 98.9 8.7 99.1 8.1 
 
Medical history (participant)  
Pre-eclampsia or pregnancy induced hypertension  7 3.1% 10 4.4% 
Pre- pregnancy hypertension requiring treatment 2 0.9% 1 0.4% 
Polycystic ovary syndrome 21 9.4% 28 12.4% 
Depression requiring treatment 71 31.8% 48 21.2% 
Anxiety requiring treatment 20 9.0% 15 6.6% 
Family history   
Cardiovascular disease 69 30.9% 71 31.4% 
Pre-eclampsia 22 9.9% 19 8.4% 
Diabetes 101 45.3% 99 43.8% 
Other 96 43.0% 109 48.2% 
 
Anthropometry   
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Height (cm)  165.1 5.9 165.5 5.9 
Weight (kg)  102.9 17.0 103.6 15.5 
BMI calculated (kg/m2)  37.7 5.6 37.8 4.9 
Waist (cm)  108.7  (222) 13.5 110.1 (225) 11.9 
Hip (cm)  126.4 (222) 12.1 127.4 (225) 11.8 
Mid arm (cm)  36.3 (220) 5.0 36.7 (221) 4.7 
Mid-thigh (cm)  64.1 (219) 7.7 64.2 (222) 6.9 
Tricep skinfold (mm)  31.2 (222) 9.7 31.9 (222) 10.8 
Bicep skinfold (mm)  25.7 (222) 10.0 27.4 (222) 10.9 
Subscap skinfold (mm)  32.0 (222) 12.2 32.6 (220) 11.8 
Maternal % fat2 46.8 (48) 5.6 48.2 (53) 5.2 
 
Blood tests recruitment visit (participant)  
Fasting glucose (mmol/L)  4.39 0.34 4.41 0.40 
                                                 
2 Measured only in Edinburgh participants 
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2 h glucose (mmol/L)3  5.50 1.09 5.20 1.08 
Fasting insulin (µIU/ml)  22.08 (189) 10.20  21.95 (188) 12.26 
HOMA-IR score4  4.36 (189)  2.16 4.36 (188) 2.76 
CRP (mg/L)  11.1 (221) 7.4 10.7 (223) 6.9 
Cholesterol (mmol/L)  4.87 (216) 1.15 4.88 (214) 1.09 
HDL (mmol/L)  1.67 (215) 0.39  1.64 (214) 0.38 
LDL (mmol/L)  2.91 (194) 0.78 2.89 (191) 0.86 
Triglycerides (mmol/L)  1.51 (216) 0.53 1.43 (214) 0.56 
IL-6 (mmol/L) 2.77 (189) 5.50 2.63 (188) 4.37 
Leptin (ng/ml)  93.6 (189) 42.1 98.5 (188) 40.3 
Serum cortisol (nmol/L) 396.4 (189) 143.6 431.0 (188) 178.8 
NEFA (mmol/L)  0.52 (189) 0.20 0.48 (188) 0.18 
PAI-1 to PAI-2 ratio  1.48 (131) 1.39 1.77 (128) 5.22 
 
                                                 
3 After a 75g oral glucose challenge 
4 Fasting glucose (in mmol/l) x insulin (in µIU/ml)/22.5 
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Putative father details  
Height (cm)  178.5 (204) 8.3 177.1 (202) 13.7 
Weight (kg)  92.3 (187) 22.5 93.5 (188) 25.8 
Ethnic origin       
   White 214  96.0% 210 (224) 93.8% 
   Mixed 4 1.8% 4 (224) 1.8% 
   Asian 0 0% 3 (224) 1.3% 
  Black 4 1.8% 6 (224) 2.7% 
  Chinese 0 0% 0 (224) 0% 
  Other 1 0.4% 1 (224) 0.4% 
Table 5 Baseline characteristics of EMPOWaR trial participants 
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From diary returns and analysis with predefined criteria, 118 (67%) of 177 women in 
the placebo group and 109 (65%) of 167 women in the metformin group were 
deemed compliant. Subsequent analysis of metformin concentrations showed that 
detectable concentrations were present in the blood of 80 (61%) of 131 women in the 
metformin group who gave a blood sample at 36 weeks’ gestation. To explore 
dosage, we identified the proportion of drug-taking days when 2500 mg or 2000 mg 
of study drug was taken. In the placebo group, for 56% of all possible tablet-taking 
days, the top dose of 2500 mg was taken, and for 68% of these days a dose of 2000 
mg or more was taken; the corresponding values in the metformin group were 38% 
and 62%, respectively.  
 
Mean birthweight at delivery was 3463 g (SD 660) in the placebo group and 3462 g 
(548) in the metformin group (Table 6). Mean birthweight percentile was high in 
both groups (table 2); the proportion of liveborn babies weighing more than the 90th 
percentile was similar between the placebo group and the metformin group (38 
[17%] of 220 and 31 [14%] of 214 babies, respectively). The primary outcome of Z 
score of birthweight percentile for babies liveborn at 24 weeks or more of gestation, 
standardised for sex, parity and gestation at delivery, was similar between the 
metformin and placebo groups, and the estimated effect size of metformin on the 
primary outcome was non-significant (Table 6). 
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 Placebo Metformin  
Primary outcome 
Mean (n) SD Mean (n) SD 
Adjusted mean 
difference 
95 % CI p-value 
Z score of birthweight percentile5  0.2680 (220) 1.0055  0.2464 (214) 1.0179 -0.029 -0.217, 0.158 0.76 
 
 Birth outcome (all births) 
Mean or number 
(n) 
SD or % 
Mean or number 
(n) 
SD or % OR6 95 % CI p-value 
Live birth at ≥ 24 weeks’ gestation 220 (222) 99.1% 214 (221) 96.8%    
Stillbirth at ≥ 24 weeks’ gestation, miscarriage or termination of 
pregnancy 
27 (222) 0.9% 78  (221) 3.2% 3.597 0.739, 17.504 0.11 
 
Birth outcome (liveborn babies at ≥ 24 weeks’ gestation)         
                                                 
5 Centile by gestational age, sex and parity for live births at ≥ 24 weeks gestation 
6 Post hoc analysis 
7 Two terminations of pregnancy, one for fetal abnormality (split hand and foot syndrome) and one following spontaneous membrane rupture at 18 weeks gestation. 
8 Of the two stillbirths, one was at 31 weeks of a baby with a known cardiac anomaly and severe hydrops, the other was an intrauterine death of a normally formed baby born at 38 weeks with a birthweight less 
than the 3rd centile for gestation. Of the four miscarriages, one occurred after a road traffic accident, the other three were spontaneous. One termination of pregnancy was performed after a diagnosis of trisomy 
21. None of the women returned diaries nor provided a blood sample for analysis of metformin. 
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Gestational age at delivery (days) 275.9 (220) 15.9  276.6 (214) 11.7     
Male sex 109 (220) 49.5% 109 (214) 50.9%     
Birthweight at delivery (g)  3463 (220) 660 3462 (214) 548     
Birthweight percentile  57.3 (220) 27.9 56.9 (214) 28.6     
Table 6 Primary and birth outcome of participants in EMPOWaR trial, intention to treat analysis.  
Data are presented as mean +/- SD or %.




We recorded no evidence of a reduction in the main secondary outcome of HOMA-
IR at 36 weeks’ gestation, nor any evidence of a clinically or statistically significant 
effect of metformin on fasting or 2 h glucose (after a 75 g oral glucose challenge) or 
fasting insulin at 36 weeks’ gestation (Table 7). By contrast, fasting glucose and 
HOMA-IR score at 28 weeks’ gestation was lower in women in the metformin group 
than in those in the placebo group (supplementary tables). Metformin had no 
significant effect on the anthropometric variables of maternal weight gain in 
pregnancy or neonatal ponderal index (Table 7). 
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 Placebo Metformin    
 
Mean (n) SD Mean (n) SD 
Adjusted mean 
difference/ratio 
95 % CI p-value 
Maternal biochemistry at 36 weeks gestation 
Fasting glucose (mmol/l)  4.42 (151) 0.48 4.35 (143) 0.45 -0.060 -0.163, 0.043 0.25 
2h glucose (mmol/l) 9  5.96 (148) 1.46 5.70 (142) 1.32 -0.251 -0.565, 0.062 0.12 
Fasting insulin (µIU/ml)  30.09 (131) 13.12 32.79 (127) 24.55 1.005 0.901, 1.120 0.93 
HOMA-IR score10   5.98 (131) 2.89 6.30 (123) 4.78 0.974 0.865, 1.097 0.67 
CRP (mg/L) 9.20 (150) 7.10 7.47 (140) 4.62 0.860 0.743, 0.996 0.04 
Cholesterol (mmol/L) 6.32 (144) 1.44 6.33 (139) 1.74 1.004 0.954, 1.056 0.88 
HDL (mmol/L) 1.70 (145) 0.38 1.76 (138) 0.43 0.051 -0.040, 0.142 0.27 
LDL (mmol/L) 3.57 (126) 1.13 3.77 (118) 1.25 1.064 0.982, 1.152 0.13 
Triglycerides (mmol/L) 2.79 (146) 0.84 2.76  (140) 0.88 0.993 0.926, 1.064 0.83 
IL-6 (mmol/L) 3.86 (131) 4.10 2.93 (127) 1.37 0.847 0.754, 0.952 0.01 
                                                 
9 After a 75g oral glucose challenge 
10 Fasting glucose (in mmol/l) x insulin (µIU/ml)/22.5  
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Leptin (ng/ml) 105.0 (131) 52.4 106.6 (127) 58.8 1.005 0.902, 1.120 0.93 
Serum cortisol (nmol/L) 821.7 (131) 232.9 867.0 (127) 225.5 1.062 0.999, 1.128 0.05 
NEFA (mmol/L) 0.47 (131) 0.18 0.46 (127) 0.19 0.947 0.859, 1.044 0.27 
PAI1/PAI2 ratio 3.20 (131) 2.61 2.97 (128) 2.79 0.913 0.771, 1.081 0.29 
Cord blood biochemical outcomes 
Glucose (mmol/l)  3.89 (79) 1.24 4.06 (74) 1.08 1.067 0.974, 1.170 0.16 
Insulin (µIU/ml)  10.95 (47) 7.49 11.41 (57) 8.80 1.060 0.767, 1.463 0.72 
HOMA-IR score10  1.92 (38) 1.39 1.91 (41) 2.00 1.012 0.701, 1.462 0.95 
CRP (mg/L) 11 4.32 (78) 19.55 2.36 (73) 2.29   0.74 
Anthropometric variables 
Maternal weight gain during pregnancy (kg) 7.23 (156) 4.91 6.70 (143) 6.00 -0.680 -1.863, 0.503 0.26 
Ponderal index (mass [g] / height3 [cm]) (live births only) 12 2.60 (143) 0.41 2.67 (130) 0.50 1.032 0.996, 1.069 0.08 
Table 7 Secondary outcomes of participants in EMPOWaR trial, intention to treat analysis.  
Data are presented as mean + SD. 
                                                 
11 Kruskal–Wallis non parametric test used 
12 Outliers outside +/- 6SD were removed, and data log-transformed for the statistical analysis, and results back transformed for this table. 
Note, all parameters with the exception of maternal glucose and HDL, and neonatal CRP were log-transformed for the statistical analysis, and converted back to original scale for this table 
 




Plasma IL-6 and CRP concentrations were both significantly lower in women given 
metformin, but no differences were shown in other biochemical outcomes (Table 7). 
Metformin did not seem to prevent gestational diabetes, as proportions of women 
fulfilling either IADSPG (Table 8) or WHO (data not shown) criteria for gestational 
diabetes at any time in pregnancy were similar between the two groups (Table 8). 
Furthermore, metformin did not delay the onset of gestational diabetes (IADPSG 
criteria): 26 women in the placebo group were diagnosed at 28 weeks’ gestation and 
ten women were diagnosed at 36 weeks compared with 11 women diagnosed at 28 
weeks and 15 women at 36 weeks in the metformin group (p=0.0718, Mantel-
Haenszel χ.; post-hoc analysis).  
 
Maternal symptoms of diarrhoea and vomiting were more common in women in the 
metformin group (Table 8). The incidence of other adverse outcomes, including 
preterm birth and low birthweight, caesarean section, and postpartum haemorrhage 
were similar in the two groups (Table 8). We recorded no adverse effects of 
metformin in post-hoc safety analyses comparing the proportion of women with a 
recordable serious adverse event between the two groups (Table 8). The increase in 
the combined adverse outcome of miscarriage, termination of pregnancy, stillbirth or 
neonatal death in women in the metformin group was not significant (Table 6). 
Admission to the neonatal unit was less common in the metformin group than the 
placebo group (Table 8). We noted no differences in outcomes at other time-points 
between the two groups (supplementary tables), with the exception of fasting glucose 
and HOMA-IR score, as mentioned above. 
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 Placebo Metformin    
 Number (n) % Number (n) % OR 95 % CI p-value 
Women or their babies with a recorded serious adverse event 41 (222) 18.5% 37 (225) 16.4% 0.869 0.533, 1.417 0.57 
Maternal delivery and postnatal  
Any caesarean section in index pregnancy 76 (222) 34.2%  65 (219) 29.7% 0.81113 0.543, 1.211 0.31 
Primary caesarean section 46 (222) 20.7% 42 (219) 19.2% 0.908 0.569, 1.449 0.69 
Postpartum haemorrhage > 1000ml 21 (216) 9.7% 20 (212) 9.4% 0.967 0.508, 1.842 0.92 
Preterm birth14 14 (220) 6.4% 18 (214) 8.4% 1.345 0.651, 2.777 0.47 
Development of gestational diabetes15 36 (153) 23.5% 26 (142)  18.3% 0.728 0.414, 1.283 0.27 
Pregnancy induced hypertension 14 (222) 6.3% 21 (221) 9.5% 1.56 0.772, 3.152 0.22 
Pre-eclampsia 3 (222) 1.4% 7 (221) 3.2% 2.39 0.61, 9.36 0.21 
Fetal and neonatal outcomes (live births only)  
Admission to the neonatal unit 29 (219) 13.2% 14 (213) 6.6% 0.46113 0.236, 0.899 0.02 
                                                 
13 Post hoc test 
14 Live births only; 4/14 preterm births in the placebo group and 3/18 in the metformin group were spontaneous preterm births following preterm labour. 
15 IADPSG criteria: Fasting glucose >= 5.1 mmol/l or 2hr glucose >= 8.5 mmol/l on either 28 and 36 weeks 
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Congenital anomaly 8 (217) 3.7% 7 (209) 3.3% 0.90513 0.322, 2.543 0.85 
Neonatal death in the delivery room 0 (220) 0% 0 (214) 0%    
Neonatal death at a later stage 2 (220) 0.91% 1 (214) 0.47%   1.00013 16 
Incidence of low birthweight <10th centile 11(220) 5.0% 14(214) 6.5% 1.330 0.590, 2.999 0.49 
Incidence of low birthweight <3rd centile 3 (220) 1.4% 3 (214) 1.4%   1.00016 
  
                                                 
16 Fisher’s Exact test reported 




 Placebo Metformin    
 n=198 n=199    
Maternal symptoms up to 36 week gestation 17 Number  % Number  % OR 95 % CI p-value 
Taste disturbance 32 16.2% 25 12.6% 0.745 0.424, 1.311 0.31 
Skin reactions 39 19.7% 36 18.1% 0.900 0.545, 1.489 0.68 
Abdominal pain 42 21.2% 49 24.6% 1.213 0.759, 1.940 0.42 
Flatulence 44 22.2% 51 25.6% 1.206 0.760, 1.915 0.43 
Constipation 57 28.8% 57 28.6% 0.993 0.643, 1.534 0.98 
Diarrhoea 37 18.7% 83 41.7% 3.113 1.975, 4.908 <0.0001 
Nausea 79 39.9% 97 48.7% 1.432 0.962, 2.132 0.078 
Vomiting 43 21.7% 63 31.7% 1.670 1.064, 2.621 0.03 
Headache 66 33.3% 65 32.7% 0.970 0.638, 1.474 0.89 
Table 8 Adverse outcomes of participants in EMPOWaR trial, intention to treat analysis.  
Data are presented as mean + SD.
                                                 
17 For all symptoms, categories are none/mild/moderate or severe. If a participant had any symptom mild, moderate or severe, at any time this is recorded as “yes”. 




Further analyses of the data on a per-protocol basis resulted in similar findings to the 
modified intention-to-treat analysis, with the exception of vomiting and CRP 
concentration, in which the direction of differences was maintained but the results 
were no longer significant (supplementary tables), and in 2 h glucose (estimated 
mean difference –0312 mmol/L, 95% CI –0.620 to –0.004; p=0.0471) and fasting 
insulin (6.04 pmol/L, 5.40–6.78; p=0.0173) at 28 weeks’ gestation, which were 
significantly lower in the metformin group than in the placebo group. 
  




To our knowledge, EMPOWaR is the first trial of a pharmacological intervention to 
reduce the risk of ill health in later life, using birthweight as a surrogate marker, in 
the off spring of obese pregnant women. By contrast with our original hypothesis, 
metformin given at a median dose of 2000 mg daily to obese and severely obese 
pregnant women (mean BMI 37.7 kg/m.) without diabetes, from 12–16 weeks’ 
gestation until delivery, had no effect on birthweight or neonatal or maternal 
anthropometry. On the basis of the study being powered to detect a clinically 
meaningful effect size, we conclude that this finding shows a true absence of effect 
of metformin on birthweight rather than a type 2 error. The absence of effect was 
apparent in both intention-to-treat and per-protocol analyses. We conclude that 
metformin does not have a role in reducing the birthweight of offspring of obese 
pregnant women.  
 
The strengths of this study are its multicenter randomised controlled design, making 
the study robust and generalisable, and that, despite women’s natural reluctance to 
take medication during pregnancy, we were able to recruit to our target sample size, 
generating adequate power to address our hypothesis.  
 
Further detail of the subjects who were not included in the final analysis is as 
follows: in the placebo group there were two terminations of pregnancy, one for fetal 
abnormality (split hand and foot syndrome) and one following spontaneous 
membrane rupture at 18 weeks’ gestation. In the metformin group, of the two 
stillbirths, one was at 31 weeks’ gestation of a baby with a known cardiac anomaly 
and severe hydrops, the other was an intrauterine death of a normally formed baby 
born at 38 weeks’ gestation with a birthweight less than the 3rd centile for gestation. 
Of the four miscarriages, one occurred after a road traffic accident, the other three 
were spontaneous. One termination of pregnancy was performed after a diagnosis of 
trisomy 21. Although there are significantly more ‘non analysed’ subjects in the 
active treatment group, none of these subjects fulfilled the eligibility criteria for 
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compliance and were therefore not included in the per-protocol analysis. This is 
reassuring from a treatment safety perspective. Additionally, there was no significant 
difference in the incidence of the combined adverse outcome of miscarriage, 
termination of pregnancy, stillbirth or neonatal death. 
 
The eligibility criteria for adherence with treatment was determined in advance of 
commencing the trial and stated in the pre-publication statistical analysis plan. 
Adherence was calculated as follows: the number of weeks that a patient was 
pregnant within the study period was calculated using the gestation at baseline and 
the gestation at delivery. This value was then halved and compared to the number of 
weeks recorded in the diary. If the patient had fewer weeks of diary entries than the 
total eligible weeks of gestation halved then she was deemed noncompliant. If a 
patient had equal or more weeks diary entries than halved total weeks, she needed to 
have taken at least one pill on at least four days to declare a compliant week. Finally 
to be treatment compliant the patient needed to have equal to or more than 50% of 
compliant weeks out of all the available weeks. This definition was felt to reflect 
what was likely to happen in clinical practice114 and thus ensure the results were 
generalisable to a real patient population. 
 
Although adherence to the intervention was lower than anticipated, this was balanced 
by the SD for birthweight also being lower. As such, the 95% CI for the primary 
comparison in both the intention-to-treat and per-protocol analyses both exclude the 
prespecified minimum clinically relevant effect size of 0.33. We conclude that the 
failure to detect a significant difference between the groups is a strong negative 
finding rather than a result of the trial being underpowered. 
 
We used a starting dose of metformin of 500mg, a maximum dose of 2500mg and up 
titrated by 500mg per week. In clinical practice, most clinicians up titrate more 
quickly. It is possible a different dosing regime may have produced a different result. 
However, a higher dose and faster up titration rate may have caused more side 
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effects and increased non-adherence rate or participant drop-out. The mean dose of 
2000mg in the active treatment group is comparable to that used in clinical practice 
and this is an effective dose for the treatment of GDM so is likely to have had its 
expected biological effect. 
 
Despite the lower than expected adherence, we believe that metformin still had its 
expected pharmacodynamic effects. Fasting glucose and insulin were lower in the 
metformin group than the placebo group at 28 weeks in the intention-to-treat 
analysis, and fasting and 2 h glucose, insulin, and HOMA-IR were all lower in the 
metformin group at 28 weeks in the per-protocol analysis. The subsequent lack of 
effect of metformin at 36 weeks is initially surprising, but might be a reflection of the 
changes in glucose homoeostasis throughout pregnancy in obese women. This is 
discussed further in Chapter 4 where insulin sensitivity is examined in detail in a 
subset of participants, using the hyperinsulinaemic euglycaemic clamp. 
 
The evaluation of the efficacy of metformin in preventing GDM was not an end point 
in our study. Our primary interest was in its efficacy as a preventer of excessive 
birthweight as this is a more clinically relevant end-point in terms of future life-risk 
to the child of developing obesity or metabolic syndrome. Post-hoc analysis of GDM 
diagnosis by two commonly used criteria (IADOSG and WHO) suggested a trend 
towards reducing risk of GDM and later development of GDM but this did not reach 
statistical significance. Studies using development of GDM as a primary outcome are 
subject to confounding, particularly multicenter studies, due to wide discrepancies in 
diagnostic criteria, types of test employed, gestation of testing, and clinical 
management of GDM. 
 
Although metformin had no effect on the primary outcome, the metformin-associated 
reduction in inflammatory markers CRP and IL-6 might be beneficial. These markers 
are found at higher concentrations in obese pregnant women than in pregnant women 
of a normal weight104 and have been associated with adverse outcomes such as 
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preterm birth and pre-eclampsia116, 117. Our findings are consistent with those in non-
pregnant individuals, in whom metformin reduces concentrations of CRP118 and 
(variably) IL-6119.  
 
Studies of other interventions aimed at reducing birthweight in obese pregnant 
women, including diet and lifestyle interventions66, 97, 115, have likewise shown no 
significant effects. Our data showing that metformin has no effect on birthweight in 
obese and severely obese pregnant women are in line with secondary outcome data 
from a smaller study of metformin in non-obese (mean 29.5 kg/m. [SD 7.0]) 
pregnant women with a history of polycystic ovary syndrome83. At the time of 
publication, we were aware of two other ongoing studies of the effect of metformin 
in obese pregnant women (Clinicaltrials.gov, number NCT01273584 and Australian 
New Zealand Clinical Trials registry, ACTRN 12612001277831). The Metformin in 
Obese Pregnancy study69 has subsequently been published. Despite some differences 
in their trial protocol (which are discussed further in Chapter 7), the authors did not 
demonstrate any difference in the primary outcome of birthweight centile. 
 
Absence of efficacy of metformin in reducing mean birthweight, despite lowering 
maternal glucose and insulin in mid-pregnancy, casts doubt on the 1952 Pedersen 
hypothesis120 that maternal hyperglycaemia drives fetal hyperglycaemia, and hence 
fetal hyperinsulinaemia and fetal overgrowth. Other investigators have hypothesised, 
by contrast with Pedersen, that excess maternal lipids might be as, or even more 
important than, excess maternal glucose in fetal fat accumulation, particularly in the 
presence of maternal obesity121. The present study provides the first experimental 
evidence that factors other than maternal glucose are important in fetal overgrowth, 
challenging conventional thinking about the factors linking maternal obesity and off 
spring macrosomia.  
 
Metformin might have a beneficial effect on future life risk of obesity and metabolic 
syndrome in offspring, even in the absence of an effect on birthweight percentile. In 
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an animal study122, prenatal metformin improved glucose tolerance, and reduced 
accumulation of body weight, and fat mass in adulthood of the off spring, despite 
having only marginal effects on birthweight. Additionally, in the Metformin in 
Gestational diabetes (MiG) study100, children of women randomised to the 
metformin group had lower visceral body fat at 2 years than did children of women 
randomised to insulin, despite similarities in birthweight. Further follow-up of babies 
born to mothers in the EMPOWaR trial is planned to explore this possibility and will 
identify longer-term outcomes on off spring of obese women given metformin in 
pregnancy. In the meantime, metformin should not be used to improve pregnancy 
outcomes in obese women. 
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3.5. Supplementary tables 
 Placebo Metformin    
 
Mean (n) SD Mean (n) SD 
Adjusted mean 
difference/ratio 
95 % CI p-value 
Fasting glucose (mmol/l)  4.49 (184) 0.47 4.38 (175) 0.41 -0.105 -0.193, -0.016 0.021 
2h glucose (mmol/l) 18 5.85 (184) 1.20 5.58 (174) 1.32 -0.250 -0.504, 0.005 0.055 
Fasting insulin (µIU/ml) 19 27.49 (154) 14.28 26.31 (144) 19.05 0.913 0.828,1.007 0.067 
HOMA-IR score20 5.56 (153) 3.30 5.23 (144) 4.17 0.895 0.803,0.998 0.047 
Supplementary table 1 Glucose, insulin and insulin resistance at 28 weeks’ gestation 
 
 36 Weeks 3 months Post-Partum 
 Placebo Metformin Placebo Metformin 
 Mean (n) SD Mean (n) SD Mean (n) SD Mean (n) SD 
Height (cm) 166.0 (153) 6.0 166.3 (142) 5.6 165.3 (125) 5.9 166.1 (127) 5.8 
BMI calculated 40.4 (153) 5.4 40.6 (141) 4.9 37.4 (124) 5.2 38.3 (124) 5.6 
                                                 
18 After a 75g oral glucose challenge 
19 This parameter was log-transformed for the statistical analysis, and results back transformed for this table  
20 Fasting glucose (in mmol/l) x insulin (µIU/ml)/22.5. This parameter was log-transformed for the statistical analysis, and results back transformed for this table 
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Waist (cm) 120.0 (155) 13.2 119.0 (142) 11.1 109.2 (124) 12.8 109.9 (125) 13.9 
Hip (cm) 130.1 (155) 12.3 131.3 (142) 11.8 127.3 (124) 12.2 128.6 (125) 13.4 
Mid arm (cm) 36.5 (154) 4.9 36.5 (142) 4.4 37.1 (123) 4.7 37.4 (125) 4.4 
Mid thigh (cm) 65.3 (154) 7.4 65.2 (139) 6.8 64.3 (122) 6.7 65.8 (124) 6.8 
Tricep skinfold (mm) 30.4 (155) 10.3 31.3 (143) 12.0 32.2 (123) 10.8 33.4 (125) 11.4 
Bicep skinfold (mm) 26.0 (155) 10.5 26.9 (143) 11.6 27.2 (123) 12.1 29.7 (125) 15.1 
Subscapular skinfold (mm) 32.7 (154) 13.5 34.5 (141) 13.9 33.2 (123) 13.1 35.9 (124) 13.2 
Maternal % fat 21 46.3 (31) 4.84 47.8 (30) 4.63 47.45 (29) 4.97 48.35 (30) 5.31 
Weight gain during pregnancy (kg) 22 7.23 (156) 4.91 6.70 (143) 6.00 -0.13 (124) 6.22 0.07 (124) 9.82 
Neonatal outcomes (live births only) At or shortly after birth At 3 months post partum 
 Placebo Metformin Placebo Metformin 
 Mean (n) SD Mean (n) SD Mean (n) SD Mean (n) SD 
Age at which measurements made (days) 1.04 (157) 2.44 0.97 (145) 2.44 99.59 (128) 13.12 97.72 (129) 14.01 
Length (cm)24 51.2 (150) 4.0 50..73 (139) 3.3 62.13 (124) 4.38 61.69 (125) 6.33 
                                                 
21 Measured only in Edinburgh participants 
22 Summary stats at week 36 are a repeat from Table 3, presented here for completeness. 
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Head circumference (cm) 34.7 (164) 4.2 34.8 (152) 3.6 41.30 (124) 2.87 41.02 (122) 4.42 
Ponderal index (mass [g] / height 3 [cm]) 23 24 2.60 (143) 0.41 2.67 (130) 0.50 2.58 (124) 0.82 2.52 (124) 1.00  
Tricep skinfold thickness (mm) 14.3 (111) 20.6 16.4 (99) 27.9 22.05 (106) 10.40 24.61 (104) 11.00 
Subscapular skinfold (mm) 13.5 (113) 20.4 15.7 (98) 28.0 17.00 (104) 23.95 23.11 (104) 31.33 
Baby % fat 25 12.1 (22) 5.7 12.9 (21) 4.5 25.88 (31) 6.13 23.19 (29) 5.91 
Weight at this time (g)24 26 3502.65 (163) 561.32 3455.18 (146) 545.08 6085.04 (128) 1276.59 5971.97 (132) 1724.20 
Supplementary table 2 Maternal anthropometry at 36 weeks’ gestation and 3 months postpartum 
 
 Placebo Metformin   
 Mean (n) SD Mean (n) SD     
CRP (mg/L)  
 
10.65 (176) 7.41 9.78 (164) 6.54     
IL-6 (mmol/L)  2.73 (154) 2.16 2.38 (144) 1.19     
Leptin (ng/ml)  104.4 (154) 46.4 102.3 (144) 50.5     
                                                 
23 Summary stats at birth are a repeat from Table 3, presented here for completeness. 
24 Outliers outside +/- 6SD were removed. 
25 Measured only in Edinburgh participants 
26 Baby weight was recorded on two occasions – at birth by delivery team (figure used for z-score calculations) and then at time of taking research measurements by research team (this second figure is 
shown here and is used for calculation of ponderal index).  
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Serum cortisol (nmol/L)  716.5 (154) 230.8 777.2 (144) 252.8     
NEFA (mmol/L) 0.42 (154) 0.14 0.43 (144) 0.16     
Supplementary table 3 Metabolic and inflammatory markers at 28 weeks’ gestation 
 
 Placebo Metformin 
 n=118 n=109 
Demographics and lifestyle  Mean or number (n) SD or % Mean or number (n) SD or % 
Age (years)  29.6 5.0 29.8 5.6 
Currently smokes 13 11.0% 13 11.9% 
Currently drinks alcohol 6 5.1% 0 0% 
Illicit drug use 0 0% 0 0% 
Highest educational qualification  
 school < 16 years  37 31.4% 26 23.9% 
school >16 years 81 68.6% 83 76.1% 
At least one previous pregnancy ≥12 weeks gestation 87 73.7% 68 62.4% 
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Systolic blood pressure (mmHg) 119.3 11.2 117.1 11.3 
Diastolic blood pressure (mmHg) 69.0 7.7 68.5 7.9 
Gestation at baseline (days) 98.9. 9.0 100.0 7.9 
 
 
Medical history  
Pre-eclampsia or pregnancy induced hypertension  3 2.5% 6 5.5% 
Pre- pregnancy hypertension requiring treatment 1 0.8% 1 0.9% 
PCOS 14 11.9% 16 14.7% 
Depression requiring treatment 33 28.0% 24 22.0% 
Anxiety requiring treatment 7 5.9% 7 6.4% 
Family history   
Cardiovascular disease 41 34.7% 31 28.4% 
Pre-eclampsia 8 6.8% 4 3.7% 
Diabetes 54 45.8% 47 43.1% 
Other 58 49.2% 57 52.3% 
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Anthropometry   
Height (cm)  166.1 6.0 165.8 5.7 
Weight (kg)  103.7 17.0 104.0 15.2 
BMI calculated (kg/m2)  37.5 5.5 37.8 4.7 
Waist (cm)  108.3 12.6 108.6 11.2 
Hip (cm)  126.8 11.6 127.5 12.2 
Mid arm (cm)  36.6 4.7 37.1 4.4 
Mid-thigh (cm)  64.2 7.3 65.3 7.0 
Tricep skinfold (mm)  33.3 9.4 32.6 9.7 
Bicep skinfold (mm)  27.4 10.1 27.8 10.7 
Subscap skinfold (mm)  35.3 11.0 34.8 11.7 
Maternal % fat27 46.2 5.2 48.6 5.0 
 
Blood tests recruitment visit   
                                                 
27 Measured only in Edinburgh participants 
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Fasting glucose (mmol/L)  4.42 0.36 4.41 0.37 
2 h glucose (mmol/L)28  5.54 1.18 5.17 1.10 
Fasting insulin (µIU/ml)  22.96 (101) 10.46  21.92 (92) 8.99 
HOMA-IR score29  4.59 (101) 2.32 4.34 (92) 1.82 
CRP (mg/L)  11.4 7.9 10.0 6.3 
Cholesterol (mmol/L)  4.86 (117) 1.16 4.82 (108) 1.13 
HDL (mmol/L)  1.67 (117) 0.38 1.64 (108) 0.39 
LDL (mmol/L)  2.98 (106) 0.75 2.90 (101) 0.90 
Triglycerides (mmol/L)  1.51 (117) 0.54 1.45 (108) 0.58 
IL-6 (mmol/L) 2.30 (101) 1.12 2.03 (92) 1.11 
Leptin (ng/ml)  90.7 (118) 46.2 99.8 (109) 39.2 
Serum cortisol (nmol/L) 384.8 (101) 135.5 438.2 (92) 186.5 
NEFA (mmol/L)  0.54 (101) 0.20 0.47 (92) 0.16 
PAI-1 to PAI-2 ratio  1.55 (91) 1.6 2.16 (82) 6.49 
 
                                                 
28 After a 75g oral glucose challenge 
29 Fasting glucose (in mmol/l) x insulin (in µIU/ml)/22.5 
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Putative father details  
Height (cm)  178.5 7.8 177.9 13.2 
Weight (kg)  92.1 21.9 94.6 27.7 
Ethnic origin      
   White 114 96.6% 101 92.7% 
   Mixed 1 0.8% 2 1.8% 
   Asian 0 0% 2 1.8% 
  Black 2 1.7% 3 2.8% 
  Chinese 0 0% 0 0% 
  Other 1 0.8% 1 0.9% 
Supplementary table 4 Baseline characteristics (per-protocol analysis) 
 
 Placebo Metformin  
Primary outcome 
Mean (n) SD Mean (n) SD 
Adjusted mean 
difference 
95 % CI p-value 
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Z score of birthweight centile30   0.3130 (117) 0.9781 0.3604 (108) 1.0580 0.068 -0.188, 0.324 0.60 
 
 Birth outcome (all births) 
Mean or number 
(n) 
SD or % 
Mean or number 
(n) 
SD or % OR31 95 % CI p-value 
Live birth at ≥ 24 weeks gestation 117 (118) 99.2% 108 (108) 100%    
Stillbirth at ≥ 24 weeks gestation, miscarriage or termination of 
pregnancy 
1 (118) 0.8% 0 0% <0.001 <0.001, >999.999 0.96 
 
Birth outcome (liveborn babies at ≥ 24 weeks gestation)         
Gestational age at delivery (days) 277.6 (117) 12.7 276.6 (108) 11.5     
Male sex 58 (118) 49.2% 54 (108) 50%     
Birthweight at delivery (g)  3539.0 (117) 553.9 3503.6 (108) 562.8     
Birthweight percentile  58.527 (117) 27.7 59.894 (108) 28.3     
Supplementary table 5 Primary outcome (per-protocol analysis) 
 
 Placebo Metformin    
                                                 
30 Centile by gestational age, sex and parity for live births at ≥ 24 weeks gestation 
31 Post hoc analysis 
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Mean (n) SD Mean (n) SD 
Adjusted mean 
difference/ratio 
95 % CI p-value 
Maternal biochemistry at 36 weeks gestation 
Fasting glucose (mmol/l)  4.43(104) 0.51 4.34(93) 0.45 -0.091 -0.221, 0.040 0.17 
2h glucose (mmol/l) 32  6.04(103) 1.53 5.79(92) 1.34 -0.248 -0.643, 0.148 0.22 
Fasting insulin (µIU/ml)  31.89(88) 13.40 32.59(79) 26.07 0.939 0.819, 1.075 0.36 
HOMA-IR score33   6.36(88) 2.96 6.22(77) 4.90 0.912 0.784, 1.060 0.23 
CRP (mg/L) 8.91(104) 6.39 7.48(93) 4.58 0.901 0.760, 1.070 0.23 
Cholesterol (mmol/L) 6.29(100) 1.54 6.16(91) 1.88 0.974 0.913, 1.039 0.42 
HDL (mmol/L) 1.71(100) 0.37 1.76(91) 0.38 0.055 -0.046, 0.155 0.29 
LDL (mmol/L) 3.67(89) 1.09 3.71(80) 1.22 1.013 0.923, 1.113 0.78 
Triglycerides (mmol/L) 2.79(101) 0.90 2.84(92) 0.96 1.031 0.942, 1.127 0.51 
IL-6 (mmol/L) 3.66(88) 3.73 2.77(79) 1.26 0.858 0.745, 0.988 0.03 
Leptin (ng/ml)  103.80(88) 55.34 101.26(79) 47.02 1.007 0.886, 1.145 0.92 
Serum cortisol (nmol/L)  806.48(88) 225.00 888.39(79) 250.73 1.092 1.010, 1.181 0.03 
                                                 
32 After a 75g oral glucose challenge 
33 Fasting glucose (in mmol/l) x insulin (µIU/ml)/22.5  
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NEFA (mmol/L)  0.47(88) 0.19 0.48(79) 0.21 1.041 0.919, 1.179 0.52 
PAI1/PAI2 ratio 3.40(91) 2.65 3.31(82) 3.09 0.895 0.721, 1.113 0.32 
Cord blood biochemical outcomes 
Glucose (mmol/l)  3.94(62) 1.25 4.02(54) 1.05 1.062 0.955, 1.181 0.26 
Insulin (µIU/ml)  11.14(37) 7.48 12.04(45) 9.21 1.137 0.805, 1.607 0.46 
HOMA-IR score10  1.83(32) 1.36 1.93(30) 2.19 1.066 0.720, 1.579 0.74 
CRP (mg/L) 34 4.85(62) 21.89 2.15(53) 1.82   0.80 
Anthropometric variables 
Maternal weight gain during pregnancy (kg) 7.40(106) 4.56 6.85(93) 6.11 -0.339 -1.769, 1.091 0.64 
Ponderal index (mass [g] / height3 [cm]) (live births only) 35 2.64(90) 0.42 2.63(79) 0.46 1.004 0.961, 1.049 0.85 
Supplementary table 6 Secondary outcomes (per-protocol analysis) 
 
                                                 
34 Kruskal–Wallis non parametric test used 
35 Outliers outside +/- 6SD were removed, and data log-transformed for the statistical analysis, and results back transformed for this table. 
Note, all parameters with the exception of maternal glucose and HDL, and neonatal CRP were log-transformed for the statistical analysis, and converted back to original scale for this table 
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 Placebo Metformin    
 Number (n) % Number (n) % OR 95 % CI p-value 
Women or their babies with a recorded serious adverse event 22 (118) 18.6 14 (109) 12.8 0.643 0.311, 1.331 0.28 
Maternal delivery and postnatal  
Any caesarean section in index pregnancy 43 (118) 36.4 31 (108) 28.7 0.702 0.401, 1.230 0.26 
Primary caesarean section 25 (118) 21.2 22 (108) 20.4 0.952 0.500, 1.811 1.0000 
Postpartum haemorrhage > 1000ml 13 (118) 11.4 9 (109) 8.5 0.721 0.295, 1.763 0.51 
Preterm birth36 4 (117) 3.4 8 (108) 7.4 2.260 0.661, 7.732 0.24 
Development of gestational diabetes37 22 (104) 21.2 15 (92) 16.3 0.726 0.351, 1.501 0.39 
Pregnancy induced hypertension38 11 (118) 9.3% 11 (109) 10.1% 1.092 0.453, 2.631 0.84 
Pre-eclampsia38 3 (118) 2.5% 3 (109) 2.8%  1.085 0.214, 5.493 0.92 
Fetal and neonatal outcomes (live births only)  
Admission to the neonatal unit 13 (116) 11.2 8 (108) 7.4 0.634 0.252, 1.595 0.33 
Congenital anomaly 4 (115) 3.5 4 (107) 3.7 1.078 0.263, 4.421 0.92 
                                                 
36 Live births only; 4/14 preterm births in the placebo group and 3/18 in the metformin group were spontaneous preterm births following preterm labour. 
37 IADPSG criteria: Fasting glucose >= 5.1 mmol/l or 2hr glucose >= 8.5 mmol/l on either 28 and 36 weeks 
38As defined by the local investigator 
 
     82 
Neonatal death in the delivery room 0 (117) 0 0 (108) 0    
Neonatal death at a later stage 0 (117) 0 0 (108) 0    
Incidence of low birthweight <10th centile 6 (117) 5.1 6 (108) 5.6 1.088 0.340, 3.482 0.89 
Incidence of low birthweight <3rd centile39 1 (117) 0.9 1 (108) 0.9   1.0000 
  
                                                 
39 Fisher’s exact test reported 
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 Placebo Metformin    
 n=118 n=109    
Maternal symptoms up to 36 week gestation 40       p-value 
Taste disturbance 20 16.9 17 15.6 0.905 0.447, 1.835 0.78 
Skin reactions 23 19.5 21 19.3 0.986 0.510, 1.905 0.97 
Abdominal pain 26 22.0 32 29.4 1.471 0.807, 2.678 0.21 
Flatulence 28  23.7 38 34.9 1.720 0.964, 3.069 0.07 
Constipation 38 32.2 37 33.9 1.082 0.622, 1.882 0.78 
Diarrhoea 24 20.3 60 55.0 4.896 2.669, 8.617 <0.0001 
Nausea 46 39.0 49 45.0 1.278 0.754, 2.168 0.36 
Vomiting 24 20.3 34 31.2 1.775 0.970, 3.249 0.06 
Headache 40 33.4 37 33.9 1.002 0.578, 1.737 0.99 
Supplementary table 7 Adverse outcomes (per-protocol analysis)
                                                 
40 For all symptoms, categories are none/mild/moderate or severe. If a participant had any symptom mild, moderate or severe, at any time this is recorded as “yes”. 
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4. Chapter 4 Assessment of whole body insulin sensitivity 
and lipolysis 
4.1. Background 
Normal pregnancy is associated with marked changes in insulin sensitivity, glucose 
homeostasis and lipid and protein metabolism. In early pregnancy, fasting glucose 
decreases by 0.11mmol/L with little further decrease by the end of pregnancy123. 
Insulin secretion increases but insulin sensitivity remains unchanged124, 125. This 
promotes lipogenesis to prepare for the rising energy needs of pregnancy and also to 
allow lipid storage in preparation for the energy demands of lactation. Glucose 
tolerance is normal at this stage, as is peripheral insulin sensitivity and hepatic basal 
glucose production125-127. By mid-pregnancy, despite the increase in insulin 
secretion, basal hepatic glucose production also increases, as does total 
gluconeogenesis to meet the increasing demands of the feto-placental unit128-130. By 
late gestation, peripheral insulin sensitivity is markedly decreased such that insulin is 
unable to suppress lipolysis allowing an increase in free fatty acids and therefore 
more energy available for gluconeogenesis131. Overall, the insulin sensitivity of late 
pregnancy is reduced by 50-70% compared to the non-pregnant state. These 
mechanisms are important to ensure a ready supply of energy substrates for the 
developing fetus. 
 
In obese pregnant individuals, these mechanisms are disordered. Obesity is 
associated with a state of diminished insulin sensitivity and so obese women enter 
pregnancy already resistant to insulin. The reduction in fasting glucose in very early 
pregnancy is diminished or absent123. By late gestation, a physiological reduction in 
peripheral insulin sensitivity by 15% has been demonstrated132. In addition, there is 
marked hepatic insulin resistance with reduced insulin-mediated glucose disposal 
and a reduction in insulin-stimulated suppression of endogenous glucose 
production133. Thus there may be an excess of free fatty acids and glucose, which are 
freely transferred across the placenta and may potentially drive fetal overgrowth and 
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programming of later life insulin resistance. However, our own work134 has 
demonstrated differences between lean and severely obese pregnant women only at 
early and mid-gestation, with a convergence in degree of insulin resistance by late 
pregnancy. 
 
There are a variety of methods for assessing insulin sensitivity. The simplest and 
most basic involve measurement of fasting glucose and insulin. Indeed a single 
fasting glucose measurement of >7.0 mmol/L is diagnostic of diabetes135. A raised 
fasting insulin concentration is a feature of conditions associated with insulin 
resistance such as obesity, pre-diabetes and type 2 diabetes. Combining these two 
measures and using mathematical models can make a more accurate assessment of 
insulin resistance. Two commonly used methods are the Homeostasis Model 
Assessment of Insulin Resistance (HOMA-IR)136 and the Quantitative Insulin 
Sensitivity Check Index (QUICKI)137. 
 
HOMA-IR is calculated as follows: 
(Fasting glucose (mmol/L) x Fasting insulin (U/mL)) / 22.5 
 
QUICKI is calculated as follows: 
1 / (log(fasting insulin U/mL) + log(fasting glucose mg/dL)) 
 
Both of these methods show reasonable correlation with hyperinsulinaemic 
euglycaemic clamp (HEC) derived data with the major advantage of only requiring a 
single fasting blood sample. However, both methods assume that hepatic (fasting 
state) and peripheral (fed state) insulin resistance are equivalent. 
 
The oral glucose tolerance test (OGTT) is a widely used to tool to assess glucose 
tolerance and insulin sensitivity. It involves the ingestion of a 75 g oral glucose load 
with blood samples for glucose concentration being taken immediately prior to this 
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and then at intervals thereafter over a 2 - 3 hour period. This can be combined with 
the Matsuda index138 which includes measurements of insulin to give a more detailed 
measure of whole-body insulin sensitivity. It is calculated as follows: 
 
10 000/√([fasting glucose (mg/dL) x fasting insulin (U/mL)] x mean glucose 
(mg/dL) x mean insulin during OGTT (U/mL)] 
 
For more detailed evaluation of insulin action in the post-prandial setting, minimal 
modeling techniques can be used, such as the frequently sampled intravenous 
glucose tolerance test (FSIGTT). Multiple samples are collected for measurement of 
glucose and insulin a mathematical model used to calculate two end point 
parameters: an insulin sensitivity index and glucose effectiveness. 
 
The hyperinsulinaemic euglycaemic clamp is considered to be the gold standard 
technique. The basic principle of this technique is that in the fasting state, the rate of 
glucose production from the liver and kidneys is equal to the rate of utilisation, 
resulting in a relatively constant level of glucose in the blood. Insulin is then 
administered resulting in suppression of glucose production, stimulation of glucose 
uptake and consequently a fall in blood glucose. This fall in blood glucose is 
countered by an infusion of exogenous glucose. The rate of glucose infusion required 
to maintain blood glucose concentration at a specific level (usually 4.5 – 5.5 
mmol/L) is an estimate of the net effect of insulin on glucose production and 
utilisation. Therefore, insulin sensitive subjects will require higher rates of glucose 
infusion compared to insulin resistant subjects. The concomitant use of stable isotope 
tracers allows the study of specific metabolic pathways. In the work described in this 
thesis, we used 6,6-d2-glucose and 1,1,2,3,3-d5-glycerol to quantify endogenous 
glucose production and lipolysis.  
 
However, HEC is a reasonably invasive procedure, it is time consuming and 
expensive and therefore less suited to large study populations. In the EMPOWaR 
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study population as a whole, we used HOMA-IR as our measure of insulin 
resistance. In the mechanistic sub-study described in this chapter we used the 
hyperinsulinaemic euglycaemic clamp to assess the effect of metformin on whole 
body insulin sensitivity and lipolysis in a sub-group of women who were adherent to 
treatment. To our knowledge, this is the first study to have employed this technique 
to examine the effect of metformin in obese pregnant women in the context of a 
double-blind, randomised, placebo-controlled trial. The characteristics of women 
were similar to those of the EMPOWaR study overall. Importantly, those who had 
developed gestational diabetes were excluded.  
 
Although metformin is widely used in pregnant women, there are no data on its 
mechanism of action in this scenario, nor whether is alters the physiological insulin 
resistance of pregnancy.  
 
4.2.  Hypothesis and aims 
In this substudy we hypothesised that: 
• We could use the hyperinsulinaemic euglycaemic clamp, with concomitant 
use of stable isotope tracers, to measure hepatic and peripheral insulin 
sensitivity and lipolysis at 36 weeks’ gestation in obese pregnant women 
participating in the EMPOWaR study. 
• Participants taking metformin, compared to those taking placebo, would 
demonstrate enhanced insulin sensitivity. 
 
The aims of the substudy were to: 
Measure hepatic and peripheral insulin sensitivity and rates of lipolysis in obese 
pregnant women, taking either metformin or placebo, at 36 weeks’ gestation. 
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4.3. Methods 
4.3.1. Patient recruitment, inclusion and exclusion criteria 
We recruited a subset of women participating in the EMPOWaR trial. All women 
participating in the trial at the Edinburgh centre were invited to take part. Inclusion 
and exclusion criteria at baseline were the same as those for main trial (see Chapter 
2). Women who had developed gestational diabetes or taken corticosteroids during 
their pregnancy were excluded. 
 
4.3.2. Participant preparation 
Participants (n=21) attended the Clinical Research Facility at the Royal Infirmary, 
Edinburgh at 0800h following an overnight fast of 8-10 hours. Height and weight 
measurements were recorded and fat free mass was measured using air displacement 
plethysmography (Bod Pod, Cosmed, www.bodpod.com). A 45mm 17 gauge 
cannula with a three-tap for sample collection was inserted into the superficial vein 
in the dorsum of one hand and kept patent with a slow infusion of 0.9% saline. This 
hand was wrapped in an electric heated blanket to arterialise venous blood for 
sample collection. A second cannula was placed in the antecubital fossa vein of the 
contralateral arm for administration of the infusates. Baseline blood samples were 
obtained for determination of baseline tracer enrichment, fasting plasma glucose, 
insulin and non-esterified fatty acids (NEFA). 
 
4.3.3. Drug preparation and dosage calculations 
Soluble insulin (Actrapid®, Novo Nordisk) was prepared in 0.9% saline at a 
concentration of 0.3U/mL. Insulin was infused at 20mU/m2/min and 40mU/m2/min, 
according to body surface area (BSA) of the subject. BSA was calculated using the 
Mostellar formula: 
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𝐵𝑆𝐴 (𝑚2) = √
𝑤𝑒𝑖𝑔ℎ𝑡 (𝑘𝑔)𝑥 ℎ𝑒𝑖𝑔ℎ𝑡 (𝑚)
3600
  
The rate of infusions in mL/min of stock insulin solution was calculated as follows: 
𝑅𝑎𝑡𝑒 𝑚𝑙 𝑚𝑖𝑛⁄ =  




Stock solutions of the stable isotope tracers 1,1,2,3,3-2H5-glycerol and 6,6-
2H2-
glucose (Cambridge Isotope Laboratories, Inc., Andover, USA) were prepared by 
Alistair Millar and Clint Waight (Senior Radiopharmacists, Royal Infirmary of 
Edinburgh), using water as dilutent. D5-glycerol was provided at a concentration of 
40mg/mL and d2-glycose at a concentration of 350mg/mL. Both tracers were 
prepared on the day of the study as a single infusion in 300mL of 0.9% saline for 
infusion at a rate of 50ml/hour. The molar weight of d5-glycerol is 97g/mol and d2-
glucose is 182g/mol. D5-glycerol was prepared at a concentration of 
0.132mol/kg/ml to achieve a delivery rate of 6.6 mol/kg/hour; d2-glucose was 
prepared at a concentration of 0.44mol/kg/ml to achieve a delivery rate of 
22mol/kg/hour. Infusion was prepared as follows in the final volume of 300ml: 
d5-glycerol: 0.132mol/kg/ml = 12.8g/kg/ml = 3.84mg/kg in 300ml 
d2-glucose: 0.44mol/kg/ml = 80g/kg/ml = 24mg/kg in 300ml 
 
4.3.4. Clamp protocol 
A priming dose of d5-glycerol (1.6mol/kg) and d2-glucose (25mol/kg) was 
administered at time 0 minutes, followed by continuous infusion of the tracers as 
described above (6.6mol/kg/h d5-glycerol and 22mol/kg/h d2-glucose) for 5.5 
hours. During the first 90 minutes, tracers were infused alone. From 90-210 minutes, 
insulin was infused at a dose of 20mU/m2/min in order to suppress endogenous 
glucose production and lipolysis. From 210-330 minutes, the dose of insulin was 
increased to 40mU/m2/min (to stimulate glucose uptake). Four steady state blood 
samples were collected at 10 minute intervals at the end of three time periods as 
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follows: 60, 70, 80, and 90 minutes; 180, 190, 200, 210 minutes; and 300, 310, 320, 
330 minutes. Samples were placed on ice then centrifuged and stored at -80oC for 
analysis of glucose, glycerol and their isotopologues, insulin and NEFA. Following 
commencement of the insulin infusion at 90 minutes, whole blood glucose was 
checked every five minutes from the sampling cannula using a bedside machine 
(AccuCheck®, Roche, UK). Dextrose 5% was infused as required to maintain 
arterialised blood glucose between 4.5 and 5.5 mmol/L. Additional blood samples 
were obtained every 30 minutes using fluoride oxalate anticoagulant for formal 
enzymatic measurement of plasma glucose. A diagrammatic summary of the clamp 




Figure 3 Summary of clamp protocol 
 
4.3.5. Calculations 
Mean glucose disposal (M) under steady state conditions was calculated in mg per kg 
fat free mass per minute according to the volume of glucose infused in the last 30 
minutes of each steady state period. Whole body glucose disposal (WGD) is 
equivalent to M during the high-dose insulin phase of the clamp. An index of insulin 
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sensitivity, glucose disposal per unit plasma insulin (M/I), was calculated by dividing 
M by the mean insulin concentration (mU/L) during each steady state period. This 
allows correction for slight differences in achieved plasma insulin in each group. 
 
Rate of appearance (Ra) and rate of disappearance (Rd) of glucose and glycerol were 
calculated using Steele’s steady state equation: 
 
Ra = Rd = (F/TTR plasma tracer –F) 
 
where F is the infusion rate of tracer and TTR is the tracer:tracee ratio. 
 
Endogenous glucose production (EGP) was calculated by subtracting the variable 
glucose infusion rate from the calculated Ra glucose. Data from glucose infusion 
studies were corrected for background 13C enrichment. No exogenous unlabelled 
glycerol was infused and the abundance of other isotopic species within the tracer 
infusion is negligible therefore no such corrections were applied in calculation of Ra 
glycerol. 
 
4.3.6. Mass spectrometry analysis 
Stable isotope enrichment was measured using gas chromatography mass 
spectrometry (GCMS). Standard curves were prepared for concentrations of glucose, 
glycerol, d2-glucose and d5-glycerol in plasma with internal standards 13C6-glucose 
(Isotec; Dorset, UK), and butanetriol according to standard procedure139. Standard 
enrichment curves for glucose and glycerol with d2-glucose and d5-glycerol 
respectively, were also prepared. Samples and standards were prepared in acetonitrile 
(Sigma Aldrich, Dorset, UK), internal standards added and incubated for 20 minutes, 
extracts collected under vacuum, eluates dried and incubated with pyridine:acetate 
anhydride (200 l,1:1, v/v) before drying again, and reconstituted in 5% acetic 
anhydride in heptane. These were analysed on a Quantum Ultra GC-MS/MS, 
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operated via Xcalibur software (Version 3.0.63, ThermoFisher Scientific, Hemel 
Hempstead, UK) using a HP-Innowax column (30m x 0.32mm x 0.25 m; Agilent 
technologies Ltd., Stockport, UK). Monitored ions were the glycerol triacetate m/z 
217, d5-glycerol triacetate m/z 222, butanetriol triacetate m/z 231 (internal standard), 
glucose pentacetate m/z 287, d2-glucose pentacetate m/z 289, and 13C6-glucose 
pentacetate m/z 293 (internal standard). 
 
Adherence to treatment was determined by measurement of metformin in plasma 
using an Aria-TSQ Quantum LC-MS/MS liquid chromatography tandem mass 
spectrometer (ThermoFisher Scientific, Hemel Hempstead, UK). Metformin was 
extracted from plasma (100 L) using an SLE+ plate (Biotage, Ystrad Mynach, UK) 
following enrichment with d6-metformin (200 ng) as internal standard (IS). 
Calibration standards ranged from 0.5-1000 ng metformin. Analytes were eluted, 
reduced to dryness under nitrogen (400C) and reconstituted in water/acetonitrile (100 
L; 80:20 v/v)). Analysis was carried out by liquid chromatography tandem mass 
spectrometry (LC-MS/MS). Chromatographic separation was achieved using an Aria 
CTC autosampler and Allegros pump on an ACE Excel Super2C18 column (100x3 
mm; 2 m, HiChrom, UK) protected by a Kinetex KrudKatcher® (Phenomenex, 
UK) and detected on a TSQ Quantum Discovery triple quadrupole MS (Thermo 
Fisher Scientific, Hemel Hempstead, UK) operated by selective reaction monitoring 
in positive electrospray ionization mode (300oC, 3 kV). The mobile phase was 0.1 % 
formic acid (FA) in water (A), 0.1 % FA in acetonitrile (B) at a flow rate of 
0.2mL/min, 300C.  Gradient elution was achieved by increasing the percentage of 
acetonitrile from 20 to 90% over a 5 minute run time. Metformin and its isotopically 
labelled internal standard eluted at 2.1 minutes. Transitions monitored for were m/z 
130.1  60.1, 71.1 and m/z 136.2  60.1, 71.1 for metformin and IS, respectively. 
Linear regression analysis of calibration standards, calculated using peak area ratios 
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4.3.7. Laboratory analysis 
Glucose concentrations were measured by a hexokinase method (Abbot Architect 
platform, Illinois, USA). NEFA were measured by colorimetric methods (Wako 
Chemicals, Neuss, Germany). Serum samples for insulin were analysed by ELISA 
(Demeditec Diagnostics, Kiel, Germany). 
 
The candidate carried out the following tasks: participant recruitment, glucose 
tolerance testing, air displacement plethysmography measurements and all clamp 
studies. Sanjay Kothiya and Natalie Homer, Wellcome Trust Mass Spectrometry 
Core Facility, measured stable isotope enrichment and metformin enrichment 
respectively. Dr Ruth Andrew reviewed all of the mass spectrometry data and 
calculations. Serum insulin and NEFA were analysed by Linda Nicol (senior 
laboratory technician, QMRI). The clinical biochemistry laboratory at the Royal 
Infirmary of Edinburgh performed the plasma glucose measurements. 
 
4.3.8. Statistical analysis 
Data are expressed as mean + SEM unless otherwise stated. Comparisons were made 
between groups using unpaired Student’s t-test. HOMA-IR data were log 
transformed to achieve normal distribution and results back transformed for 
reporting. Glycerol steady state data could not be transformed into a normal 
distribution and were therefore compared using Mann Whitney test. Significance was 
set at p<0.05. No adjustment was made for multiple comparisons. GraphPad Prism 
software (version 6.0) was used for statistical analysis. All statistical analyses were 
carried out by the candidate. 
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4.4. Results 
Of the 119 participants randomised to the main trial in the Edinburgh site, 21 
remained eligible and willing to participate in this sub-study at 36 weeks’ gestation. 
In one participant, intravenous access failed during the procedure and could not be 
re-established and so data were not acquired. Hence data were obtained from 20 of 
the 21 subjects who attended for a clamp study. Clamp studies were performed blind 
to treatment allocation. End-of-study unblinding revealed final cohort numbers as 
follows; placebo group, n=11; metformin group, n=9. All participants (placebo and 
metformin groups) were compliant with their study medication by diary entries. One 
woman in the metformin group did not have detectable levels of metformin in her 
blood at 36 weeks’ gestation, and her data were therefore excluded from analysis. 
Hence the final sample size was 11 women in the placebo group and 8 women in the 
metformin group. This is summarised in Figure 4 . 
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Figure 4 Consort diagram of recruitment of HEC substudy participants 
 
Participant baseline characteristics are shown in Table 9. There were no obvious 
differences between those in the placebo and metformin groups and the 
characteristics of those in the substudy were similar to those in the EMPOWaR study 





87 consented to HEC sub-study at baseline visit 
21 attended for clamp study 
40 subsequently declined HEC study 
17 ineligible for HEC study 
- non-compliant with medication (16) 
- no longer pregnant (1) 
9 unable to contact 
141 subjects attended for EMPOWaR consent and 
screening visit in Edinburgh centre 
Data acquired for 20 subjects 
IV access failed and study abandoned (1) 
119 subjects randomised to participate in EMPOWaR 
 
Data analysed for 19 subjects 
Exclusions in metformin group when metformin levels undetectable (1)  
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 Placebo Metformin 
 Mean or n SD or % Mean or n SD or % 
 n=11 n=8 
Age (years) 29.6 3.6 32.6 3.7 
Nulliparity n=5 46% n=3 38% 
BMI at baseline 
(kg/m2) 
35.7 3.5 38.5 4.4 
Body fat % at time 
of clamp (%) 
46.2 5.3 49.1 3.9 
Gestation at time of 
clamp (days) 
256.9             2.1 257.3 3.4 
Table 9 Demographic characteristics of participants in HEC sub-study.  
Data are presented as mean + SD or %. 
 
4.4.1. Isotopic enrichments 
Isotopic enrichment of d2-glucose and d5-glycerol was achieved for both placebo 
and metformin groups during each steady state period, indicating technical success of 




Figure 5 D2-glucose and d5-glycerol enrichments during steady state.  
Data are presented as mean +/- SEM. 
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4.4.2. Clamped glucose, insulin, glycerol and NEFA 
Mean plasma glucose, insulin, glycerol and NEFA concentrations during each steady 
state period are shown in Figure 6 . Clamped glucose was similar in both the 
metformin and placebo groups (Table 10). Achieved plasma insulin concentrations 
were lower in the metformin group during both the low dose insulin and high dose 
insulin phases of the clamp (Table 10). The expected insulin-mediated suppressions 
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Figure 6 Clamped plasma glucose (A), insulin (B), NEFA (C) and glycerol (D) in placebo and 
metformin groups.  
Data are presented as mean +/- SEM. 
 
4.4.3. Endogenous glucose production and glucose disposal 
Whole body glucose disposal (WGD) was calculated in milligrams per kilogram fat 
free mass (mg/kgFFM) per minute at steady state during the high dose insulin phase 
of the clamp. WGD is an indirect measure of insulin sensitivity, where a greater 
glucose disposal rate implies greater insulin sensitivity. Glucose disposal per unit 
plasma insulin (M/I) was also calculated to correct for slight differences in achieved 
plasma insulin. M/I, but not WGD, was higher in the metformin treated group 
compared with the placebo group (difference between means 0.02 [95% CI 0.001 to 
































no insulin low dose insulin high dose insulin
Placebo


































no insulin low dose insulin high dose insulin
Placebo
 
     99 
0.03], p=0.04, and difference between means 0.78 [95% CI -0.12 to 1.67], p=0.08 
respectively) (Figure 7 ,Table 10). There was no significant difference in HOMA-IR 
scores between the two groups (difference between means -0.87 [95% CI -3.31 to 
1.57], p=0.46) ( 
Table 10).  
 
 
Figure 7 M/I ratios and whole body glucose disposal in placebo and metformin groups.  
Data are expressed as mean +/- SEM. *p<0.05. 
 
In the absence of insulin, the rate of disappearance of glucose (Rd) and endogenous 
glucose production (EGP) are equivalent. This steady state period represents fasting 
conditions. EGP was greater in the metformin treated group than in the placebo 
group in this phase of the clamp (difference between means 0.54 [95% CI 0.08 to 
1.00], p=0.02). During low dose insulin infusion, EGP was again higher in the 
metformin treated group (difference between means 0.43 [95% CI 0.02 to 0.84], 
p=0.04)(Figure 8 ,Table 10). There was no significant difference in the percentage 
suppression from basal EGP to EGP during low dose HEC between the two groups 
(difference between means 2.89 [95% CI -7.65 to 13.42], p=0.57). The rate of 
disappearance (Rd) of glucose was also significantly greater in the metformin group 
compared to the placebo group during the low dose insulin phase of the clamp 
(difference between means 0.36 [95% CI 0.22 to 1.18], p=0.007). At high dose 
insulin infusion, Rd was increased further but there was no significant difference 
between the treatment groups (difference between means 0.35 [95% CI -0.79 to 



















































Figure 8 Endogenous glucose production (EGP) and rate of disappearance (Rd) of glucose per 
kg fat-free mass following low dose and high dose insulin infusion in placebo and metformin 
groups.  
Data are presented as mean +/- SEM. *p<0.05 **p<0.01.  
 
4.4.4. Lipolysis 
Glycerol turnover (or Rd glycerol) per kilogram fat free mass is shown in Figure 9 . 
There was no difference in glycerol turnover between the metformin and placebo 
treated participants (no insulin difference between means 0.03 [95% CI -0.12 to 
0.18], p=0.67; low dose insulin difference between means 0.02 [95% CI -0.06 to 
0.10], p=0.64; high dose insulin difference between means -0.01 [95% CI -0.10 to 
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glycerol in both groups. High dose insulin resulted in no further suppression of Rd in 
either group. Participants taking metformin had lower circulating glycerol levels 
during the low dose insulin phase of the clamp but NEFA levels were similar 
between the two groups throughout the study (Table 10).  
 
 
Figure 9 Glycerol turnover per kg fat-free mass following low and high dose insulin infusion. 
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 Placebo (n=11) Metformin (n=8)     
 Mean SEM or IQR Mean SEM or IQR Mean/median 
difference 
95% CI p value Significance 
Fasting pre-insulin         
Glucose (mmol/L) 4.26 0.09 4.20 0.11 -0.05 -0.35 to 0.25 0.71  
Insulin (pmol/L) 217.40 25.76 192.10 21.83 -25.30 -100.4 to 49.77 0.49  
HOMA-IR 6.04 0.89 5.17 0.58 -0.87 -3.31 to 1.57 0.46  
NEFA (mmol/L) 0.58 0.07 0.52 0.05 -0.06 -0.25 to 0.13 0.52  
Glycerol (microm/L) 52.61 12.99 43.81 7.60 -8.81 -43.92 to 26.30 0.60  
         
During tracer infusion without insulin         
Glucose (mmol/L) 3.94 0.07 4.13 0.18 0.19 -0.17 to 0.56 0.28  
Insulin (pmol/L) 221.20 10.88 182.40 6.13 -38.80 -66.31 to -11.29 0.006 ** 
NEFA (mmol/L) 0.61 0.02 0.56 0.02 -0.05 -0.12 to 0.02 0.18  
Glycerol (microm/L) 34.43a 19.52-60.23b 21.37a 12.07-33.25b -13.06c 492d 0.05 *  
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EGP (mg/kgFFM/min) 3.14 0.15 3.68 0.14 0.54 0.08 to 1.00 0.02 * 
Rd glucose (mg/kgFFM/min) 3.14 0.15 3.68 0.14 0.54 0.08 to 1.00 0.02 * 
Ra glycerol (mg/kgFFM/min) 0.45 0.05 0.48 0.05 0.03 -0.12 to 0.18 0.67  
         
During low-dose insulin infusion         
Glucose (mmol/L) 4.61 0.03 4.49 0.07 -0.12 -0.27 to 0.02 0.10  
Insulin (pmol/L) 468.00 19.27 389.10 17.11 -78.85 -132.5 to -25.22 0.005 ** 
NEFA (mmol/L) 0.28 0.01 0.28 0.02 -0.001 -0.04 to 0.04 0.95  
Glycerol (microm/L) 15.78 a 6.25-28.18b 9.03 a 2.62-14.46b -6.75c 497d 0.03  *  
EGP (mg/kgFFM/min) 1.73 0.13 2.16 0.14 0.43 0.02 to 0.84 0.04 * 
Rd glucose (mg/kgFFM/min) 4.25 0.13 4.95 0.21 0.70 0.22 to 1.18 0.007 ** 
M value (mg/kgFFM/min) 2.73 0.08 3.05 0.16 0.32 -0.03 to 0.68 0.07  
Ra glycerol (mg/kgFFM/min) 0.31 0.02 0.32 0.03 0.02 -0.06 to 0.10 0.64  
         
During high-dose insulin infusion         
Glucose (mmol/L) 4.68 0.08 4.63 0.07 -0.06 -0.27 to 0.16 0.61  
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Insulin (pmol/L) 685.80 36.49 559.90 27.35 -126.0 -223.1 to -28.77 0.01 * 
NEFA (mmol/L) 0.12 0.01 0.13 0.01 0.02 -0.01 to 0.04 0.25  
Glycerol (microm/L) 14.49 a 0.23-26.33b 8.71 a 0.49-24.93b -5.78c 631d 0.44  
         
EGP (mg/kgFFM/min) 1.84 0.24 1.70 0.21 -0.14 -0.87 to 0.59 0.70  
Rd glucose (mg/kgFFM/min) 6.01 0.40 6.37 0.26 0.36 -0.79 to 1.50 0.52  
WGD or M value (mg/kgFFM/min) 4.51 0.21 5.29 0.41 0.78 -0.12 to 1.67 0.08  
M/Ie 0.05 0.01 0.07 0.01 0.02 0.001 to 0.03 0.04 * 
Ra glycerol (mg/kgFFM/min) 0.31 0.03 0.30 0.03 -0.007 -0.10 to 0.08 0.87  
 
aMedian, bInterquartile range, cMedian difference, dMann Whitney U, eM/I is an index of insulin sensitivity calculated by dividing M value 
(mg/kgFFM/min) by mean insulin concentration (mU/L) during that part of the clamp 
 
Table 10 Average concentrations of all analytes during steady state.  
Data are presented as mean +/- SEM or median +/- IQR. *p<0.05, **p<0.01. 
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4.5. Discussion 
We hypothesised that administration of metformin to obese pregnant women would 
increase hepatic and peripheral insulin sensitivity when measured in the third 
trimester. In support of this, we have shown that subjects taking metformin 
demonstrated greater insulin stimulated glucose disposal (M/I) and lower circulating 
levels of glycerol during high dose insulin infusion. These changes were not detected 
using HOMA-IR when measured in both the clamp participants and the larger 
EMPOWaR study population as a whole, where we found no difference in HOMA-
IR, glucose or insulin at 36 weeks’ gestation, either in the intention to treat analysis, 
or the per protocol analysis140. These data confirm that the HEC is a more sensitive 
measure of insulin resistance than HOMA-IR, at the end of pregnancy. 
 
Analysis for this mechanistic substudy included all participants in the placebo group 
but was restricted to subjects in the treatment group with detectable levels of 
metformin in their blood, as measured by mass spectrometry. Any detectable level of 
the drug was taken as being indicative of compliance rather than a specific range of 
metformin concentration, as this could have been variable depending on the 
individuals dosing regime and rate of metabolism. This meant that one subject in the 
active treatment groups was excluded from analysis, as there was no detectable level 
of metformin in her blood sample. According to her treatment diary entries, she was 
eligible for inclusion in the per protocol analysis. This perhaps highlights one of the 
limitations of using patient treatment diary entries as our measure of compliance. 
However, as there is no equivalent biological measure of placebo compliance, using 
diary entries is the most appropriate measure of compliance. 
 
In addition to greater insulin stimulated glucose disposal in the participants taking 
metformin, we observed enhanced rate of disappearance of glucose in the active 
treatment group, suggesting improved peripheral insulin sensitivity. However, 
endogenous glucose production was higher in the metformin treated subjects, 
suggesting that, if anything, those on metformin exhibit reduced ability to suppress 
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hepatic glucose production in response to insulin and enhanced glucose release on 
fasting. This is perhaps surprising given that metformin is though to exert its action 
principally via the liver, inhibiting gluconeogenesis and reducing hepatic glucose 
production141, though an effect mediated via peripheral glucose disposal has also 
been shown142, 143. More recently, metformin has been shown to stimulate 
endogenous glucose production in healthy fasting individuals who are not 
pregnant144 but its mechanism of action in pregnancy has, to our knowledge, never 
been fully assessed. We are aware of one other study that used the HEC to assess the 
effect of metformin in pregnant women with polycystic ovarian syndrome 
(PCOS)145, but there was no control ‘untreated’ group so the independent effects of 
metformin could not be determined. 
 
Our data suggest enhanced glucose flux in the metformin treated women, i.e. higher 
liver production and higher peripheral disposal of glucose. In normal pregnancy, 
insulin resistance increases by almost 50%, with most of this increase occurring in 
the third trimester126. This promotes maternal lipogenesis in preparation for 
breastfeeding and supports the rapid phase of fetal growth that occurs at this stage of 
pregnancy. A decline in peripheral insulin sensitivity (primarily as a consequence of 
placental lactogen) results in progressive shift from lipogenesis to lipolysis, with 
increased levels of free fatty acids and increased gluconeogenesis and hepatic 
glucose production146, with a corresponding increase in maternal insulin secretion. In 
obese women, there is pre-existing insulin resistance so the existing reduced 
peripheral insulin sensitivity is merely exacerbated by the pregnancy. Our clamp data 
suggest that metformin has had some effect on improving peripheral insulin 
sensitivity but the increased hepatic glucose production of late pregnancy is too 
overwhelming for there to be any net benefit.  
 
Interpretation of this is perhaps complicated by the presence of the feto-placental 
unit, which represents a significant proportion of the fat free mass at 36 weeks’ 
gestation, is a major consumer of maternal glucose at term147, 148, and may affect the 
validity of the HEC. Glucose uptake by the fetoplacental unit may act as a glucose 
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‘sink’ which could in turn lead to an overestimation of insulin sensitivity with an 
increased contribution of the fetoplacental unit to apparent maternal glucose 
disposal. It is not possible to measure the specific rate of glucose uptake by the fetus 
and placenta in vivo but data from a rat model suggest that placental glucose 
transport is not directly sensitive to maternal insulin concentrations149. With these 
limitations in mind, the HEC technique remains the gold standard method of 
assessment of insulin sensitivity in pregnant women. We assume the placenta itself 
does not produce glucose, although this is controversial with some studies suggesting 
it may produce a small amount150. Metformin does not appear to have a direct effect 
on placental glucose transport in an isolated placental cotyledon model151 but it does 
cross the placenta152, 153 and likely drives increased fetal insulin sensitivity and 
glucose uptake. Therefore, any potentially beneficial effects of metformin in limiting 
fetal weight gain by increased peripheral insulin sensitivity and glucose disposal in 
the mother, may be offset by the increased glucose flux, particularly across the 
placenta, which would have a growth promoting effect on the fetus. This balance 
may explain the lack of effect of metformin to prevent high birth weight in the main 
EMPOWaR trial140 and in another recently published trial also testing the effect of 
metformin in obese pregnant women69. 
 
In animal studies and other patient groups metformin treatment has been associated 
with a beneficial effect on circulating lipid profile154-157 although the mechanism of 
this effect remains incompletely understood. We found minimal effects of metformin 
on the lipolytic pathway, only that glycerol levels were lower in the metformin group 
during each phase of the clamp. Maximal suppression of lipolysis (around 70%) was 
achieved with low dose insulin in both treatment groups demonstrating equal 
sensitivity of the lipolytic pathway to insulin. There were no differences in glycerol 
disposal or NEFA levels between the metformin and placebo groups.  
 
Accurate assessment of glycerol by mass spectrometry is technically challenging and 
this is reflected by the wide variance in measurements obtained. The rate of 
appearance of glycerol (which should be equal to the rate of disappearance or 
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glycerol turnover under steady state conditions) should be a reasonably accurate 
measure of lipolysis as this is the only source of glycerol. However, the technical 
difficulties of the assay may have limited the validity of this assessment. An 
alternative means of assessing lipolysis is by measurement of rate of appearance of 
fatty acids but this requires the use of fatty acid tracers, which are complexed with 
albumin and not approved for use in pregnant women. 
 
Enhanced rates of lipolysis are thought to be increasingly important towards the end 
of normal pregnancy to provide maternal substrates for gluconeogenesis and 
triglyceride synthesis and spare glucose to facilitate normal fetal growth. Gestational 
hyperlipidaemia is exaggerated in obese women, compared to lean women158 and 
reaches a peak in the second trimester, earlier than in lean women. Obese women 
appear to demonstrate less metabolic flexibility in their response to pregnancy and, 
as with the glucose response, perhaps these changes are so profound by the third 
trimester we are not seeing any effect of metformin.  
 
Reduced third trimester lipolysis is associated with fetal growth restriction159 so 
these data are perhaps reassuring on the safety of metformin in pregnancy in terms of 
not increasing the risk of intrauterine growth restriction. Alternatively, the lack of 
effect of metformin on the lipolytic pathway may be an alternative explanation for 
the failure of its use as an agent to limit birthweight in obese women69, 140. 
 
We performed these clamp studies at the end of pregnancy, when we anticipated that 
insulin resistance would be at its most profound62, and any impact of an insulin 
sensitising agent would be greatest. In retrospect, this may be incorrect. In the full 
cohort of participants in the EMPOWaR study, both glucose and HOMA-IR were 
lower in the metformin group (compared to the placebo group) at 28 weeks’ 
gestation, hence clamp studies at this gestation may have been more informative, 
with more profound differences between the groups. In support of this, previous 
work by our group comparing lean and obese pregnant women showed higher insulin 
stimulated endogenous glucose production and lipolysis and lower glucose disposal 
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in obese compared with lean women at 19 weeks’ gestation, but not at 36 weeks’ 
gestation134. It may be that by the end of pregnancy, the physiological effects of 
pregnancy are dominant over differences that may be induced either pathologically 
by obesity or pharmacologically by metformin. 
 
In conclusion, these data confirm that metformin improves peripheral insulin 
sensitivity in obese pregnant women at 36 weeks’ gestation. However, this may be 
offset by increased insulin clearance, and increased hepatic glucose production and 
therefore glucose flux across the placenta, potentially explaining a lack of effect on 
limiting excess fetal growth. 
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5. Chapter 5 MRI assessment of maternal and fetal body 
composition 
 
5.1.  Background 
5.1.1. Maternal body composition 
Body mass index is the most commonly used measure of nutritional status in adults. 
BMI describes weight relative to height and is expressed in kg/m2. It is calculated 
using the following formula: 
 
BMI = weight (kg) / [height (m)]2 
 
The World Health Organising categorises BMI into six bands to classify nutritional 
status (Table 11). 
 
Nutritional status BMI (kg/m2) 
Underweight <18.5 
Normal weight 18.5 – 24.9 
Pre-obesity 25.0 - 29.9 
Obesity class I 30.0 – 34.9 
Obesity class II 35.0 – 40.0 
Obesity class III >40.0 
Table 11 WHO classification of BMI 
BMI is easily measured and simple to calculate which makes it a commonly used 
tool for large population data gathering and useful proxy for adiposity. However, a 
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major limitation is that it does not distinguish between fat and fat-free mass, and 
indeed other components of body weight. So, for example, it will overestimate 
adiposity in those with increased lean body mass such as athletes. It also does not 
account for distribution of body fat, and it is has long been evident that it is the site, 
rather than the total quantity of body fat that is important in determining associated 
risk of morbidity and insulin sensitivity160-163. 
 
More recently, it has also been recognised that deposition of lipid in ‘ectopic’ sites, 
namely the liver and skeletal muscle are major contributors to the development of 
insulin resistance164, 165. It remains unclear whether increasing adiposity causes the 
deterioration in insulin sensitivity or vice versa. The ‘portal hypothesis’ of obesity 
suggests an increase in central abdominal fat leads to elevated delivery of free fatty 
acids and inflammatory cytokines to the liver and consequently hepatic insulin 
resistance develops and drives glucose upwards166. The ‘spillover hypothesis’ 
suggests that in the context of obesity, the subcutaneous compartment becomes 
saturated and leads to the accumulation of visceral fat and deposition of lipid in 
ectopic sites such as the liver and muscle167. Clearly the two hypotheses are not 
mutually exclusive and it is likely both are contributory mechanisms. Regardless of 
the exact cause, there is no doubt that excess lipid accumulation is associated with 
impaired insulin sensitivity and morbidity such as type two diabetes. 
 
Fat distribution in normal and obese pregnancy and in pregnancy associated with 
diabetes is less well studied and the contribution it pays to maternal and fetal 
outcomes and longer-term health is not clear. However, gestational weight gain is 
one of the most important predictors of postpartum weight retention168 and thus 
contributes significantly to the obesity epidemic among young women169. Gestational 
weight gain, and its relative composition, is highly variable but in lean women the 
contribution from fat tends to be predominantly in the subcutaneous compartments, 
largely trunk and thigh170, 171. Obese women actually tend to gain less weight than 
lean women during pregnancy but the fat mass that they do gain tends to be more 
central and therefore potentially more metabolically harmful172. 
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5.1.2. Fetal body composition 
Gestational weight gain and pre-existing obesity also impact on fetal growth. 
Glucose is the major substrate that determines fat accumulation in the fetus, the 
greater the glucose supply the greater the deposition of fat173. There is a linear 
association between maternal glucose tolerance and neonatal adiposity at birth61 and 
a strong positive correlation between degree of maternal insulin resistance and 
neonatal fat mass at birth63. Increasing maternal BMI has also been show to be 
associated with increased intrahepatocellular lipid in the newborn, assessed by MR 
proton spectroscopy174.  
 
The conventional strategy for measurement of fetal growth is typically by ultrasound. 
Estimation of fetal weight is based on measurement of the fetal head circumference, 
femur length and abdominal circumference, with the abdominal circumference being 
the most individually sensitive predictor of fetal macrosomia175, 176. The abdominal 
circumference is predominantly affected by the size of the fetal liver and is positively 
correlated with hepatic glycogen stores, which increase towards term177, 178.  
 
Trans-abdominal ultrasound is undoubtedly more difficult to perform and less 
accurate in obese subjects179. The adipose tissue layer, by absorbing the associated 
energy, attenuates the ultrasound signal. To improve depth of penetration of the 
ultrasound signal, a lower frequency probe is required but this sacrifices image 
quality. 
 
5.1.3. Magnetic resonance imaging and spectroscopy 
Magnetic resonance imaging is a technique that employs the properties of atomic 
nuclei within a strong magnetic field to create images. It is an excellent imaging 
modality for producing high-resolution images of soft tissues enabling distinction to 
be made easily between different tissue types. Image quality is not affected by the 
body habitus of the individual being scanned. Additionally, it does not involve the 
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use of ionising radiation, thus making it a suitable imaging modality for scanning 
pregnant women. 
 
Magnetic resonance spectroscopy is an additional analytical tool, which can be used 
to study the metabolic properties of tissues. It produces a spectrum, as opposed to an 
image. The most widely used element in clinical spectroscopy is hydrogen. The 
behaviour of the hydrogen protons (1H) in the magnetic field depends on the 
chemical structure of the molecule it is part of and thus characteristic spectra are 
generated for different metabolites. The technique allows both the identification and 
quantification of specific metabolites and thus we were able to quantify ectopic lipid 
(triglyceride) deposits in sites such as the liver and skeletal muscle, which would not 
be visible on standard imaging. 
 
MRI has been used for many years in pregnant women with no apparent adverse 
effects on the mother or developing fetus180, 181. Most MRI machines in clinical use 
field strength of 1.5 Tesla (T). We used a 3T magnet, which affords better image 
quality and potentially slightly shorter scan times. However, there are fewer safety 
data on 3T scans in pregnancy. There are two theoretical safety concerns; exposure 
of the fetus to overheating and exposure of the fetus to excess acoustic noise. With 
regard to heat exposure, studies in a sheep model and mathematical modelling of 
heat exchange in a pregnant human model are reassuring182, 183. However, the degree 
of heating required to which would pose a teratogenic risk to the fetus is not known 
and scanning at 3T is not recommended in the first trimester of pregnancy. Our scans 
were performed in the third trimester where any effect is not likely to be significant. 
Measures taken to minimise the risk of harm were maintenance of a cool temperature 
in the scan room with air conditioning and a fan, and ensuring the subject wore 
minimal, loose fitting clothing during the scan. We also limited the scan time to 60 
minutes, even if this sacrificed the acquisition of all desirable data. The second safety 
consideration is acoustic damage. MRI scanners are noisy and subjects are given ear 
protectors to wear throughout the scan. The amniotic fluid, the muscular wall of the 
uterus and the abdominal wall protect the fetus so the impact of noise on the fetus is 
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likely to be minimal. There are few long-term follow up studies on children exposed 
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5.2. Hypotheses and aims 
 
In this sub-study we hypothesised that: 
• MR imaging could be used to quantify intra-abdominal fat distribution in 
pregnant women. 
• Improving insulin sensitivity with metformin would result in less deposition 
of lipid in the more insulin sensitive sites (i.e. visceral, hepatic and skeletal 
muscle). 
• MR imaging could be used to quantify fetal liver volume and fetal 
subcutaneous fat and hepatic lipid deposition. 
• Fetuses of mothers exposed to metformin in pregnancy would accumulate 
less excess fat. 
 
The aims of the sub-study were to: 
• Quantify and compare fat distribution in obese pregnant women exposed to 
either placebo or metformin in early and late third trimester. 
• Quantify and compare hepatic and skeletal muscle lipid in obese pregnant 
women exposed to either placebo or metformin in early and late third 
trimester. 
• Optimise an imaging protocol for measurement of fetal liver volume, fetal 
subcutaneous fat and fetal hepatic lipid deposition. 
• Quantify and compare fetal liver volume, fetal subcutaneous fat and fetal 
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5.3. Methods 
5.3.1. Patient recruitment, exclusion and inclusion criteria 
All women participating the EMPOWaR trial at the Edinburgh site were invited to 
attend for an MRI scan at 28 and 36 weeks’ gestation. Women with an absolute 
contraindication to MRI or severe claustrophobia were excluded. Informed consent 
was obtained at the baseline visit at the time of recruitment to the trial, and 
reconfirmed at the relevant gestations. All investigations and analyses were 
performed blind to treatment allocation. 
 
5.3.2. Scan protocol 
Whole body MRI and 1H-MRS studies were performed on a Siemens Magnetom 
Vario 3 Tesla system (Siemens AG, Healthcare Sector, Erlangen, Germany) at the 
Clinical Research Imaging Centre (CRIC), Queen’s Medical Research Institute, 
Edinburgh.  
 
Participants were positioned in the magnet in a full left lateral position to avoid 
aorto-caval compression. Data from the abdomen and thigh were acquired using a 
combination of spine and body matrix coil elements. Aural protection was provided 
by use of earplugs and headphones. Contact between the participant and scanning 
staff was maintained at all times. Heart rate and oxygen saturations were monitored 
continuously throughout the scan period; blood pressure was measured at the start of 
the scan and every 10 minutes throughout the procedure. 
 
Scans were performed by the CRIC radiographers, led by Annette Cooper (senior 
MR radiographer). Image analysis was carried out by the investigator (CC). Dr 
Calum Gray (physicist) carried out the spectroscopy analysis and post-processing 
work. Dr Scott Semple (MR physicist) developed and optimised the imaging 
protocols and over saw all data acquisition. He also carried out the image analysis as 
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a second observer for the inter-rater reproducibility data. All scans were reviewed for 
clinical reporting by Dr Jane Walker (consultant radiologist). 
 
5.3.3. Scan sequences 
Standard localising sequences were acquired to confirm organ and fetal position. 
MRI and MRS were acquired with a combination of body matrix and spine matrix 
elements. Two-dimension multi-slice fast low angle shot (FLASH) images were 
acquired axially, central to the right lobe of the maternal liver with water and lipid 
signals in and out of phase. MRI and MRS were also acquired in maternal right 
quadriceps muscle. 
 
5.3.3.1. Maternal measurements 
Quantification of maternal abdominal adipose tissue 
To quantify maternal subcutaneous and visceral fat, a 3D T1 weighted volumetric 
interpolated breath-hold examination (VIBE) sequence was acquired axially through 
the liver. Lipid signals were defined using a semi-quantitative thresholding technique 
using the commercial software SliceOmaticTM (TomoVision, Quebec, Canada). 
 
Adipose tissue appears bright on T1 weighted images. Regions of interest with 
attenuation above an investigator-defined threshold were coloured to define visceral 
adipose tissue and subcutaneous adipose tissue (Figure 10) Intra-abdominal adipose 
was defined as all adipose tissue below the abdominal wall musculature. This 
included omental, mesenteric and paranephric deposits but did not distinguish 
between intra- and retro-peritoneal fat. Subcutaneous deposits included all adipose 
inferior to the skin but outwith the abdominal cavity. Breast tissue was excluded 
from analysis. Adipose tissue volumes were calculated using the extracted areas of 
the regions of interest (mm2) multiplied by the width of each slice (2mm) to give a 
unit of volume in mm3. This was then expressed expressed as a percentage of the 
total abdominal volume of the region being examined. 
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A multi-slice approach was used. The left renal pelvis was identified in all subjects 
and adipose tissue was measured in 20 x 2mm slices cranial to this level. The renal 
pelvis was used as a landmark as it was within the region of interest, easily 
identifiable in all subjects, and not likely to be subject to a significant degree of 
movement with advancing gestation. 
 
A    B  
Figure 10 Maternal adipose tissue MRI images 
Uncoloured (A) and coloured (B) axial slices to show subcutaneous (green) and visceral (red) fat 
distribution 
 
Quantification of maternal intrahepatic and skeletal muscle lipid concentration 
For 1H-MRS measurement of intramyocellular and intrahepatocellular lipid, single 
voxel spectra localised to the right quadriceps muscle and the right lobe of the liver 
were acquired using a point resolved sprectroscopy (PRESS) sequence (TR 5000 ms/ 
TE 30 ms) with and without water suppression and with 8 signal averages. The voxel 
size was 2cm3 in the muscle and 3cm3 in the liver. The voxel site was chosen to 
avoid large blood vessels or subcutaneous adipose tissue. Lipid concentration was 
calculated from the water-suppressed acquisition using the spectroscopy analysis tool 
jMRUI (MRUI Consortium, Brno, Czech Rebuplic). 
Examples of spectra obtained are shown in (Figure 11). 
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Figure 11 Representative MR spectra from liver (left) and skeletal muscle (right) 
 
In addition to MRS, in- and out-of-phase imaging was used to calculate hepatic and 
skeletal muscle fat fraction. This is also known as the Dixon method. The lipid signal 
was calculated by subtraction of in and out of phase images (2.46ms and 8.61ms), 
and T2* decay during this time corrected using the two in-phase images (2.46ms and 
4.92ms) according to protocols which are well established for use in adult liver.189-191 
 
5.3.3.2. Fetal measurements 
Estimation of fetal liver volume 
A T2 half-fourier acquisition single-shot turbo spin echo (HASTE) sequence was 
acquired of the fetus to cover the fetal liver in the axial, sagittal and coronal planes 
(dependent on degree of fetal movement during the acquisition period). 
 
The fetal liver is identifiable by the investigator on these images using standard 
anatomical landmarks. The entire liver was coloured as the area of interest on every 
slice it was visible using the same software as was used for the maternal fat 
measurements (Figure 12). The area of the coloured region was extracted and 
converted into a unit of volume (mm3) by multiplying the area (mm2) by the width of 
each slice (2mm). 
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A B  
C D  
Figure 12 Fetal liver MRI images 
Uncoloured (A and C) and coloured (B and D) axial (A and B) and sagittal (C and D) slices to 
show the fetal liver. 
 
Estimation of fetal hepatic fat 
A T1 weighted fast low angle shot (FLASH) sequence was acquired for the in- and 
out-of-phase fetal liver fat fraction.  The slice thickness was 8mm.  The lipid signal 
was calculated by subtraction of in and out of phase images (2.46ms and 8.61ms), 
and T2* decay during this time corrected using the two in-phase images (2.46ms and 
4.92ms) according to protocols which are well established for use in adult liver189-191. 
 
Estimation of fetal subcutaneous fat 
For the fetal subcutaneous fat, a fat excitation FLASH sequence was used, again with 
8mm slice width. Shoulder to shoulder coverage of the fetus was obtained in the 
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sagittal plane and a single slice at the level of the umbilical cord insertion was used 
in the axial plane. The subcutaneous fat was coloured on every available slice in the 
sagittal plane (Figure 13) and on the single slice in the axial plane using the same 
technique as described for the maternal subcutaneous and visceral fat and fetal liver 
volume. The amount of fat was expressed as a percentage of the total volume of the 
area examined. These protocols were subject to method development during the 
study process. 
 
A B  
Figure 13 Fetal subcutaneous fat MRI images 
Uncoloured (A) and coloured (B) sagittal slices through the fetus to show the subcutaneous fat. 
 
5.3.4. Statistical analysis 
Comparisons between groups were made using unpaired t test or Mann Whitney test 
where data were not normally distributed. Comparisons within groups were made 
using paired t test, or Wilcoxon test where data were not normally distributed. 
Kruskal Wallis was used to compare differences between the groups over the two 
time points. Significance was set at p<0.05. 
 
5.3.5. Reproducibility 
The intra-observer and inter-observer variability for measurement of the maternal 
abdominal adipose tissue using this same method has previously been validated and 
found to be highly correlated192. Intra-observer variability for measurements of fetal 
liver volume and fetal subcutaneous fat were assessed by the same observer (CC) 
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defining the region of interest on all relevant slices from five subjects on two 
separate occasions. Inter-observer variability was assessed by comparison of data 
from all relevant slices for five subjects by two independent observers (CC and SS). 
 
For each paired data set, a correlative plot of the data sets around the line of equality 
is presented. Agreement was assessed by construction of Bland Altman plots with 
95% limits of agreement as follows: upper 95% limit of agreement = mean 
difference + 2SD; lower 95% limit of agreement = mean difference - 2SD. 
 
5.3.5.1. Fetal liver volume reproducibility 
Following repeated measures by the same investigator (intra-rater) and of the same 
images by two investigators (inter-rater), measurements of the fetal liver volume 
were found to be well correlated in both the axial (Figure 14, Figure 14 Axial fetal 
liver volume intra-rater reproducibility and Figure 18) and sagittal (Figure 16, Figure 
16 Sagittal fetal liver volume intra-rater reproducibility and Figure 19) planes with 
the majority of points scattered evenly around the line of no difference and within the 
upper and lower 95% limits of agreement. Measurement in the axial plane shows the 
best reproducibility. This may be due to the fact that there is less rotation of the fetus 
on this axis and more reliable images were obtained.  
 
Intra-rater variability in the axial plane 
 
Figure 14 Axial fetal liver volume intra-rater reproducibility 
 






























Observer 2: Repeated axial fetal liver volume measurements
Line of equality
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Figure 15 Axial fetal liver volume intra-rater reproducibility: Bland Altman analysis 
Observer 1: n=71 pairs, mean difference (lower – upper 95% limits of agreement) -2965 (-8335 
to 2404) mm3 
Observer 2: n=80 pairs, mean difference (lower – upper 95% limits of agreement) -852.9 (-8575 
to 6869) mm3 
 
 
Intra-rater variability in the sagittal plane 
 
Figure 16 Sagittal fetal liver volume intra-rater reproducibility 
 
 
Figure 17 Sagittal fetal liver volume intra-rater reproducibility: Bland Altman analysis 
Observer 1: n=93 pairs, mean difference (lower-upper 95% limits of agreement) -1015 (-3228 to 
1198) mm3 
Observer 2: n=99 pairs, mean difference (lower-upper 95% limits of agreement) -495 (-3003 to 
2014) mm3 














Observer 1: Repeated axial fetal liver volume measurements














Observer 2: Repeated axial fetal liver volume measurements
















































Observer 1: Repeated sagittal fetal liver volume measurements















Observer 2: Repeated sagittal fetal liver volume measurements
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Inter-rater variability in the axial plane 
 
Figure 18 Axial fetal liver volume inter-rater reproducibility 
Bland Altman analysis 
n=77 pairs, mean difference (lower-upper 95% limits of agreement) -92.84 (-8255 to 8069) mm3 
 
Inter-rater variability in the sagittal plane 
 
Figure 19 Sagittal fetal liver volume inter-rater reproducibility  
Bland Altman analysis  
n=96 pairs, mean difference (lower-upper 95% limits of agreement) -1110 (4284 to 2065) mm3 
 
5.3.5.2. Fetal subcutaneous fat  
Intra-rater variability 
Repeated measures by the same investigator were performed. Repeated measures for 
this parameter were less highly correlated, as demonstrated by a wider scatter of 
points around the line of equality and between the 95% limits of agreement (Figure 
20). This is likely to reflect both the smaller number of suitable images for analysis 






























Repeated axial fetal liver volume measurements
































Repeated sagittal fetal liver volume measurements
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of fetal subcutaneous fat and the fact that this was a novel technique that required 
significant method development during the study period. 
 
 
Figure 20 Fetal subcutaneous fat intra-rater reproducibility  
Bland Altman analysis n=67 pairs, mean difference (lower-upper 95% limits of agreement) 1530 
(-5630 to 8691) mm3 
 
  






























Repeated fetal subcutaneous fat measurements
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5.4. Results 
Demographic characteristics of the participants are shown in Tables 12 and 13. 
There is an inevitable unavoidable selection bias in recruitment to the sub-study as it 
is likely that the more motivated participants agreed to undergo the extra tests. 
However, there were no significant differences in baseline demographic 
characteristics between the sub-study population and the trial group as whole (see 
Table 12). Importantly BMI distribution was the same as the main trial group. All 
participants in the sub-study were also in the per-protocol analysis group in the main 
trial, i.e. they fulfilled the pre-defined criteria for compliance with the study 
treatment.  
 
37 participants (n=18 and 19 in placebo and metformin groups respectively) 
underwent MRI and 1H-MRS studies at both 28 and 36 weeks’ gestation. A further 
10 participants (n=6 and 4 in placebo and metformin groups respectively) underwent 
MRI at 28 weeks’ gestation only and 10 participants (n=6 and 4 in placebo and 
metformin groups respectively) at 36 weeks’ gestation only. 
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Table 12 Demographic characteristics of the participants in MR sub-study.  
Data are presented as mean + /-SD or %. Data are show for the participants in the whole trial population for comparison (ITT – intention to treat population, 




 Placebo Metformin Placebo ITT Metformin ITT Placebo PP Metformin PP 
 n=30 n=27 (n) (n) (n) (n) 
 Mean or n SD or % Mean or n SD or % Mean or n SD or % Mean or n SD or % Mean or n SD or % Mean or n SD or % 
Age (years) 29.4 4.5 30.1 5.5 28.9 5.1 28.7 5.8 29.6 4.9 29.6 5.6 
Nulliparity 11/30 36.7% 11/27 40.7% 84/223 37.7% 100/226 44.2% 59/155 38.1% 66/139 47.5% 
BMI at baseline 
(kg/m2) 
38.2 5.6 39.4 4.7 37.7 (223) 5.6 37.8 (226) 4.9 37.5 (155) 5.4 37.8 (139) 4.9 
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 Placebo Metformin Placebo ITT Metformin ITT Placebo PP Metformin PP 
 n=30 n=27 (n) (n) (n) (n) 
 Mean or n SD or % Mean or n SD or % Mean or n SD or % Mean or n SD or % Mean or n SD or % Mean or n SD or % 
Male sex 14/30 46.7% 11/27 40.7% 110/223 49.8% 109/226 50.2% 76/155 49.0% 71/139 51.0% 




548 3551.5 (153) 573.6 3498.5 (556.9) 138 
Birthweight centile 51.7 29.6 63.4 25.8 57.3 (220) 27.9 56.9 (214) 28.7 59.8 (153) 26.9 58.6 (138) 28.2 
Ponderal index at birth 3.44 4.6 2.60 0.32 3.01 (145) 3.68 2.67 (131) 0.5 3.19 (106) 4.28 2.64 (95) 0.44 
Fat % 12.53 5.7 12.63 4.3 12.08 (22) 5.74 12.86 (21) 4.5 12.7 (18) 5.64 12.8 (20) 4.56 
Triceps skinfold at birth (mm) 11.38 18.1 8.30 2.5 14.34 (111) 20.6 16.4 (99) 27.9 14.7 (90) 21.1 15.9 (83) 28.6 
Subscapular skinfold at birth 
(mm) 
10.06 13.9 7.11 2.3 13.46 (113) 20.4 15.7 (98) 27.96 13.4 (91) 20.2 14.6 (82) 28.1 
 
Table 13 Demographic characteristics of the babies of the participants in MR sub-study.  
Data are presented as mean + /-SD or %. Data are show for the participants in the whole trial population for comparison (ITT – intention to treat population, 
PP – per protocol population). There were no significant differences between the characteristics of the sub-study population compared to either the ITT or 
PP populations.
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5.4.1. Maternal subcutaneous and visceral fat masses 
There was no difference in the subcutaneous fat mass (expressed as a percentage of 
the abdominal volume examined) between the placebo and metformin groups at 28 
weeks’ gestation (difference between means -3.45, 95% CI -7.63 to 0.73, p=0.10) or 
at 36 weeks’ gestation (difference between means -3.43, 95% CI -7.63 to 0.76, 
p=0.11). There was no difference in visceral fat mass (expressed as a percentage of 
the abdominal volume examined) at 28 weeks’ gestation (difference between means -
0.02, 95% CI -1.93 to 1.89, p=0.98) or at 36 weeks’ gestation (difference between 
means 0.18, 95% CI -2.17 to 1.82, p=0.86)(Figure 21). 
 
Both groups demonstrated significant loss of subcutaneous fat mass between 28 and 
36 weeks’ gestation (paired t test: placebo mean of differences -2.14, 95% CI -3.27 
to -1.01, p=0.0009; metformin mean of differences -2.15, 95% CI -3.38 to -0.923, 
p=0.0018). There was no significant difference in the percentage change in 
subcutaneous fat mass from 28 to 36 weeks’ gestation in the placebo group 
compared to the metformin group (difference between means -0.45, 95% CI -4.71 to 
3.82, p=0.83)(Figure 22).  
 
Neither group demonstrated any change in visceral fat mass between 28 and 36 
weeks’ gestation and thus there was no difference in change in visceral fat mass 
between 28 and 36 weeks’ gestation between the groups (Mann Whitney test, 
p=0.60)(Figure 22). 
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Figure 21 Maternal subcutaneous (SC) and visceral (V) fat mass (%) at 28 and 36 weeks’ 
gestation.  
Data are presented as mean +/- SEM. *p<0.05, **p<0.01, ***p<0.0001.  
 
Figure 22 Percentage change in subcutaneous and visceral fat mass between 28 and 36 weeks’ 
gestation.  
Data are presented as mean +/- SEM.  
 
5.4.2. Maternal skeletal muscle and hepatic fat fraction  
5.4.2.1. In- and out-of-phase imaging method 
The mean (SD) hepatic fat fraction (%) at 28 weeks’ gestation was 3.93 (1.35) and 
4.90 (2.76) in the placebo and metformin groups respectively. At 36 weeks’ gestation 

































































Change in visceral fat mass between 28 and 36 weeks
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The mean (SD) skeletal muscle fat fraction (%) at 28 weeks’ gestation was 2.84 
(0.90) and 3.20 (1.33) in the placebo and metformin groups respectively. At 36 
weeks’ gestation it was 3.43 (1.29) and 3.62 (1.82) for the placebo and metformin 
groups respectively. 
 
There were no significant differences in fat fraction measured by this method by 
gestation or treatment group in either the skeletal muscle (p=0.55) or the liver 




Figure 23 Maternal hepatic and skeletal muscle fat fraction (%) in placebo and metformin 
groups at 28 and 36 weeks gestation using the Dixon method.  
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5.4.2.2. 1H-MRS method 
The mean (SD) hepatic fat fraction (%) at 28 weeks’ gestation was 1.24 (1.26) and 
0.87 (1.22) in the placebo and metformin groups respectively. At 36 weeks’ gestation 
it was 1.11 (1.80) and 0.86 (0.71) for the placebo and metformin groups respectively.  
 
The mean (SD) skeletal muscle fat fraction (%) at 28 weeks’ gestation was 7.13 
(3.77) and 7.55 (4.86) in the placebo and metformin groups respectively. At 36 
weeks’ gestation it was 10.99 (9.60) and 9.10 (4.46) for the placebo and metformin 
groups respectively. 
 
There were no significant differences in fat fraction measured by 1H-MRS by 
gestation or treatment group in either the skeletal muscle (p=0.64) or the liver 
























     133 
 
Figure 24 Maternal hepatic and skeletal muscle fat fraction (%) in placebo and metformin 
groups at 28 and 36 weeks gestation using 1H-MRS.  
Data are presented as mean +/- SEM.  
 
5.4.3. Fetal liver volume, hepatic fat fraction and subcutaneous fat 
There was no statistically significant difference in fetal liver volume at 28 or 36 
weeks’ gestation between the placebo and metformin treatment groups. Both groups 
demonstrated a significant increase in liver volume over time (p<0.0001), as would 
be expected, but the percentage increase was not significantly different between the 
two groups when measured in either plane (Figure 25 and Figure 26). There was no 
change in the fetal hepatic fat fraction by gestation or treatment group (Figure 27). 
There was no difference in subcutaneous fat, measured in the sagittal and axial plane 
(expressed as a percentage of body volume) at 36 weeks’ gestation between the two 
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Figure 25 Fetal liver volume (mm3) in the axial plane.  




Figure 26 Fetal liver volume (mm3) in the sagittal plane.  
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Fetal liver volume (sagittal)
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Figure 27 Fetal hepatic fat fraction (%) measured using in and out of phase imaging. 
Placebo n=17, metformin n=16 (paired samples)  
 
 
Figure 28 Fetal subcutaneous fat volume (%) in sagittal and axial planes. 
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5.5. Discussion 
The purpose of this sub-study was to assess whether distribution body fat in obese 
pregnant women was altered by metformin. We also examined the fetus with the aim 
of assessing effect on liver volume, hepatic fat content and fetal subcutaneous fat 
deposits. We aimed to scan 40 participants at both 28 and 36 weeks’ gestation. 
Ultimately we scanned 57 participants, with longitudinal maternal data available for 
37 participants (those who attended for both scans). We obtained longitudinal fetal 
hepatic lipid data in 17 and 16 of the participants allocated to placebo and metformin 
respectively. Liver volume was successfully measured in the axial plane in 25 and 22 
fetuses at 28 and 36 weeks respectively in participants allocated to placebo and in 22 
subjects at both time-points allocated to metformin. Liver volume was successfully 
measured in the sagittal plane in 25 and 23 fetuses at 28 and 36 weeks respectively in 
participants allocated to placebo and in 22 metformin subjects at both time-points. 
Subcutaneous fat mass was measured in the sagittal plane in 14 and 25 subjects 
allocated to placebo and metformin respectively. In the axial plane it was 
successfully measure in 8 and 5 subjects in the placebo and metformin groups 
respectively. 
 
We have demonstrated that the maternal scanning protocols work well in obese 
pregnant women, with good inter- and intra-rater correlation. We have shown it is 
possible to obtain the fetal data as we had planned, though not in every subject 
scanned due to fetal movement and time limitation, with priority being given to 
acquisition of the maternal data. There was reasonably good inter- and intra-rater 
correlation for the fetal liver volume data. Correlation was less good for the 
subcutaneous fat measurements but the cohort numbers were small for this study. 
 
In summary, participants in both placebo and metformin arms of the study lost 
subcutaneous fat over the course of pregnancy but there was no difference in the 
percentage change between the two groups. We saw no differences in amounts of 
visceral fat either between treatment groups or by gestation. Ectopic lipid deposition 
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in both the liver and skeletal muscle was also the same in both groups and did not 
change between 28 and 36 weeks’ gestation.  
 
Mean hepatic fat fraction in both groups was relatively low, particularly when 
measured by 1H-MRS. It is not surprising to see a difference in actual values when 
comparing the two techniques as they are measuring slightly different things. MRS 
should be more accurate as it is specifically measuring lipid, whereas the Dixon 
method is measuring ‘non-water’. However, MRS is more prone to artefact and in 
our particular study population practical considerations, e.g. asymmetrical loading of 
the subject into the scanner and satisfactory voxel placement away from the dilated 
hepatic blood vessels, limited spectra acquisition.  
 
When measured using the Dixon method, fat fraction was higher than we have 
previously seen in a cohort of 10 lean and 10 obese non-diabetic pregnant women192 
but still lower than in a cohort of obese non-pregnant women193 and certainly below 
the diagnostic threshold for non alcoholic fatty liver disease194. Mean skeletal muscle 
fat fraction measured by 1H-MRS was similar to that in our previous cohort of obese 
pregnant women192 and to that of a group of normally glucose tolerant obese (mean 
BMI 30kg/m2) non-pregnant women195. This suggests that pregnancy itself, rather 
than metformin, may be exerting a protective effect on the liver, which deters 
accumulation of lipid in this site. 
 
Several studies have identified the liver as the primary site of action of metformin in 
the non-pregnant population143, 196, 197 but there are limited data examining whether 
hepatic insulin sensitisation by metformin is associated with a change in liver fat 
content. While some studies have demonstrated a reduction in hepatic lipid198, others 
have shown a neutral effect despite improvement in hepatic insulin sensitivity199. 
However, there are no studies where metformin has been used in isolation in subjects 
with obesity only without other co-pathologies such as diabetes or non-alcoholic 
fatty liver disease. 
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The fetal data must be interpreted with a greater degree of caution. The scanning 
protocols are not well established and were subject to some method development 
during the study period. Fetal movement during the image acquisition period is an 
extra challenge. We aimed to limit the scan duration to 60 minutes, which was the 
limit of acceptability for the participants, and we prioritised the acquisition of the 
maternal data in this time.  However, we still acquired a reasonable amount of data 
suitable for analysis and have not demonstrated any differences in the fetal liver 
volumes or hepatic and subcutaneous fat depots between the placebo and metformin 
groups. This is in keeping with the primary outcome of the EMPOWaR trial, which 
demonstrated no difference in birthweight of the babies, and also among the 
secondary outcomes we saw no difference in neonatal fat mass measured by air 
displacement plethysmography, or between neonatal skin-fold thicknesses. The fetal 
hepatic fat fraction we measured was higher than the maternal measures by the same 
technique (Dixon). To our knowledge, ours is the first study to attempt to measure 
fetal hepatic fat fraction so no data are available for comparison. There are some data 
to suggest hepatic fat fraction in neonates, measured by 1H-MRS, is positively 
correlated with maternal BMI174 so in our cohort of obese subjects it is possible that 
the fetal hepatic fraction is high for this reason. However, the fetus undergoes a 
marked period of body fat accretion during the third trimester200 so it is not possible 
to directly compare the fetal data with neonatal data.  
 
In conclusion, we have not demonstrated any effect of metformin in obese pregnant 
women on maternal or fetal body fat distribution at 28 and 36 weeks’ gestation. 
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6. Chapter 6 Effect of metformin on endothelial function 
6.1. Background 
Hypertensive disorders are more prevalent in obese populations201 including those 
who are pregnant202. Obese women are at greater risk of chronic hypertension, 
pregnancy-induced hypertension and pre-eclampsia203-206: for a woman with a BMI > 
35 kg/m2, the risk of pre-eclampsia is twice that of a lean woman207. The causal 
mechanisms behind these associations are not clear but insulin resistance may play a 
role. Women with diabetes of all types during pregnancy have a heightened risk of 
pre-eclampsia and women with pre-eclampsia have an increased risk of type 2 
diabetes in later life208. Other possible contributory mechanisms include endothelial 
dysfunction, inflammation, dyslipidaemia and oxidative stress: all of which are 
associated with both obesity and pre-eclampsia104, 209, 210. 
 
The vascular endothelium is the layer of endothelial cells between the blood vessel 
wall and the blood stream. It is a key regulator of vascular homeostasis, acting not 
only as a barrier but also as an active signal transducer for circulating influences that 
modify the vessel wall tone and phenotype211. Endothelial dysfunction is 
characterised by a shift of the actions of the endothelium towards reduced 
vasodilatation, and a more pro-inflammatory and pro-thrombotic state212. Nitric 
oxide (NO) is a key endoethlium-derived molecule essential for vascular 
relaxation213. Mechanisms that participate in the reduced vasodilatory responses 
include reduced nitric oxide bioavailability and oxidative stress212. Endothelial 
dysfunction is associated with most forms of cardiovascular disease, such as 
hypertension, coronary artery disease, diabetes, and chronic renal failure, and often 
precedes their clinical manifestations214. It has also been demonstrated in disease 
states in the absence of overt cardiovascular complications, such as the metabolic 




Endothelial dysfunction in pregnancy has been most widely studied in the context of 
pre-eclampsia where impaired maternal vascular function has been reported217. 
Gestational diabetes is associated with increased oxidative stress and overexpression 
of inflammatory cytokines, both of which contribute to endothelial dysfunction218. 
Obesity in pregnancy shares these features and impaired endothelial function has 
been demonstrated in obese pregnant women104, 158. Given that insulin resistance and 
hyperglycaemia are linked to inflammation, vascular dysfunction and hypertension, 
these processes are potential mediators for these upstream causative pathways 
linking endothelial dysfunction with cardiovascular disease in obese pregnant 
women.  
 
Metformin might be the ideal agent to address and to reverse these abnormalities in 
obese pregnant women. In addition to its primary function as an insulin sensitising 
agent, metformin has beneficial effects on the vascular endothelium, lipid profile and 
oxidative stress98, 219. These effects appear independent of metformin’s glucose 
lowering and insulin sensitising effects. Metformin also improves vascular function 
in a variety of clinical syndromes associated with insulin resistance, for example 
reducing cardiovascular disease risk in patients with type 2 diabetes220, and 
improving endothelial function in patients with type 1 diabetes, metabolic syndrome 
and polycystic ovary syndrome145, 219, 221-223. 
 
6.1.1. Assessing endothelial function 
Several different methods of assessment of endothelial function have been developed 
over the past few decades224. Currently these methods are restricted to use in the 
research context and none have as yet been incorporated into clinical practice. The 
various techniques available for the assessment of endothelial function rely on the 
basic principle that healthy arteries dilate in response to physical, physiological or 
pharmacological provocation of the endothelium to release NO and/or other 
endothelium derived vasoactive substances and then measure the response of the 
blood vessel being studied. In disease states, the endothelium-dependent dilatation is 
diminished or absent. However, the vascular response is not only determined by the 
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function of the endothelium, but also but the structural condition of the arteries. 
Therefore, to differentiate between the endothelium-dependent and endothelium-
independent response, an exogenous NO donator (e.g. glycerol trinitrate) must also 
be used. 
 
Early techniques employed the use of coronary angiography and intracoronary 
infusion of acetylcholine with the vascular response begin measure by quantitative 
angiography225. Subsequently less invasive techniques have been developed using 
predominantly the forearm circulation as a surrogate for the coronary arteries226, 227 
which are more suited to patients who do not otherwise require a coronary 
angiogram for clinical reasons. 
 
6.1.1.1. Forearm plethysmography 
This is a semi-invasive technique that measures change in forearm blood flow by 
venous plethysmography in both arms, before and after infusion of vasoactive 
substances (e.g. GTN, acetylcholine) into a cannulated brachial artery226. Its main 
advantage is that the endothelium-dependent and independent response can be 
quantified in a dose dependent manner. It is useful for studying differences in blood 
flow to various stimuli in the same individual. However, comparison between groups 
are of limited value due to baseline differences in forearm size, arterial pressure, 
blood flow and other factors228. 
 
6.1.1.2. Finger plethysmography 
The EndoPAT™ (Itamar Medical) device records endothelium-mediated changes in 
the digital pulse waveform using a pair of plethysmographic probes on the index 
finger of each hand229. It works on the principle that an increase in arterial blood 
volume in the fingertip causes an increase in pulsatile arterial column changes, thus 
increasing the measured signal. A blood pressure cuff is place on the arm and 
inflated to suprasystolic pressure for five minutes to induce reactive hyperaemia. The 
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contralateral arm acts as an internal control and an index between the two arms is 
calculated by the equipment software. It is totally non-operator dependent and the 
equipment is much cheaper than that required for other techniques. Its limitation is 
that augmentation of the pulse amplitude after reactive hyperaemia is not solely 
dependent on NO but is also influenced by changes in flow and digital microvessel 
dilatation (i.e. non endothelial factors)230. 
 
6.1.1.3. Flow-mediated dilatation 
This technique, first described by Celermajer et al.227, measures the ability of the 
brachial or radial artery to respond to the release of endothelial NO during reactive 
hyperaemia following a 5-minute occlusion of the brachial artery with a blood 
pressure cuff. The diameter of the artery is measured before and after arterial 
occlusion using ultrasound, a response that has been shown to be mainly NO 
dependent231, 232. Specialist edge detection software is employed to improve accuracy 
and reproducibility. The endothelial-independent response is then assessed following 
administration of GTN. There are several technical considerations to bear in mind in 
order to standardise the use of the technique as numerous factors affect FMD, 
including temperature, food, drugs and sympathetic stimuli233. Participants should 
fast for 8 to 12 hours before the study and the procedure should be conducted in a 
quiet, temperature controlled room. Subjects should not exercise, smoke, ingest 
caffeine or vitamin C for 4 to 6 hours prior to the test. The technique is non-invasive 
but it is challenging to perform well and requires significant training and practice to 
optimise technique. Despite these limitations, FMD is considered the gold-standard 




6.2. Hypotheses and aims 
 
In this sub-study we hypothesised that: 
 
• Improving insulin sensitivity in obese pregnant women with metformin 
would result in improved endothelial function in late pregnancy, compared to 
those taking placebo. 
 
The aims of the sub-study were to: 
 
• Optimise the technique of FMD for use in obese pregnant women. 
• Measure FMD in early and late pregnancy in obese pregnant women 
participating in the EMPOWaR trial. 
• Compare endothelial function in obese pregnant women taking metformin 








6.3.1. Patient recruitment, inclusion and exclusion criteria 
We recruited a subset of women participating in the EMPOWaR trial. All women 
participating in the trial at the Edinburgh centre were invited to take part. Inclusion 
and exclusion criteria at baseline were the same as those for main trial (see Chapter 
2). Additionally, subjects with a pre-existing hypertensive disorder or who were 
taking any antihypertensive medications or aspirin were excluded. Women with 
gestational diabetes were excluded. The characteristics of participants in the sub-
study were similar to those of the EMPOWaR study overall. We also included a 
comparator ‘control’ group of lean pregnant subjects who, with the exception of 
BMI, were matched for baseline characteristics to the EMPOWaR study population. 
These participants were recruited from local ‘low risk’ antenatal booking clinics. 
Participants in the EMPOWaR trial were assessed at 12-16 weeks’ gestation 
following randomization but prior to commencing study treatment, and at around 36 
weeks’ gestation whilst receiving trial medication. All measurements were 
performed blind to treatment allocation. Lean control subjects were assessed at both 
12-16 and 36 weeks’ gestation.  
 
6.3.2. Endothelial Function 
We assessed endothelial function by measuring flow-mediated dilatation in the 
brachial artery. Subjects were asked to refrain from eating, smoking or consuming 
alcohol or caffeine in the preceding four hours. Measurements were obtained in a 
temperature-controlled room with the subject resting in a semi-recumbent position on 
a bed. Subjects in late pregnancy had a left lateral tilt applied to avoid aorto-caval 
compression.  
 
Measurements were made using ultrasound imaging (CX50 Ultrasound system with 
a 7 MHz linear array transducer, Philips Medical Systems, Guildford, UK) of the 
brachial artery, 2-5 cm above the antecubital fossa. A baseline rest image was 
acquired for a period of 60 seconds. Arterial occlusion was performed using a 
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sphygmomanometric cuff applied below the antecubital fossa, inflated to 
suprasystolic pressure for five minutes and then released to induce hyperaemia. The 
brachial artery ultrasound image was recorded for 30 seconds before and five 
minutes after cuff deflation. Images were acquired with electrocardiogram gating, 
with measurements made in end-diastole, corresponding to the onset of the R wave. 
To minimize movement, the scan probe was held in place with a probe-retaining 
device throughout the period of the study. Images were stored digitally and 
measurements made using edge-detection software (Vascular Research Tools 5, 
Medical Imaging Applications LLC, www.mia-llc.com)(Figure 29). Results were 
expressed as change in arterial diameter (D) divided by baseline diameter: 
 
𝐹𝑀𝐷 (%) = ( 
𝐷𝑝𝑒𝑎𝑘 − 𝐷𝑏𝑎𝑠𝑒𝑙𝑖𝑛𝑒
𝐷𝑏𝑎𝑠𝑒𝑙𝑖𝑛𝑒
 ) × 100 
 
The peak diameter (Dpeak) was taken as the mean of the diameter measurements taken 
five seconds either side of the peak diameter. The baseline diameter (Dbaseline) was 
taken as the mean of the 60 seconds of baseline recording. We then measured 
endothelium-independent vasodilatation. After 10 minutes of rest, a second baseline 
image was obtained for 60 seconds and then a single low dose (25 µg) of sublingual 
nitroglycerin (GTN) spray was given and measurement recorded for five minutes. 
Again, the baseline diameter was taken as the mean of the first 60 seconds and the 
peak diameter was taken as the mean of the measurements five seconds either side of 
the peak. 
 
All image analysis was observed as it progressed in real time by the investigator. The 
image analysis edge-detection software allows for manual correction of caliper 
placement where the image is not sufficiently crisp. If accurate automated or manual 
caliper placement was not possible due to poor image quality, the subject was 









FMD response    GTN response 
 




6.3.3. Statistical analysis 
Graphical data are presented as mean ± standard error of the mean. Comparisons 
between placebo, metformin and lean groups at both time points were made using 
one-way analysis of variance (ANOVA). Two-way ANOVA was used to examine 
differences over time in the various treatment groups. Comparisons between early 
and late pregnancy within groups were made using Students unpaired t-test. 
Significance was taken as a two-sided p<0.05.  
 
The candidate carried out all participant recruitment, flow mediated dilatation 






Forty-one eligible women in the EMPOWaR study agreed to participate in the sub-
study. However, the majority of EMPOWaR participants were unable or unwilling to 
attend for the two study visits: only one and two of the placebo and metformin 
subjects respectively attended both visits. In contrast, all women in the lean control 
group attended both visits except one lean subject who was ineligible at 36 weeks’ 
gestation due to a pre-term birth. No participants had developed any hypertensive 
complications of pregnancy or were receiving any medications other than the study 
tablets. Images from nine subjects had to be discarded as they were of insufficient 
quality for analysis. The final study population (Table 14) was therefore 28 subjects 
(6 placebo, 12 metformin and 10 lean) at 12-16 weeks’ gestation, and 26 subjects (8 
placebo, 9 metformin and 9 lean) at 36 weeks’ gestation. All image analysis was 
carried out prior to unblinding. Following unblinding, all EMPOWaR participants 
were in the per-protocol analysis group, i.e. they fulfilled the pre-defined eligibility 
criteria for treatment compliance. 
 
Data are presented for 28 subjects at baseline and 25 subjects at 36 weeks’ gestation.  
 
There were no differences in FMD between the placebo, metformin and lean groups 
at baseline or at 36 weeks’ gestation (one-way ANOVA; baseline p=0.88, 36 weeks 
p=0.89) (Table 15 and Figure 30). There was a decline in endothelial function in late 
pregnancy compared to early pregnancy across all groups (two-way ANOVA 
p=0.03). There were no differences in endothelium-independent vasodilatation 








 Placebo Metformin Lean  
Mean or % SD Mean or % SD Mean or % SD  
n=13 n=19 n=10 p-value 
Age (years) 31.5 4.4 27.3 6.1 35.6 4.1  
Nulliparity 46.7% 68.8% 70%  
Current smoking 6.7% 18.8% 0%  
BMI at baseline (kg/m2) 38.4 4.9 37.7 5.7 23.05 3.5  
SBP at baseline (mmHg) 121.7 10.8 117.3 9.7 109.9 15.4 0.06 
DBP at baseline (mmHg) 69.1 7.3 69.1 9.5 65.9 10.3 0.63 
SBP late pregnancy (mmHg) 123.2 9.1 118.0 15.3 123.8 11.0 0.39 
DBP late pregnancy (mmHg) 75.0 6.0 70.4 8.5 73.8 9.6 0.26 
Mean gestation at time of study (days)  
Baseline 100.2 10.5 105.2 7.7 100.3 7.7  
Late pregnancy 252.1 4.7 253.3 6.8 257.0 5.6  
Table 14 Demographic characteristics of participants in endothelial function substudy.  













 Placebo Metformin Lean  
Mean SD Mean SD Mean SD  
n=13 n=19 n=10 p-value 
FMD (%)        
Baseline (n)  10.16 (6) 5.0 8.58 (12) 6.9 10.22 (10) 10.6 0.88 
Late pregnancy (n) 6.08 (8) 5.3 5.10 (9) 4.0 5.40 (9) 3.0 0.89 
GTN-mediated dilatation (%)        
Baseline (n) 12.74 (6) 9.7  9.07 (12) 5.6 11.98 (10) 9.0 0.57 
Late pregnancy (n) 11.04 (8) 8.1 9.61 (8)* 4.4 8.50 (9) 4.0 0.66 
Table 15 Results of endothelial function substudy.  
Data are presented as mean +/- SD. *One GTN image had to be discarded as it was of 







Figure 30 Flow mediated dilatation at 16 and 36 weeks’ gestation.  
Data are presented as mean +/- SEM. Participant numbers as follows: 16 weeks placebo n=6, metformin n=12, lean n=10; at 36 weeks placebo n=8, 
metformin n=9, lean n=9. No significant differences between placebo, metformin and lean groups at 16 or 36 weeks (1-way ANOVA; 16w p=0.88, 36w 































Figure 31 GTN mediated dilatation at 16 and 36 weeks’ gestation.  
Data are presented as mean +/- SEM. Participant numbers as follows: 16 weeks placebo n=6, metformin n=12, lean n=10; 36 weeks placebo n=8, metformin 

























































We have used flow-mediated vasodilatation, the gold-standard non-invasive method 
of assessing endothelial function, in obese and lean pregnant women as part of the 
EMPOWaR study. Whilst demonstrating a selective gestation-associated decline in 
endothelium-dependent vasodilatation, we saw no differences in endothelial function 
across obese and lean groups, nor any effect of the treatment intervention, 
metformin. This suggests that pregnancy is associated with altered endothelial 
function and this is independent of body weight or glucose sensitivity. 
 
There was a decline in endothelial function between early and late pregnancy in 
participants in all three groups. This is contrary to the finding of one longitudinal 
study of endothelial function in eight normal weight women who demonstrated 
increasing FMD across the three trimesters of pregnancy234. However, a much larger 
study of 157 normal weight pregnant women235 demonstrated an increase in FMD in 
pregnant compared to non-pregnant subjects, apparent from 10 weeks’ gestation but 
a progressive decline in FMD to pre-pregnancy levels from around 30 weeks’ 
gestation, in keeping with our data in both the lean and obese participants. 
 
To our knowledge, this is the first study of the effect of metformin on endothelial 
function in pregnant women. It is not clear why metformin does not appear to have 
had an effect on the vascular endothelium in the study population when this has been 
demonstrated in other insulin resistant populations. Pregnancy is associated with 
major vascular and haemodynamic changes, the primary event probably being a fall 
in peripheral vascular resistance236. This is most likely mediated by endothelium-
dependent factors including nitric oxide synthesis up regulation by oestradiol and 
possibly vasodilatory prostaglandins237-239. The consequent fall in systemic vascular 
resistance leads to a compensatory increase in cardiac output. Larger vessels dilate 
less than smaller ones227. It is possible that the increased vessel diameter of 
pregnancy, along with stimulated nitric oxide activity of pregnancy may obscure any 
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effect of metformin on the endothelium. However, we did not see any differences in 
endothelium-independent vasodilatation, which we would expect to see if this was 
purely a vessel size effect or related to increased nitric oxide consumption. The 
duration of metformin treatment of 24 weeks may also be a factor in the apparent 
lack of effect. However, other studies have demonstrated an effect on endothelial 
function with only a three-month duration of treatment223, 240. 
 
Flow-mediated dilatation of the brachial artery is accepted as the gold standard for 
the non-invasive measurement of endothelial function since it is widely used, well-
tolerated, low risk and importantly for our study population, suitable for use in 
pregnant women. There are however some limitations. Most notably for our study 
population, measurement of the vessel diameter can be technically challenging, 
particularly in the obese where visualization of the intima is difficult as the 
ultrasound signal is attenuated but the subcutaneous fat.  
 
A further limitation of this study is the lack of longitudinal data for subjects other 
than those in the lean group. Having baseline and 36-week data for the same groups 
of subjects would enhance the statistical power of the findings but this was not 
possible. This is one of the challenges of performing nested studies within the 
confines of a larger RCT. Participants often do not have the time or willingness to 
have multiple extra investigations over and above those required for participation in 
the ‘main’ trial. This is perhaps particularly true of a population of young women 
who already require various appointments for their basic pregnancy care and also 
often have jobs, children or other demands on their time.   
 
Further exploratory analysis using a linear regression model to examine the 
association between endothelial function and other continuous variables in addition 
to metformin such as blood pressure, inflammatory markers (e.g. CRP, IL-6) and 
HOMA-IR would be interesting but without the longitudinal FMD for each subject it 




Other limitations include the small sample size and the variability of baseline 
demographics (e.g. age, smoking status and parity) within the unblinded groups. This 
makes it difficult to identify true differences within the small sample size. Clearly an 
imbalance in treatment group allocation is purely due to chance and unavoidable in 
the context of a double-blind trial but a larger sample size would help to control for 
this. 
 
It is possible our sub-study was under-powered. However, we have demonstrated 
change in FMD over the course of pregnancy (and an absence of change in GTN-
mediated dilatation) of a magnitude consistent with other published data. 
Additionally, in the larger EMPOWaR cohort as a whole, we saw no differences in 
blood pressure or the incidence of hypertensive disorders of pregnancy, which we 
may have expected if the placebo group had impaired endothelial function compared 
to the metformin group. This suggests our findings of no difference between the two 
groups may be correct rather than a type two error. In conclusion, we have not 






7. Chapter 7 General discussion and conclusions  
7.1. Summary of findings 
In this thesis, we have presented the findings from the first randomised controlled 
trial of a pharmacological intervention, metformin, to reduce the risk of excessive 
birthweight in the offspring of non-diabetic obese pregnant women. Contrary to our 
hypothesis, metformin had no effect on our primary outcome of birthweight. In 
addition, we did not see any effect on our secondary outcomes of insulin sensitivity 
at 36 weeks’ gestation; maternal and neonatal anthropometry; neonatal CRP, glucose 
and insulin measured in cord blood.  
 
The inflammatory markers CRP and IL-6 were both lower in the metformin group. 
These markers are known to be elevated in obese pregnant women compared to lean 
pregnant women104 and may be associated with adverse pregnancy outcomes such as 
pre-term birth and pre-eclampsia116, 117. 
 
Fasting glucose and insulin were lower in the metformin group at 28 weeks’ 
gestation in the intention to treat analysis. On per-protocol analysis fasting and two-
hour glucose, insulin and HOMA-IR score were all lower in the metformin group. 
The lack of effect at 36 weeks’ gestation may reflect the changes in glucose 
homeostasis throughout pregnancy with the physiological insulin resistance of 
pregnancy being to overwhelming at this gestation to be influenced by metformin. 
 
The intervention was acceptable to the women who agreed to participate in the trial. 
No participants were withdrawn specifically because of treatment side effects. 
Overall adherence was around 60% by both diary entries and detectable levels of 
metformin in the 36 weeks’ gestation blood sample. The median dose taken was 




The lack of effect overall was evident in both the intention-to-treat and per-protocol 
analyses. Our study was adequately powered and we can conclude that our results 
reflect a true lack of effect of the intervention, rather than a type two error. 
 
We also examined the effect of metformin in a series of nested mechanistic 
substudies. We did not see an effect of metformin on endothelial function, or on 
maternal and fetal body fat distribution. In subjects undergoing a hyperinsulinaemic 
euglycaemic clamp study, with concomitant use of stable isotope tracers at 36 
weeks’ gestation we saw higher endogenous glucose production and insulin 
stimulated glucose disposal in participants taking metformin, but no differences in 
whole body glucose disposal or lipid metabolism. Although the numbers of 
participants taking part in the substudies was small, they were characteristically 
similar to the study population as a whole and the findings concur with the overall 
findings in the main trial. 
 
7.2. Strengths and limitations  
This was a multicentre study with a double-blind randomised-controlled design 
making the findings robust and generalisable.  
 
Recruitment to the trial was challenging. The majority of women we approached 
declined to participate. We were unable to formally assess the reasons for this but 
anecdotally there was an understandable reluctance among pregnant women to take 
medication in pregnancy and also a lack of awareness of the potential harm 
associated with obesity in pregnancy. Although we were formally unable to quantify 
this, our impression was that women felt stigmatised at being identified as obese and 
immediately rejected the study on that basis. Additionally, it was difficult to explain 
to potential participants the risks of maternal obesity and high birthweight for the 
child. Women did not see having a large baby as an adverse outcome and so the 
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concept of taking a tablet to prevent this was insufficient to overturn the generic 
advice not to take medications in pregnancy, unless absolutely necessary. 
 
Despite challenges with recruitment, we were still able to recruit our target sample 
size and we had adequate power to address our hypothesis. 
 
We have used a recognised surrogate, birthweight centile, as a marker of future life 
risk of obesity in the offspring. There is good evidence that birth weight is a valid 
marker to use, from both a systematic review17 and further supported by large 
epidemiological studies15, 16. A limitation of the study is that follow up is limited to 
the early postnatal period and longer term conclusions about the effect of metformin 
on the offspring will require long-term follow-up studies. Indeed, the greatest 
differences in offspring weight as a result of an intervention in pregnancy may not 
happen until childhood, as was seen in the 2-year follow-up study101 of the infants 
whose mothers participated in the MiG trial100. Additionally, the large number of 
secondary outcomes means that conclusions about these results (even where p <0.05) 
are potentially subject to a Type I error.  
 
We did not attempt to assess whether blinding was effective. Metformin causes 
gastrointestinal side effects, so it is possible that some women (and their caregivers) 
may have correctly inferred their treatment allocation from their side effect profile. 
However, the majority of the clinical outcomes (e.g. birthweight centile) are unlikely 
to be significantly affected by observer bias, so we do not think this will have 
adversely affected the results. 
 
Duration of treatment may have also had an impact. Participants commenced 
treatment between 12 and 16 weeks’ gestation. In studies of metformin use in 
pregnant women with PCOS, treatment is initiated before or around conception. A 
longer duration of treatment is associated with greater weight reduction241. However, 
clearly an intervention to be used in pregnancy is limited by the length of the 
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gestation. It also practically challenging to identify, recruit and randomise women 
very early in pregnancy before they have registered with antenatal services. 
 
Since publishing the results of the EMPOWaR study140, another group has published 
a similar study, with a slightly smaller sample size, and has again found no effect of 
metformin on birthweight in obese pregnant women without diabetes. The 
Metformin in Obese Nondiabetic Pregnant Women (MOP) trial69 was a double-blind, 
placebo-controlled trial of metformin versus placebo in pregnant women without 
diabetes who had a BMI greater than 35 kg/m2. Four hundred and fifty participants 
were randomised from three UK NHS hospitals, of which 50 withdrew consent 
following randomisation, leaving 202 in the treatment group and 198 in the placebo 
group for inclusion in the primary outcome analysis. The primary outcome was 
neonatal birthweight z score adjusted for gestational age. Secondary maternal 
outcomes included gestational weight gain, gestational diabetes, pre-eclampsia, 
pregnancy induced hypertension, delivery by caesarean section, and postpartum 
haemorrhage. Secondary fetal outcomes included death before 24 weeks’ gestation, 
stillbirth after 24 weeks’ gestation, preterm birth, large for gestational age, birth 
trauma, low Apgar score, hypoglycaemia at birth, hyperbilirubinaemia, and 
respiratory distress. There were no significant differences between the metformin 
group and the placebo group in the median neonatal birthweight z score (metformin 
group 0.05 (IQR -0.71 to 0.92), placebo group 0.17 (IQR -0.62 to 0.98, p=0.66). The 
authors report significant differences in median gestational weight gain (4.6kg (IQR 
1.3 to 7.2) versus 6.3kg (IQR 2.9 to 9.2), p=<0.001) and incidence of pre-eclampsia 
(3% in metformin group versus 11.3% in placebo group, OR 0.24 (95% CI 0.10 to 
0.61) p=0.001) in favour of metformin treatment. There were no significant 
differences in any of the other maternal or fetal secondary outcomes. 
 
There were some notable differences between the MOP trial and EMPOWaR. 
Women required a BMI of 35kg/m2 for entry into MOP, which is higher than the 
30kg/m2 for EMPOWaR. There is a linear relationship between BMI and risk of 
adverse pregnancy outcome, increasing BMI being associated with increasing risk. 
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The MOP group used 35kg/m2 cut-off to enable the study to have adequate power 
with a smaller sample size. However, they acknowledge the study remains 
underpowered for any of the secondary outcomes including incidence of pre-
eclampsia. It could potentially have made the findings less applicable to the obese 
population (defined as BMI>30kg/m2) had they demonstrated benefit of treatment. 
 
The exclusion criteria with regard to diabetes history for participants in the MOP 
study are not clear. In the pre-published protocol (available at NEJM.org), ‘diabetes 
at booking’ is given as an exclusion criterion. The definition of diabetes (e.g. type 1 
or 2 or GDM) is not given, and the diagnostic criteria applied are not stated. In the 
published paper, GDM in a previous pregnancy is listed as an exclusion criterion, but 
not diabetes at booking. Participants underwent an OGTT at the recruitment visit 
(12-18 weeks’ gestation) but it is not clear whether the results of this test were 
revealed to the study team or clinical team or whether this occurred before or after 
randomisation. 
 
In our study, women underwent an OGTT at the baseline visit, prior to 
randomisation and were excluded if the results met the diagnostic criteria for GDM 
as per IADPSG, WHO or any locally used criteria. We anticipated that women 
diagnosed with GDM after enrolment would wish to withdraw and be treated with 
metformin as a first-line agent. Hence, this baseline test would prevent withdrawals 
(and protocol violations) by identifying early women who would later be diagnosed 
with GDM. In practice, this approach may have ‘screened out’ women most likely to 
have had had a macrosomic baby and as such most likely to have benefited from 
treatment. However, this approach allows us to more reliably assess the impact of 
obesity on pregnancy outcomes rather than hyperglycaemia per se. 
 
Whether the MOP trial included or excluded women with GDM, and by which 
diagnostic criteria, is not known from the groups published material but it is 
interesting that there was no effect of treatment on the primary outcome regardless of 
this. They also did not see any difference in the number of women who developed 
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gestational diabetes at 28 weeks’ gestation (although again, no diagnostic criteria are 
stated).  
 
We used a starting dose of metformin of 500mg, with a maximum allowable daily 
dose of 2500mg, and up titrated by 500mg per week. In the MOP study, the starting 
dose was 1000mg, with a maximum dose of 3000mg, and the up titration rate 
similar. In clinical practice, most clinicians up titrate more rapidly. It is possible that 
a different dose regime may have produced a different result. Metformin clearance is 
faster in pregnancy and our study population were obese so a higher dose may have 
been more effective. The MOP trial researchers chose to use the higher dose to avoid 
potential criticism, in the event of no effect, that the dose was inadequate. However, 
the MOP study also did not demonstrate any effect of metformin on the primary 
outcome of birthweight centile.  
 
In the MOP trial, adherence to treatment was assessed by counting of tablets returned 
by the participant at each visit. If a patient forgot to return the tablets, verbal report 
was relied upon. No metrics are given as to how frequently verbal report was relied 
upon. Adherence was deemed to be good if the total number of tablets consumed was 
at least 50% of the total prescribed and poor if it was less than 50%. Adherence was 
good in 82.7% of those taking metformin and 76.3% of those taking placebo, with no 
significant between-group differences in either adherence or maximum tolerated 
dose. In EMPOWaR, the maximum tolerated dose in the metformin group was lower 
than in the placebo group (2000mg compared to 2500mg). We used participant diary 
records in addition to counting of returned tablets as our assessment of adherence. If 
no diary or tablets were returned, the participant was assumed to be non-compliant, 
rather than relying on a verbal report. A further difference is we considered the 
participant to be compliant if they took at least one tablet on at least 50% of the 
available tablet-taking days, rather than 50% of the total prescribed. This is a lower 
dose compared to the MOP study but still compatible with an effective treatment 
dose. We also examined adherence in the active treatment group using GCMS 
analysis for presence or absence of metformin in a blood sample taken from the 
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participants at 36 weeks’ gestation. This measure was not used as our primary 
measure of adherence as no such similar test was available for the placebo group. 
However, detectable levels of metformin were present in 61% of participants who 
gave a sample at 36 weeks, which correlates very favourably with the 67% deemed 
compliant by our pre-defined criteria. 
 
In both MOP and EMPOWaR, significantly more participants in the metformin 
group experienced gastro-intestinal side effects, which also suggests that those in the 
active treatment group were taking their treatment. 
 
A further difference between the two studies was ethnicity of recruits. Our study was 
restricted to white women, primarily to minimise the effect of ethnicity on 
birthweight. There was no such restriction on recruitment to the MOP study. Over 
30% of participants in MOP were of other ethnic groups, with the majority of those 
being black. There is some evidence to suggest that the efficacy of metformin on 
glycaemic control is influenced by ethnicity. For example, one study242 demonstrated 
a statistically significantly greater impact of metformin on lowering HbA1c in 
African-Americans compared to European-Americans. The inclusion of all ethnic 
groups may have made the MOP trial results more generalisable to their local 
population. However, the potential influence on efficacy must be borne in mind, 
along with the well-recognised impact of ethnicity on birthweight.  
 
It may be that we did not observe an effect of treatment on our primary outcome 
because of suboptimal study drug adherence. However, we believe metformin did 
have its expected pharmacodynamic effect given the differences in measures of 
insulin sensitivity at 28 weeks’ gestation. There was also evidence of a maternal 
benefit in the active treatment group by a significant reduction in inflammatory 
markers CRP and IL6. The MOP protocol states that blood samples would also be 
taken for fasting insulin and inflammatory variables at baseline and 28 weeks’ 
gestation. The group have not yet published any of these results so we do not know 
whether there was a similar effect of treatment on insulin resistance and 
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inflammation in mid-gestation that we observed in EMPOWaR but this would be 
interesting data especially given the reduction in incidence of pre-eclampsia that this 
study reported.  
 
7.3. Implications for healthcare and recommendations for future research 
Obesity is a major public health concern of our time. Rates of obesity among young 
women of reproductive age are ever increasing and the cycle of disadvantage is thus 
being perpetuated to the next generation.  On the basis of this research, we can 
conclude that metformin should not be used to improve pregnancy outcomes in obese 
pregnant women without gestational diabetes. Follow up studies of the babies born to 
the women who participated in EMPOWaR will be important to determine whether 
there are any longer term benefits (or indeed harms) of metformin taken during 
pregnancy.  
 
As previously discussed, despite not seeing an effect on our primary outcome, 
longer-term effects may become apparent in years to come, such as was observed in 
the MiG TOFU study101. These effects may be beneficial such as a more favourable 
body fat distribution or cardiometabolic profile for the offspring. However, we must 
be mindful of the intricate and complex effects the intrauterine environment has on 
future life risk of health and disease and there is potential that intervention with 
metformin may have caused harm.  
 
It is biologically plausible that therapy could cause a mismatch in fetal potential and 
development and thus an adverse adult phenotype. The harmful effects of a 
mismatch between the intrauterine and extrauterine environment were originally 
described in relation to lower birth weight and increased rates of cardiorespiratory 
disease in adulthood243. This ‘developmental origins of health and disease’ 
hypothesis originated from UK data but has since been replicated worldwide244. The 
original association with birthweight was graded across the normal range of 
birthweights, not just those born prematurely or with a birthweight low for 
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gestational age245-247. Subsequent animal models have provided clear evidence that 
the intrauterine environment influences the biology of offspring and that early 
environmental influence can induce metabolic or endocrine changes in later life248.  
 
It is possible that the link between early life environment and adult disease may have 
an evolutionary basis. The ‘predictive adaptive responses’ hypothesis proposes that 
there is an evolutionary advantage to an organism to alter its development to 
optimise its survival in a predicted postnatal environment249. This theory suggests 
long-term consequences may be particularly harmful if there is a mismatch between 
the ‘predicted’ postnatal environment and the actual postnatal environment. This has 
perhaps been most clearly demonstrated in societies where there has been rapid 
economic or social change, for example in India where there has been a significant 
population move from a rural, active lifestyle with low calorie diet to a more urban, 
sedentary lifestyle with a more typically Western diet and consequently a very high 
prevalence of cardiometabolic disease. Maternal disease, such as obesity, or therapy 
during pregnancy may similarly cause the fetus to adjust its development 
inappropriately and thus be less well adapted to cope with a mismatched extrauterine 
environment. We know offspring of women who are obese in pregnancy are born 
with existing metabolic compromise; they are more resistance to insulin and have a 
greater degree of adiposity. We would argue that this perpetuates the cycle of the 
disadvantage of obesity but offspring may have made this adaptive response to the 
obesogenic intrauterine environment to prepare for the likely obesogenic extrauterine 
environment in which they will be raised. Pharmacological intervention during 
pregnancy may protect the fetus from being born in a metabolically disadvantaged 
state, which intuitively would seem beneficial but may in fact be harmful if this 
induces a ‘mismatch’. Without long-term follow up studies it is impossible to be 
certain.  
 
Attention should perhaps instead be focused on lifestyle intervention strategies, 
although our findings of no beneficial effect are similar to those of other trials of 
various dietary and lifestyle interventions aimed at reducing birthweight in obese 
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individuals. However, what is more promising about lifestyle intervention strategies, 
compared to pharmacotherapy, is that as a consequence of participating in a lifestyle 
modifying trial, women may be more informed and therefore motivated to maintain a 
healthier lifestyle and make better food choices in the postnatal period for both 
themselves and their children.  
 
An alternative approach would be to optimise the diagnosis of GDM in obese 
pregnant women. Although national recommendations are that obese women should 
have a glucose tolerance test at 28 weeks to test for GDM, these recommendations 
are incompletely applied. Additionally, given that glucose levels are high in obese 
women from the beginning of pregnancy, deferring diagnosis until 28 weeks allows 
high maternal glucose to impact adversely on fetal growth for the first two thirds of 
pregnancy. Hence earlier diagnoses for GDM might be appropriate.  
 
In conclusion, antenatal dietary, lifestyle and drug interventions for obese women 
have thus far not been shown to have a meaningful impact on birth outcomes. It 
seems the focus of intervention must shift towards reducing weight and optimising 
health in young girls and women prior to embarking on pregnancy and continuing to 
prioritise the care of women in the postnatal period to help optimise their health in 
preparation for subsequent pregnancies. This is unarguably a much greater challenge, 
which will require broad social change. This must begin with increasing awareness 
among the general public of the impact of obesity on both immediate and long-term 
pregnancy outcomes. This heightened public awareness will help to drive the 
pressing need for the political will to change policies, in line with the 
recommendations of the United Nations Sustainable Development Goals on the 
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